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Abstract
Federal support and funding for human embryonic stem cell (hESC) research in the
United States lags behind stem cell programs in many countries because of the divisive
debate over hESC research and the continually evolving federal policies that have
hindered research efforts. The purpose of this phenomenological study was to explore the
perceptions of stem cell researchers, stakeholders, and investors in the United States
about the effects of the current federal stem cell policy on stem cell research in the United
States, the moral disagreement with stem cell research, and their recommendations to
improve stem cell research policy in the United States. Rogers’s diffusion of innovation
theory and Kingdon’s agenda-setting theory served as the theoretical frameworks for this
study. Data were collected through telephonic semistructured interviews with a snowball
sample of 21 participants. Data were analyzed using Attride-Stirling’s 6 steps of thematic
coding. Findings indicated the need to educate laypersons and legislators, involve the
public in the stem cell research policy debate, increase federal funding, and exclude
religious considerations from political discussions. The implications for positive social
change are directed at stem cell policymakers to focus attention and resources on creating
a cohesive federal hESC funding policy to ensure that stem cell research improves in the
United States with the goal of developing treatments for conditions that are currently
untreatable.
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Chapter 1: Introduction to the Study
The uncertain stem cell policies in the United States have been a great challenge
for stem cell researchers, especially for those who work with human embryonic stem
cells (hESCs; Levine, 2011). Levine (2011) reported that in 1995, President Clinton
banned federal funding for research that would destroy human embryos. In 2001, the
Bush administration’s restriction resulted in only 21 viable lines that could be used in
federally funded research. However, in 2009, President Obama issued an executive order
(EO) with the goal of strengthening hESC research in the United States (Levine, 2011;
Nature Cell Biology, 2010). President Obama’s new stem cell policy, however, did not
approve the 21 hESC lines that were eligible under the Bush administration (Levine,
2011). Nature Cell Biology (2010) reported that hESC lines have to meet the National
Institutes of Health (NIH) strict ethical policies. According to the NIH (2015a), applicant
institutions proposing research using hESCs derived from embryos donated in the United
States should be derived from human embryos that were created using in vitro
fertilization (IVF) for reproductive purposes and were no longer needed for this purpose.
In addition, the hESCs should be donated by individuals who sought reproductive
treatment and gave voluntary written consent for the human embryos to be used for
research purposes. Therefore, it is still not possible to create new hESC lines from viable
embryos using federal funds, and verifying that the hESC lines were derived from donors
who had given their informed consent has been very time-consuming for researchers
(Nature Cell Biology, 2010). Questions still remain as to whether U.S. stem cell
researchers have really benefited from President Obama’s more relaxed funding policies.
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The use of hESCs in stem cell research has been a very divisive and controversial
issue (Levine, 2011; Mintrom, 2013). Mintrom (2013) discussed morality politics that are
associated with hESC research. Mintrom noted that hESC research is controversial
because it raises questions about what counts as human life and who gets to make that
decision. Sano (2013) argued that for hESC research to flourish in the United States, a
cohesive federal hESC public financing policy is needed. In this phenomenological study,
I explored the perceptions of 21 stem cell researchers, stakeholders, and investors in the
United States regarding the effects of the current federal stem cell policy on stem cell
research in the United States, the moral disagreement with stem cell research, and
recommendations to improve stem cell research policy in the United States. Stem cell
researchers are scientists who study the biological properties of stem cells and the
potential use and effect of stem cells in treating diseases (NIH, 2009). Stakeholders are
“individuals whose collective actions are guided by or directly serve the mandate of an
overarching organizational framework” (Downey & Geransar, 2008, p. 70). Stakeholders
play a major role in the stem cell debate as well as in stem cell research and policy
development, such as patient groups in alignment with the medical community (Downey
& Geransar, 2008). Investors are individuals who invest in stem cell research with the
intent on making a profit (Zucchi, 2015).
This study was significant because findings may encourage stem cell
policymakers to focus attention and resources on creating a cohesive, bipartisan federal
hESC funding policy to ensure that stem cell research succeeds in the United States.
Having a unified federal hESC funding policy may lead to positive social change in the
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health care field. Chapter 1 includes the background of the study, statement of the
problem, purpose of the study, research questions, theoretical framework, nature of the
study, definition of terms, assumptions, scope and delimitations, limitations, significance
of the study, and a summary.
Background of the Study
In the late 1990s, breakthroughs in the cloning of mammals and the isolation of
hESC lines resulted in science policy debates at the national and state levels (Levine,
Lacy, & Hearn, 2013). Levine et al. (2013) indicated that these debates tend to focus on
hope and controversy of these scientific breakthroughs. Levine et al. noted that most
scientists believe that hESC research offers great promise in understanding human
disease and developing treatments for conditions that are currently untreatable. Other
researchers have noted that hESC research may provide advances in treatment of
numerous diseases and may provide stem-cell-based therapies for a number of conditions
such as strokes, spinal cord injuries, Alzheimer’s disease, and Parkinson’s disease
(California Institute for Regenerative Medicine [CIRM], 2015b; Holland, Lebacqz, &
Zoloth, 2001; Mason & Manzotti, 2010).
However, hESC research is controversial because it involves the use and
destruction of early human embryos (Levine, 2011; Levine et al., 2013; Mintrom, 2013).
Levine et al. (2013) reported that for hESC research to reach its highest potential, cloning
technology may be needed to create embryos that are genetically matched to potential
patients, which is also called therapeutic cloning. Levine et al. reported that although this
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technique has been performed only in animals, it creates controversy because it is viewed
as creating an opportunity for the cloning of humans for reproductive purposes.
Due to these scientific advances, President Clinton banned the use of federal
funds for human cloning (Levine et al., 2013). With the successful isolation of hESCs in
1998, a legal review was conducted by the National Bioethics Advisory Committee
(NBAC) in 1999, which indicated that the federal government could legally fund hESC
research; however, funds could not be used for derivation of stem cell lines (Levine et al.,
2013; Walter, 2001). Levine et al. (2013) reported that in 2000, the Clinton
administration issued guidelines supporting research in the stem cell field, and the NIH
invited scientists to apply for research funding. However, before the Clinton
administration guidelines could be adopted and the first grant meeting could take place,
President Bush was elected. Levine et al. noted that in 2001, President Bush restricted
federal funds for hESC research on existing stem cell lines. In 2009, the Obama
administration relaxed some of the Bush administration’s restrictions on federal funding
for hESC research, such as authorizing the use of federal funds on ethically derived hESC
lines despite the date of derivation; however, the implementation of this policy has been
hindered by legal challenges (Levine, 2011; Levine et al., 2013; Nature Cell Biology,
2010). For example, the Dickey-Wicker Amendment (the amendment) was the response
of the Republican-controlled House and Senate to ethical concerns surrounding federal
funding for research involving human embryos. Since 1996, the amendment has been
attached to appropriations bills for the Department of Health and Human Services, Labor,
and Education (Kearl, 2015). Therefore, uncertainty persists about the future of federal
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funding for hESC research (Couch, Lane, & Black, 2012; Levine, 2011; Levine et al.,
2013).
Due to the divisiveness of the hESC research debate, a cohesive or bipartisan
federal ESC public financing policy is still uncertain (Levine, 2011; Levine et al., 2013;
Mintrom, 2013; Sano, 2013). As a result, hESC researchers face continued policy
fluctuations, legal challenges, and other hurdles to their future research (Levine, 2011;
Levine et al., 2013; Mintrom, 2013; Sano, 2013). A review of literature indicated that
there is a gap in stem cell research that focuses on U.S. stem cell researchers’,
stakeholders’, and investors’ perceptions regarding the effects of the current federal stem
cell policy on stem cell research in the United States, the moral disagreement with stem
cell research, and recommendations to improve stem cell research policy in the United
States; in this phenomenological study, I addressed that gap. This study was needed to
encourage policymakers to focus attention and resources on creating a consistent federal
hESC funding policy to ensure that stem cell research succeeds in the United States.
Statement of the Problem
On March 9, 2009, President Obama issued EO 13505, Removing Barriers to
Responsible Scientific Research Involving Human Stem Cells, which changed the way the
NIH can support and conduct human stem cell research (NIH, 2011). The EO removed
limitations on scientific inquiry and expanded the NIH support for the exploration of
stem cell research, with the purpose of enhancing the contributions of U.S. scientists to
make important discoveries and create new therapies for the benefit of humanity (Obama,
2009). However, despite President Obama’s reversal of some of the barriers to hESC
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research, questions remain about the extent to which U.S. stem cell researchers have
benefited from this more relaxed federal funding policy (Nature Cell Biology, 2010;
Wolinsky, 2009).
The problem is that despite the new federal stem cell policy, federal support and
funding for hESC research in the United States are still behind stem cell programs in
many countries, and the evolving federal policies have hindered research efforts (Nature
Cell Biology, 2010). Nature Cell Biology (2010) reported that although federal funds can
now be used for research on any hESC line that is found to meet the NIH’s strict ethical
policies, creating new hESC lines from viable embryos using federal funds is still not
possible. Mintrom (2013) noted that hESC research is controversial because
consideration has to be given to what counts as human life and who gets to make that
decision. In addition, Nature Cell Biology related that an essential element of NIH
approval is verifying that hESC lines were derived from donors who provided informed
consent, and this has proven to be extremely time-consuming. As of July 2010, 64 hESC
lines were eligible for use in research supported by U.S. federal funds. In contrast, 120
hESC lines are available in the United Kingdom (UK) Stem Cell Bank registry, and new
hESC lines can be created in the UK, which are subject to licensing by the Human
Fertilization and Embryology Authority. China, Japan, and some European countries
such as Belgium and Sweden have similarly liberal policies regarding the creation of new
hESC lines.
Although it is unavoidable that each state government will set restrictive policies
for stem cell research within their borders (and several states have already done so), a
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liberal policy at the federal level could soften the tone of the hESC debate and promote
greater acceptance of such research within the United States (Nature Cell Biology, 2010).
From a policy perspective, more remains to be done to ensure that stem cell research
flourishes in the United States. A qualitative phenomenological study was needed to
explore the perceptions of stem cell researchers, stakeholders, and investors in the United
States about the effects of the current federal stem cell policy on stem cell research in the
United States, the moral disagreement with stem cell research, and recommendations to
improve stem cell research policy in the United States.
Purpose of the Study
The purpose of this phenomenological study was to explore the perceptions of 21
stem cell researchers, stakeholders, and investors in the United States about the effects of
the current federal stem cell policy on stem cell research in the United States, the moral
disagreement with stem cell research, and recommendations to improve stem cell
research policy in the United States. There are many different types of stem cells, each
with different potential to treat disease (CIRM, 2013). The CIRM (2013) reported that
adult stem cells come from any organ, are the source of new cells throughout the life
of the organism, and are also called tissue stem cells. “The pluripotent cells, which have
the ability to form all cells in the body, can be either embryonic or induced pluripotent
stem (iPS) cells” (CIRM, 2013, para. 1).
Stem cell researchers, biotechnology companies, and laboratories are highly
mobile actors who have the ability to relocate in response to liberal regulatory
environments and public funding offers (Marzotto & Alt, 2012). According to Marzotto
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and Alt (2012), commercial companies have created active research programs to develop
stem cell technologies and therapies. Due to electoral politics and federal restrictions on
publicly funded stem cell research, some states have provided their own legislation and
significant public funding to promote stem cell research. However, controversies over
hESC research continue, especially during tough economic times where there are
concerns about losing jobs to other states or countries.
Research Questions
To explore the perceptions of 21 U.S. stem cell researchers, stakeholders, and
investors about the effects of the current federal stem cell policy on stem cell research in
the United States, the moral disagreement with stem cell research, and recommendations
to improve stem cell research policy in the United States, I asked the following research
questions:
1. What are U.S. stem cell researchers’, stakeholders’, and investors’ perceptions
about the effects of the current federal stem cell policy on stem cell research
in the United States?
2. What are U.S. stem cell researchers’, stakeholders’, and investors’ perceptions
about the moral disagreement with stem cell research?
3. What do U.S. stem cell researchers, stakeholders, and investors recommend to
improve stem cell research policy in the United States?
Theoretical Framework
Rogers’s (1962) diffusion of innovation (DOI) theory and Kingdon’s (1995)
agenda-setting theory served as the theoretical framework for this study. A brief
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overview of the theories is provided in this section with a more detailed explanation
provided in Chapter 2. This section is organized in the following subsections: diffusion of
innovation theory and Kingdon’s agenda-setting theory.
Diffusion of Innovation Theory
DOI theory refers to the process of how and why innovation of new ideas and
technology are communicated to a culture or social system as well as the rate at which
they spread (Rogers, 2003). There are four main elements in the DOI theory: innovation,
communication channels, time, and social systems (Rogers, 2003, Sahin, 2006).
According to Rogers (2003), innovation refers to an idea, practice, or object that an
individual perceives to be new. Communication channels refer to the ways in which
messages travel from one person to another. Time refers to the innovation-decision
period, which is the length of time that is needed to pass through the innovation-decision
process. Time also refers to the rate of adoption, which is the speed an innovation is
adopted by members of a social system. Social systems refer to a set of interrelated units
that are engaged in joint problem solving to accomplish a common goal.
The innovation decision process consists of five stages of adoption: knowledge,
persuasion, decision, implementation, and confirmation (Rogers, 2003). Sahin (2006)
noted that in the knowledge stage, individuals learn about the existence of innovation and
seek information about the innovation. In the persuasion stage, individuals have negative
or positive attitudes toward the innovation; however, this does not always lead to an
adoption or rejection of the innovation. In the decision stage, individuals choose to adopt
or reject the innovation. In the implementation stage, the innovation is put into practice.
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Finally, in the confirmation stage, the innovation decision has been made, but individuals
seek support for their decision. Dresser (2010) indicated that the debate over stem cell
research offers an opportunity to examine a variety of ethical and policy issues raised by
biomedical innovation.
Kingdon’s Agenda-Setting Theory
Kingdon’s agenda-setting theory refers to how agenda setting affects the policy
process in the planning stages and how it shapes the behavior of others (Kingdon, 1995).
Kingdon (2003) argued that governmental agenda pertains to subjects that people in and
around government are giving serious attention. Kingdon described the policymaking
process around three streams and a policy window (Soroka, 1999). Soroka (1999)
reported that the three streams or processes are problems, policies, and politics. Kingdon
(1995) described the problem stream as the process of convincing policy decision-makers
to overlook one problem for another. Chayabunjonglerd (2012) observed that for public
officials to create policies, there must first be problems that they can address through
policymaking. For example, with the successful isolation of hESCs in 1998, problems
with hESC research arose. The policy stream represents the process by which policy
proposals are created, discussed, revised, and adopted for serious consideration (Kingdon,
1995). Chayabunjonglerd noted that since 1998, many officials and interest groups have
considered alternative policies on hESC issues. In 2001, these ideas were formulated into
proposals, such as the Responsible Stem Cell Research Act of 2001. The open policy
window provided the policy stream with different possible solutions.
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In the politics stream, politics are political factors that influence agendas, such as
changes in elected officials, political climate or mood (e.g., conservative, tax averse), and
the voices of advocacy or opposition groups (Kingdon, 1995). Chayabunjonglerd (2012)
reported that due to the opening of the policy window and the general public support of
hESC research, intense political activity took place in Congress. Chayabunjonglerd noted
that the majority of Democrats and moderate Republicans argued in support of hESC
research. On the other hand, the majority of conservatives opposed hESC research. All
three streams, plus the opening of the policy window, resulted in the issue of public
funding for hESC being placed on the decision agenda. The possibility of change is at its
greatest when all three streams come together (Soroka, 1999).
Nature of the Study
In this phenomenological study, I explored the perceptions of 21 stem cell
researchers, stakeholders, and investors in the United States about the effects of the
current federal stem cell policy on stem cell research in the United States, the moral
disagreement with stem cell research, and recommendations to improve stem cell
research policy in the United States. I chose a phenomenological design to explore
participants’ experiences to obtain rich descriptions of a reaction to an event or
phenomenon (see Creswell & Miller, 2000). This design allowed me to understand and
reveal multiple facets of the issue (see Creswell & Miller, 2000). A phenomenological
design provides an understanding of a phenomenon by revealing the meaning that
underpins participants’ perceptions (Moustakas, 1994; Waters, 2016; Waugh & Waugh,
2004).
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Data were collected for this study through in-depth telephonic semistructured
interviews with 21 stem cell researchers, stakeholders, and investors in the United States.
The relationship between saturation and sample size was sufficient in this study because
through the use of snowball sampling, I recruited 21 participants to obtain the richest data
possible. Individual telephonic interviews were conducted at a time that was convenient
for each participant. Using snowball sampling, which is a subset of purposive sampling, I
recruited seven stem cell researchers, seven stem cell stakeholders, and seven stem cell
investors to participate in the study. I contacted potential participants by e-mail or
telephone. Selection criteria included men or women who were researchers at a
government organization, private company, or university; faculty members at a univeristy
where stem cell research was being conducted; or investors who worked for a
government organization or private company that invests in stem cell research in the
United States. Prospective participants were sent an invitation letter to participate in the
study and were asked to recommend other stem cell researchers, stakeholders, or
investors who met the selection criteria (see Appendix A). I transcribed the interviews,
managed the data with NVivo, and analyzed the data using Attride-Stirling’s (2001) six
steps of thematic coding. The study was conducted in accordance with Walden
University’s Institutional Review Board (IRB) guidelines to ensure the ethical protection
of research participants. The nature of the study is discussed in further detail in Chapter
3.
Definition of Terms
Adopters: Individuals who adopt an innovation (Rogers, 2003).
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Adult stem cells: Found in the various tissues and organs of the human body and
thought to exist in most organs where they are the source of new cells throughout the life
of the organism (CIRM, 2015a). They replace cells lost to natural turnover or to damage
or disease (CIRM, 2015a).
Bioethics: “Bioethics is the application of ethics to the field of medicine and
healthcare” (Center for Practical Bioethics, 2015, para. 1).
Diffusion: “The process in which an innovation is communicated through certain
channels over time among the members of a social system” (Rogers, 2003, p. 5).
Diffusion of innovation (DOI) theory: The process of how and why innovation of
new ideas and technology are communicated to a culture or social system as well as the
rate in which they spread (Rogers, 2003).
Embryonic stem cells (ESCs): Come from pluripotent cells, which exist only at
the earliest stages of embryonic development and in humans, do not exist after about 5
days of development (CIRM, 2015a). When isolated from the embryo and grown in a lab
dish, pluripotent cells can continue dividing indefinitely.
Groupthink: Groupthink occurs when a homogenous highly cohesive group is so
concerned with maintaining unanimity that they fail to evaluate their alternatives and
options (Janis, 1972).
Innovation: An idea, practice, or object that a person perceives as new (Rogers,
2003).
Investors: In this study, individuals who invest in stem cell research with the
intent on making a profit (Zucchi, 2015).
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In vitro: Embryos that have developed from eggs that have been fertilized outside
of the body (Small & Doherty, 2011).
Kingdon’s agenda-setting theory: How agenda setting affects the policy process
in the planning stages and how it shapes the behavior of others (Kingdon, 1995).
Pluripotent cells: Pluripotent means many potentials, and “these cells have the
potential of taking on many fates in the body, including all of the more than 200 different
cell types” (CIRM, 2015a, para. 3). ESCs and induced pluripotent stem (iPS) cells
(reprogrammed from adult tissues) are pluripotent cells (CIRM, 2005).
Stakeholders: In this study, “individuals whose collective actions are guided by or
directly serve the mandate of an overarching organizational framework” (Downey &
Geransar, 2008, p. 70). Stakeholders play a major role in the stem cell debate as well as
in stem cell research and policy development, such as patient groups in alignment with
the medical community (Downey & Geransar, 2008).
Stem cell researchers: Scientists who study the biological properties of stem cells
and the potential use and effect of stem cells in treating diseases (NIH, 2009).
Stem cells: “Have the ability to divide and create an identical copy of themselves,
a process called self-renewal” (CIRM, 2015a, para. 2). In addition, stem cells “can also
divide to form cells that mature into cells that make up every type of tissue and organ in
the body” (CIRM, 2015a, para. 2).
Assumptions
Assumptions made for this study were as follows:
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•

Stem cell researchers, stakeholders, and investors had experience with the
stem cell research process.

•

Stem cell researchers, stakeholders, and investors would be willing to take
part in the study because of its significance to focus attention and resources on
creating a consistent federal hESC funding policy to ensure that stem cell
research succeeds in the United States.

•

The in-depth telephonic semistructured interviews would be appropriate to
explore U.S. stem cell researchers’, stakeholders’, and investors’ perceptions
about the effects of the current federal stem cell policy on stem cell research
in the United States, the moral disagreement with stem cell research, and
recommendations to improve stem cell research policy in the United States.

•

The in-depth semistructured interview questions were worded so that the
participants could understand the questions being asked.

•

The participants would honestly and openly answer the interview questions by
sharing their perceptions about the questions asked.

•

The results of the study would lead to positive social change as findings are
directed at stem cell policymakers to focus attention and resources on creating
a consistent federal hESC funding policy to ensure that stem cell research
succeeds in the United States.
Scope and Delimitations

The study’s participants included 21 stem cell researchers, stakeholders, and
investors in the United States. I focused on participants’ perceptions about the effects of
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the current federal stem cell policy on stem cell research in the United States, the moral
disagreement with stem cell research, and recommendations to improve stem cell
research policy in the United States. I excluded stem cell researchers, stakeholders, and
investors from other countries. I did not include anyone with whom I had a personal
relationship, which included family members, friends, coworkers, or professional and
personal associates. This prevented perceived coercion to participate due to any existing
or expected relationship between the participants and me. However, I asked personal and
personal associates if they knew individuals who fit the study criteria to get snowball
sampling going.
Limitations
There were several limitations in this study. First, findings were limited by the
snowball sample of seven stem cell researchers, seven stem cell stakeholders, and seven
stem cell investors; each category of participants contained a smaller number than the
overall sample of 21. Due to the small sample size for each category of participant,
caution has to be taken in transferring the findings to similar populations of U.S. stem
cell researchers, stakeholders, and investors. In addition, the results of the study may not
be transferrable to other populations or countries. As a result, in future research, the
sample population for each type of participant could be increased to achieve a broader
understanding of their stem cell research policy experiences. In future studies, a different
sampling strategy could also be used, such as random sampling.
Second, social desirability bias was considered as stem cell researchers,
stakeholders, and investors may have wanted to be perceived positively, so they may not

17
have responded honestly to the interview questions. However, I assumed that participants
would honestly and openly answer the interview questions by sharing their perceptions
about the phenomenon. Third, there were limitations with self-reported data as
participants may not have accurately or fully evaluated themselves. However, I assumed
that participants accurately and fully self-evaluated.
Significance of the Study
Policy entrepreneurs, who are political figures who seek policy changes to
existing areas of public policy, have faced significant opposition to government funding
and favorable regulations to advance hESC research due to morality issues (Mintrom,
2013). The most restrictive stem cell laws are in countries where Roman Catholicism is
the dominant religion or Christian democratic parties are on the rise (Fink, 2008;
Mintrom, 2013). Mintrom (2013) reported that the UK has a permissive approach to
hESC research regulation and that it is correlated with the low percentage of adults who
identify with the Roman Catholic faith (9%) in the UK. Mintrom noted that in the UK,
moral issues have been widely investigated and extensively debated; however, they have
not inhibited scientific research.
Unlike in the UK and other permissive countries, hESC research in the United
States is divisive and controversial, which has resulted in stem cell policy uncertainty
(Levine, 2011; Levine et al., 2013; Mintrom, 2013). In 2010, 24% of Americans
identified with the Roman Catholic faith (Pew Research Center, 2013, para. 11). There is
no consistent federal hESC funding policy, which impedes the United States from being a
leading country in the advancement of hESC research (Mintrom, 2013; Sano, 2013). U.S.
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hESC researchers continue to face policy fluctuations, legal challenges, and other hurdles
to their research (Levine, 2011; Levine et al., 2013; Mintrom, 2013; Sano, 2013). There is
a gap in stem cell research regarding U.S. stem cell researchers’, stakeholders’, and
investors’ perceptions about the effects of the current federal stem cell policy on stem cell
research in the United States, the moral disagreement with stem cell research, and
recommendations to improve stem cell research policy in the United States. In this study,
I addressed this gap by making an original contribution to the public policy and
administration literature on this topic. Individuals working in public policy and
administration, including the fields of biology and regenerative medicine and agencies
such as the CIRM and the NIH, may be interested in the findings.
Findings may encourage policymakers to focus attention and resources on
creating a cohesive federal hESC funding policy to ensure that stem cell research
succeeds in the United States. Implementation of a bipartisan federal hESC funding
policy may lead to positive social change in the health care field as hESCs can be used
for cell-based therapies to replace ailing or destroyed tissues resulting from macular
degeneration, spinal cord injury, stroke, burns, heart disease, diabetes, osteoarthritis, and
rheumatoid arthritis (NIH, 2015b). In addition, hESCs can be used to treat Alzheimer’s
and Parkinson’s disease; however, the need for transplantable tissues and organs far
outweighs the available supply (CIRM, 2015b; NIH, 2015b).
Summary
I explored seven U.S. stem cell researchers’, seven U.S. stakeholders’, and seven
U.S. investors’ perceptions about the effects of the current federal stem cell policy on
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stem cell research in the United States, the moral disagreement with stem cell research,
and recommendations to improve stem cell research policy in the United States. Data
were collected using in-depth telephonic semistructured interviews. Using snowball
sampling, I recruited 21 participants for the study. Findings may encourage stem cell
policymakers to focus attention and resources on creating a more unified federal hESC
funding policy to ensure that stem cell research succeeds in the United States. A cohesive
federal hESC funding policy may lead to positive social change in the health care field by
creating cell-based therapies to replace ailing or destroyed tissues.
In Chapter 1, I included the introduction, background of the study, statement of
the problem, purpose of the study, research questions, theoretical framework, nature of
the study, definitions of terms, assumptions, scope and delimitations, limitations,
significance of the study, and a summary. In Chapter 2, I include the introduction,
literature search strategy, theoretical foundation, Dickey-Wicker Amendment, United
States national policies, international communities’ stem cell policies, bioethics and the
moral debate, embryonic stem cell research, and a summary and conclusions. In Chapter
3, I include the research design and rationale, role of the researcher, methodology, issues
of trustworthiness, and a summary. In Chapter 4, I include the introduction, setting,
demographics, data collection, data analysis, evidence of trustworthiness, results, and a
summary. In Chapter 5, I include the introduction, interpretation of findings, limitations
of the study, recommendations, implications, and a conclusion.
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Chapter 2: Literature Review
In Chapter 2, I provide a review of relevant and current scholarly resources
related to my study on the effects of the current federal stem cell policy on stem cell
research in the United States, the moral disagreement with stem cell research, and
recommendations to improve stem cell research policy in the United States. The literature
review includes the introduction, literature search strategy, theoretical foundation,
Dickey-Wicker Amendment, U.S. policies, international communities’ policies, bioethics
and morality debate, embryonic stem cell research, and a summary and conclusions.
According to Rogers (2003), innovation is adopted through a five-step process (i.e.
relative change, compatibility, complexity, trialability, and observability). The problem is
with constant change from one administration to the next, too much change hinders
policy growth and development.
Literature Search Strategy
I searched all Walden University library databases including ProQuest and
EBSCOhost databases such as Academic Search Complete, Health and Medical
Complete, LexisNexis Academic, and PubMed. In addition, I searched Gwinnett County
Public Library databases. Search terms included public policy and human embryonic stem
cell, public policy funding for stem cells, historical innovation on stem cells, U.S. policy
on stem cell development, Obama policy on stem cells, Bush policy on stem cell research,
and legislative policies or statutes on stem cells. I examined additional articles after
reviewing the reference section from each article and dissertation. Furthermore, I
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examined relevant organizational websites such as the NIH and placed emphasis on the
most recent literature.
Theoretical Foundation
Rogers’s (1962) DOI theory and Kingdon’s (1995) agenda-setting theory served
as the theoretical foundation of this phenomenological study. This section is organized in
the following subsections: diffusion of innovation theory and Kingdon’s agenda-setting
theory.
Diffusion of Innovation Theory
Rogers’s (1962) DOI theory is used to explain how an idea or product gains
momentum and diffuses through a specific population or social system. According to
Rogers (1995), the goal of diffusion is for people who are part of a social system to adopt
a new idea, behavior, or product as new or innovative. Rogers reported that the DOI
theory addresses how policy and agendas are set, how policy moves through the political
process, and the effect of policy once it is created. The purpose of diffusion is to create a
dialogue with those who are against change.
What is learned from previous innovations results in more advanced innovations
being created and adopted (Rogers, 1995). Rogers (1995) related that the success of an
innovation determines the rate of adoption for a similar innovation. Rogers noted that
groupthink tends to limit the spread of innovation. Leaders of a group exert influence
over the behaviors and beliefs of individuals and adopters in their networks (Anderson,
2006; Janis, 1989; Rogers, 1983). Limiting the spread of innovation also slows down
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growth (Amidon, 2005). According to Amidon (2005), individuals in political or social
settings tend to accept groupthink as a form of solidarity and unanimity.
Groupthink, diffusion, innovation, and adopter are important terms in DOI theory.
Groupthink was first introduced by Janis in 1972 to explain why groups sometimes make
poor decisions. According to Kretchmar (2009), groupthink comes from the application
of those who were part of a political advisory group to four U.S. presidents. Groupthink
is often used when one cannot explain a phenomenon, and is often seen in consensus
seeking and when evidence is not readily available. Diffusion is the means of how
information is shared among a group of people in a network. Diffusion may impede a
new product, idea, or practice from being accepted by others of a particular culture or
network (Rogers, 1995). Rogers (1995) noted that innovation is a new product or service
being introduced to potential adopters. Adopters are those who are affected by the new
product, and adopters’ behavior may be influenced by the opinion of a leader.
Diffusion of innovation is connected to an individual’s perception of a new
product or service, while invention is new (Therin, 2012). Therin (2012) noted that with
the perception of newness, there must be knowledge about the service or product;
otherwise, that perception is not relevant. In addition, any new innovation must be known
among the targeted population of potential adopters, and a clear perception should be
established. Once the knowledge about the product and service has been conveyed, there
should be a theoretical framework in place to rate the adoption of the new innovation.
According to Rogers (2003), there are five factors that influence the adoption of
innovation probability rate: (a) relative advantage, (b) compatibility, (c) complexity, (d)
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trialability, and (e) observability. These factors can be seen in Figure 1 under the
persuasion stage, which is one of the five innovation-decision processes: (a) knowledge,
(b) persuasion, (c) decision, (d) implementation, and (e) confirmation.

Figure 1. Five stages of Rogers’s (2003) innovation-decision process model. Reprinted
from Diffusion of innovations (5th ed.), by E. Rogers, 2003: New York, NY: The Free
Press. Copyright 2003 by the Free Press. This source was taken from Creative Commons
3.0.

Relative advantage is defined as the degree to which an innovation is perceived as
better than available products or services (Therin, 2012). Therin (2012) reported that this
can be measured in terms of quality, satisfaction, or social status. Compatibility is
determined by the acceptability of social or religious norms in the country, which may
forbid certain practices, attitudes, or behaviors. Complexity pertains to the perception of
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the difficulty of understanding, implementing, integrating, and using an innovation.
Trialability is the possibility of experimenting with an innovation before adopting it.
Observability is the degree to which the results of the implementation of an innovation
are visible. If potential adopters can witness what happens after an innovation is
implemented, they will be reassured about other factors and potential concerns about
health and safety.
The persuasion stage occurs when individuals interested in the innovation actively
seek information about the innovation (Rogers, 2003). The other four innovation-decision
process stages include knowledge, decision, implementation, and confirmation.
According to Rogers (2003), in the knowledge stage individuals are first exposed to an
innovation, but they do not have information about it. In the decision stage, individuals
consider the advantages and disadvantages of using the innovation and make decisions
about whether to use or reject it. In the implementation stage, individuals use the
innovation at different degrees depending on the situation. In the confirmation stage,
individuals make final decisions about whether to continue to use the innovation.
According to Rogers (1995), there are six steps in the innovation-development
process:
1. Recognizing a problem or need: Research and development activities are
started to address a problem or need, and scientists seek to produce research to
find a solution to an issue.
2. Basic and applied research: Research is conducted to determine whether there
is a need for more in-depth investigation. Basic research leads to applied
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research, which provides a more scientific process to help eradicate practical
problems. If this does not work, a new technology is designed to address the
problem.
3. Development: The development process involves new ideas designed to meet
the needs of a particular audience. During the development phase, there is a
high rate of uncertainty about the innovation while trying to meet the needs of
its adopters. With regard to policy, regulation, and competitor’s perspective,
the system of information exchange about technological innovation is a
pervasive issue that can have an unwavering effect on the outcome. A new
industry may be developed around a radical innovation.
4. Commercialization: The product is ready for manufacturing, marketing,
packaging, and distribution. The end product at the time of commercialization
may include two or more innovations to facilitate a more widely acceptable
product to potential adopters.
5. Diffusion and adoption: This is the most difficult step in the innovationdevelopment process, which involves diffusing the product to potential
adopters. As with all new products, there is pressure to move it to market due
to the problem and need being high priority. Sometimes public funds are used
until there is a positive outcome that will be beneficial to potential adopters.
The move to market is when scientists seem to have the greatest concern
around innovation, which includes unveiling the product and putting it into
practice.

26
6. Consequences: In this stage, the innovation addressed or did not address the
original need or problem.
Hematology inventions spread rapidly, and factors that affect the introduction,
international diffusion, and durability of innovation use are not well understood
(Gratwohl et al., 2010). Gratwohl et al. (2010) used the DOI theory as the theoretical
foundation in their study. The researchers used 251,106 hematopoietic stem cell
transplants from 591 teams in 36 European countries. Gratwohl et al. analyzed the
increase and decrease in such transplants for breast cancer and chronic myeloid leukemia
and the replacement of bone marrow by peripheral blood as the source of stem cells as
processes of diffusion. The results indicated that gross national income per capita, World
Bank category, team density, team distribution, team size, team experience, and team
innovator status were all significantly associated with some or all of the changes. The
researchers concluded that adoption of any new medical technology and its diffusion
correlate with four main elements: economics, evidence, external regulations, and
expectations. These four factors may form the basis for any process of diffusion.
In the debate over ESC research, ethical and policy issues should be considered
(Dresser, 2010). Dresser (2010) suggested that many of the ethical and policy issues that
stem cell research presents apply to biomedical research in general, such as questions
about appropriate research priorities and allocation of limited resources for research and
health care. Dresser argued that the debate over stem cell research offers an opportunity
to examine a variety of ethical and policy issues raised by biomedical innovation. Ethical
considerations sometimes justify setting limits on scientific innovation (Dresser 2010).
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Dresser noted that some individuals believe that there should be severe limits on research
involving early human embryos, while others disagree. Dresser claimed that these
disagreements cannot be settled by science because they are value conflicts. In struggling
with these conflicts, Dresser suggested that individuals should maintain respect for those
holding differing views and should look for policies that are consistent with as many of
those views as possible.
Kingdon’s Agenda-Setting Theory
Kingdon’s agenda-setting theory pertains to how agenda setting affects the policy
process in the planning stages and how it shapes the behavior of others (Kingdon, 1995).
According to Kingdon (1995), setting an agenda is the main step in the policy process. At
this stage, the policy agenda is set up with a list of issues or problems that need to be
reviewed by various government officials before their session for the year has ended. As
the agenda is set and reviewed, a government official may decide to make changes to the
order in which it is reviewed based on the priority assigned.
Kingdon (1995) described the policymaking process around three streams and a
policy window. The three streams or processes are problems, policies, and politics
(Kingdon, 1995). Kingdon described the three streams as follows:
1. Problems: The process of convincing policymakers to overlook one
problem for another. A particular policy proposal’s chance of rising on
the agenda is much greater if the associated problem is perceived as
serious. Problem recognition can be influenced by how problems are
described through data, indicators, crisis events like a disaster, and
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constituent feedback. Budget crises are a special consideration in
problem recognition as they often override other problems.
2. Policies or proposals: This stream represents the process by which
policy proposals are created, discussed, revised, and adopted for
serious consideration. Proposals can be attached to the same problem,
and getting a proposal on the short list typically takes time and the
willingness to pursue it by using many tactics. Proposals tend to be
more successful if they are seen as technically feasible, compatible
with decision-maker values, reasonable in cost, and appealing to the
public.
3. Politics: In this stream, politics are political factors that influence
agendas, such as changes in elected officials, political climate or mood
(e.g., conservative, tax averse), and the voices of advocacy or
opposition groups.
When all three streams come together, policy initiation or change is at its greatest
(Soroka, 1999). Kingdon (1995) noted that the three streams operate parallel in a policy
area until one or more of the streams meet in a window of opportunity that represents a
possibility that policy may develop or change. Similarly, Soroka (1999) related that the
combination of streams can result in a policy window due to changes in the problem or
political streams. Windows can predictably or unpredictably appear due to events such as
election results or a sudden crisis, respectively (Kingdon, 1995).
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In the United States, the stem cell controversy opens a window to a larger moral
problem (Dresser, 2010). According to Dresser (2010), the social justice inquiry about
what justifies the United States substantial investment in biomedical innovation, when
millions of people in the United States and abroad are denied access to proven medical
interventions, raises questions about the priority that stem cell and other basic science
studies should have in the competition for limited resources. Dresser argued that if
government officials and health advocates want to help patients, meaningful help would
also come from a system that supplied adequate health care to more people, both across
the nation and worldwide.
In regard to Kingdon’s (1995) three streams (problems, policies, and politics),
problems with hESC began with the 1998 discovery, which introduced new possibilities
(Chayabunjonglerd, 2012). Chayabunjonglerd (2012) reported that scientists sought to
gain more funding through governmental sponsorship and argued that the Dickey-Wicker
Amendment that banned the use of human embryos in federally funded projects hindered
significant advances in health care. The author noted that the issue of federal funding of
hESC research raised the important question of whether the government should and can
fund hESC research. Chayabunjonglerd (2012) claimed that President Bush’s
inauguration represented significant change in the political stream, which opened a policy
window for him to push forward his solution on hESC research. This resulted in the
policy stream, where President Bush issued a Presidential Statement in 2001 that limited
federal funding of research involving hESCs (Chayabunjonglerd, 2012; Obama, 2009).
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Kingdon’s agenda-setting theory served as the theoretical foundation in
Fukushima’s (2013) study of chemical biology as part of postgenomic research agenda.
Specifically, Fukushima analyzed how three different levels, laboratory practices,
community of scientists, and policy processes, are mutually important. In addition,
Fukushima analyzed Japanese scientists’ and policy makers’ belief that chemical biology
is important in science and policy. Findings indicated that the three levels have developed
in parallel by joining different theoretical traditions. In addition, different elements
beyond the laboratory and policy process facilitated or accelerated these developments:
the character of policy entrepreneurs, the international environment, and the cultural
mood, which promoted parallel developments.
Dickey-Wicker Amendment
The amendment, authored by Representative Jay Dickey of Arkansas and Roger
Wicker of Mississippi, was created as a response to the 1994 recommendations of the
NIH Embryo Research Panel (the Panel; Kearl, 2015). According to Kearl (2015), the
Panel consisted of ethicists, public policy analysts, and patient advocates who evaluated
when and under what circumstances human embryo research should be federally funded.
They also assessed what moral and ethical controversies would be raised by this research
and compiled their findings in a report on September 27, 1994, titled, Report of the
Human Embryo Research Panel. The Panel recommended that research on unused
gametes and embryos from fertility procedures like IVF should be allowed with the
informed consent of the donor. The Panel also approved the creation of embryos for
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research purposes; however, President Clinton immediately rejected this part of the
proposal.
Since 1996, the amendment has been attached to appropriations bills for the
Department of Health and Human Services, Labor, and Education (Kearl, 2015). Kearl
(2015) reported that the amendment was the response of the Republican-controlled House
and Senate to ethical concerns surrounding federal funding for any research involving
human embryos. Kearl related that this amendment restricts the use of federal funds for
creating, destroying, or knowingly injuring human embryos. However, the amendment
only prohibited federal funding for experimentation using human embryos. Thomson,
researcher from the University of Wisconsin, created the first human stem cell line using
private funds in 1998. As a result of Thomson’s discovery, Rabb, a lawyer at the
Department of Health and Human Services, argued that experimentation with the lines
derived using private funds could receive federal funding. Rabb’s legal interpretation was
endorsed by the Clinton administration and revised guidelines were created in August
2000 for when federal funds could be provided to researchers. However, in 2001,
President Bush withdrew the Clinton administration’s guidelines. On March 9, 2009,
President Obama EO 13505, Removing Barriers to Responsible Scientific Research
Involving Human Stem Cells, lifted restrictions to federally funded stem cell research.
Kearl noted that the amendment was renewed on March 11, 2009 in the 2009 Omnibus
Appropriations Act, Pub. L. 188-8, and remains the only legal obstacle to the federal
funding of experimentation on human embryos.
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United States National Policies
This section discusses the United States’ stem cell policies. It is organized in the
following subsections: United States’ stem cell policy and adoption of new policy
guidelines.
United States’ Stem Cell Policy
In this subsection, the U.S. stem cell policy will be discussed in further detail.
According to Keiper and Levin (2010), in 1999, the Clinton administration’s Department
of Health General Counsel noted its support to fund stem cell research with hESCs that
were discarded, destroyed, injured, or at risk. However, the funds could not be used to
destroy the embryos. The authors noted that the Clinton administration may have sent the
wrong message to scientists by allowing them to destroy embryos with private funding
and then use federal funds to conduct further research. However, President Clinton’s
policy did not take effect because his second term ended before funds were released.
In 2001, the Bush administration decreased the number of hESC lines that could
be funded by the federal government (Keiper & Levin, 2010). Keiper and Levin (2010)
noted that further constraints were placed on stem cell development in the United States.
Researchers were given permission to work on approximately 60 to 78 hESC lines.
President Obama overturned President Bush’s policy on ESC research. He instructed the
NIH to create guidelines that would allow researchers to receive federal funding while
working on stem cell lines that were created from extra embryos frozen in IVF clinics,
with parents’ permission.

33
The continuous changes in the policy by each President have been a source of
great concern for representatives of states such as California, who support hESC research
(Adelson & Weinberg, 2010). Adelson and Weinberg (2010) related that in some states,
additional revenue was added to the budget to further stem cell research programs. For
example, in 2004, after President Bush’s policy denied the use of federal funds to further
research, California officials created the California Research Cures Initiatives to continue
with their research after law was passed to stop federal funding to support stem cell
research and to ban those who continued their study on stem cells from using laboratories
and facilities that were supported by federal funds. California went on to create the CIRM
to provide oversight and created funding for all research in their state. The CIRM agreed
to contribute $3 billion over a decade and create another $3 billion through the sale of
public bonds and the state general fund to aid in the study of stem cells.
Adoption of New Policy Guidelines
Policy uncertainty affects researchers’ plans more significantly than temporary
funding bans (Levine, 2011). In 2009, President Obama reversed previous decisions of
his predecessor to move forward with a more vigorous program to increase stem cell
research (Wolinsky, 2009). According to Wolinsky (2009), the policy put in place by the
previous president has been removed, but researchers that are involved in stem cell
research taken from human embryos are still fighting red tape and are not able to gain
access to federal funds for ESC research.
New guidelines for research initiatives were introduced in 2009; 9 weeks after
President Obama took office (Wolinsky, 2009). Wolinksky (2009) related that President
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Obama asked Congress to develop new legislation that would coincide with the new bill
to support the use of federal funding since public support had increased and had been
unprecedented in recent years. Wadman (2009) reported that while President Obama
changed the ESC funding policies of his predecessors, U.S. Representatives Diana
Degette of Colorado and Mike Castle of Delaware, urged Congress to support and fund
stem cell lines, where parental permission was given for the use of embryos leftover at
infertility clinics. Levine (2011) noted that a legal challenge, which claimed that Obama’s
policy violated the Dickey-Wicker Amendment, was filed following the Obama
administration’s stem cell policy and this resulted in uncertainty in the field. U.S. District
Court Judge Royce Lamberth granted a preliminary injunction, which prevented the
implementation of the Obama administration’s policy. However, the Obama
administration appealed and on April 29, 2011, the U.S. Court of Appeal for the District
of Columbia allowed the NIH to resume funding hESC research while the case
proceeded. On July 27, 2011, Federal District Court Judge Lamberth dismissed the
plaintiff’s suit, which was in line with decision of the U.S. Court of Appeal panel
(Association of American Medical Colleges [AAMC], 2015a).
There is renewed interest in stem cell research to treat numerous diseases, but
U.S. regulations and restrictions have had a negative effect on ESC research efforts
(Cyranoski, 2013). Cyranoski (2013) related that stem cell researchers are frustrated with
the policy surrounding stem cells as it places universities at risk because they struggle to
locate funding from private sources. Kington (2011) related that researchers were
concerned about NIH published draft guidelines for research involving hESCs that gave
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proponents of stem cell research an opportunity to become beneficiaries of hESC funding
due to an existing patent. Therefore, this would result in insufficient funding for research
under the established guidelines that offered financial gains to donors, where policies
were not directly established. Biomedical scientists are struggling to continue their
research as funds are limited and organizations have considered merging to hold on to the
research that they have completed.
International Communities’ Stem Cell Policies
Differences in national regulatory approaches have generated competition to
implement stem cell programs that will give countries an edge in the global knowledge
economy (Gottweis, Salter, & Waldby, 2009). Countries such as China, India, South
Korea, and Singapore have been identified as emerging biotech powers (Wahlberg,
2012). This section briefly examines stem cell policies in China, Singapore, UK,
Australia, India, and Canada, who are all members of the International Stem Cell Forum
(ISCF, 2016). The ISCF was founded in January 2003 to encourage international
collaboration and funding support for stem cell research, with the overall aim of
promoting global good practice and accelerating progress in this area of biomedical
science (ISCF, 2016).
China’s Stem Cell Policy
Biotechnologies such as stem cell science, genetic testing, and reproductive
medicine are being examined by scholars (Wahlberg, 2012). The author noted that China
has moved in an aggressive manner to become a super power in biotechnology. In a 2009
workshop, the leader of the Chinese biomedical program displayed in bold print a map
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that aggressively moves toward being recognized as a major party in the exploration of
ESC research. China policy on ESC research is permissive, which has allowed them to be
competitive by building an infrastructure that attracts scientist from various countries
(Lysaght & Capps, 2012). State-led investment programs have lured young researchers
from Europe and the United States to China (Wahlberg, 2012). In addition, Wahlberg
(2012) claimed that political mobilization around biotechnology as a source of economic
growth, aspiration in the global race to be the first, and biosecurity risk anxieties, have all
been highlighted as facilitators of Asia’s rising science and technology strength.
Singapore’s Stem Cell Policy
Singapore is another Asian country that has adopted research-friendly stem cell
policies to secure a competitive edge in the global marketplace (Lysaght & Capps, 2012).
Lysaght and Capps (2012) noted that Singapore’s approach has attracted scientists from
other countries and has resulted in the development of local industries in stem cell
science. Singapore’s approach included the establishment of a national funding body
called the Agency of Science, Technology, and Research, and strategic plans to compete
in the global bioeconomy. The strategic plans include provision of taxation incentives
and venture capital schemes to encourage public and private partnerships as well as the
creation of highly educated workers through the use of university scholarships and
graduate placements under international renowned scientists. Other important strategies
included technological infrastructure and the development of science parks and the
creation of national ethical boards.

37
United Kingdom’s Stem Cell Policy
The UK has in place a comprehensive regulatory framework for stem cell
research (Small & Doherty, 2011). According to Small and Doherty (2011), the Human
Fertilization and Embryology Authority is responsible for granting licenses for stem cell
research. Research can only take place on embryos created in vitro; thus, embryos that
have developed from eggs that have been fertilized outside of the body. The majority of
embryos used in the UK for stem cell research is obtained from embryos that were
originally created for fertility treatment, but were not used. The surplus IVF embryos
have to be donated with parental consent for use in stem cell research. The UK made
hESC research a priority and set aside $556 million for stem cell research (Nature Cell
Biology, 2010). Gough (2013) related that hESC approval in the UK is based on the
needs of the people and the policy is transparent and supported by evidence that
demonstrates a level of critical appraisal and willingness to review and amend in light of
progress.
Australia’s Stem Cell Policy
Stem cell research conducted by Australian scientists adds knowledge to the field
of human stem cells and the application of stem cell technologies (Australia Law Reform
Commission, 2015). The Australian Law Reform Commission (2015) reported that
publicly funded organizations and companies are involved in adult and ESC research in
Australia. Waldby and Carrol (2012) related that human embryos and oocytes or eggs
have become the focus of intense scientific research. Both are key tissues in regenerative
medicine with the aim to treat degenerative conditions through in vivo tissue growth
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instead of organ transplant. The researchers noted that “oocytes are essential elements in
a type of stem cell research termed somatic cell nuclear transfer (SCNT), sometimes
called therapeutic cloning” (Waldby & Carol, 2012, p. 513). Australia has a permissive
legislation in place for SCNT, but has a conservative approach to research donation
regulation. Australia’s Prohibition of Human Cloning for Reproduction and the
Regulation of Human Embryo Research Amendment Act 2006 legislation allows the
practice of SCNT. However, unlike the UK, Australia’s legislation does not allow for the
use of animal oocytes for experimental purposes. In addition, in contrast to the United
States, Australia’s legislation also does not permit the development of a reproductive
oocyte market. In Australia, strict regulated gifting is used to transfer oocytes from donor
to recipient.
India’s Stem Cell Policy
India has introduced policies that are designed to improve their global competitive
position in the stem cell research field (Mittal, 2013). Mittal (2013) reported that India
has ethical guidelines for biomedical research that was published by the Indian Council
for Medical Research (ICMR); however, limited boundaries for hESC research is used.
India’s IVF clinics are noted to be an established source of embryos for research and
foreign scientists visit these clinics for supplies. Due to negative publicity, India’s
government announced that they would take steps to counter the international view of
India as “an embryo surplus nation” (Mittal, 2013, p. 106). However, due to a lack of
legal backing for the ICMR ethical guidelines for biomedical research, India’s stem cell
scientists make their own decisions. Mudur (2005) found that in the absence of any
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powers of enforcement, only 40 of India’s 179 institutional ethics committees followed
the principles noted in the document.
Canada’s Stem Cell Policy
Canada did not have any laws, guidelines, research ethics boards, or funding
agencies to govern stem cell research until March 2002 (Canadian Institutes of Health
Research [CIHR], 2014). The CIRC (2014) reported that this urgent need was recognized
and they announced guidelines for stem cell research in March 2002. The federal granting
agencies, the CIHR, the Natural Sciences and Engineering Research Council (NSERC),
and the Social Sciences and Humanities Research Council (SSHRC) adopted the
measures and agreed that no stem cell research would be funded without the prior review
and approval of the Stem Cell Oversight Committee (SCOC), which conforms the CIHR
guidelines. Canada’s federal government also worked on legislation on assisted human
reproduction, which included the use of human embryos for research. In March 2004, the
Act called, Respecting Assisted Human Reproduction and Related Research, became law.
The Act pertains to the derivation of stem cells from human embryos. With the guidelines
in place, Canadian researchers have moved forward and remained at the forefront of their
field while conducting their research according to explicit ethical standards.
Bioethics and the Moral Debate
The ethical and moral disagreement on hESC research and the destruction of
embryos continues between religion and science (Doerflinger, 2010). Stem cell research
remains highly controversial as there are still unresolved questions about human cloning,
therapeutic abortions, and reproductive rights (Adelson & Weinberg, 2010). Lysaght and
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Campbell (2012) reported that there are still concerns over the last decade that has
generated political and public bioethical issues. Fadel (2012) discussed the issue of ethics
in stem cell research and noted that it remains a lengthy and heated debate in the
scientific literature, religious circles, and the political arena. The author noted that the
debate includes the need to protect human life from the time of inception versus curing
many debilitating diseases.
There are 220 original hESCs (Fadel, 2012). Aznar and Navarro-Illana (2014)
related that much of the controversy surrounding stem cells focus on pluripotent, ESCs,
which are destroyed at 5 to 6 days old. According to Mintrom (2013), the question of
what constitutes independent life is at the center of the debate about the use of hESCs in
research and research-based therapies. Thus, there are questions about whether life begins
at conception when the human egg is fertilized or at some later stage of development. In
addition, the researcher noted that there are questions about the point in development of
the embryo or fetus when human rights and other legal protections should be assigned.
Thus, hESC research is controversial as consideration must be given to what counts as
human life and who makes that decision.
Some religious groups, such as representatives of the Roman Catholic Church and
other Christian traditions, have argued that human life begins at conception; therefore, the
embryo or fetus should be given the full respect and rights as a human being (Mintrom,
2013). Therefore, destruction of the embryo is immoral (Mintrom, 2013). Fink (2008)
found that the most restrictive stem cell laws are in countries where Roman Catholicism
is a dominant religion or Christian democratic parties have been on the rise. On the other
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hand, Mintron (2013) reported that those who support hESC research have argued that
eggs are often fertilized but they do not implant in the uterus. Even though a fertilized
egg has the potential for human life, proponents argue that it cannot be considered equal
to a human being until it has been successfully implanted in a woman’s uterus.
Furthermore, some supporters also consider hESC research justifiable for the
advancement of scientific knowledge.
There is also the possibility that there might be an extensive growth in markets
that trade human eggs (Mintrom, 2013). As a result, Mintrom (2013) noted that women
may be incentivized to produce and sell eggs that would then be fertilized to create
embryos for the purpose of destroying them at the blastocyst stage (5 to 7 days after
fertilization) in order to harvest the stem cells. Withrow (2007) pointed out that trading of
human eggs is a common response to the demands of infertile couples who want to gain
access to donor eggs to make a baby. In treating infertility, Mintrom (2013) reported that
more eggs are produced than are used to create viable embryos. Thus, surplus of eggs are
stored, discarded, or donated to research. As a result, those in support of hESC research
have argued that it is morally permissible to use surplus embryos for biomedical research
that may save many lives. However, those who oppose hESC research do not agree with
this argument and have argued that such research would still support the destruction of
embryos. Levine (2011) related that due to the divisiveness of the hESC research debate
and the history of policymaking in other morally charged areas, policy certainty will
continue to prove difficult. Hence, some degree of uncertainty may be unavoidable and as
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a result, hESC researchers should prepare for continued policy changes, legal challenges,
and other challenges to their research.
Embryonic Stem Cell Research
This section discusses effective procedures that should be used when conducting
biomedical research, ESCs in relation to regenerative medicine, and possible ways to
improve stem cell research policy in the United States. It is organized in the following
subsections: improvements in biomedical research, embryonic stem cell and regenerative
medicine, and improving stem cell research in the United States.
Improvements in Biomedical Research
To develop future innovations in health care and prevention, research is needed
across a wide range of biomedical science (AAMC, 2015b). The AAMC (2015b) related
that this includes basic and translational research, which would be used to implement
science and comparative effectiveness research. Maintaining a valid and sound
foundation for credible research with an enriched mission statement is needed to provide
long-term healthcare outcomes, maintain a patient-centered environment, and minimize
health disparities. Further, the AAMC reported that they work to ensure that integrity,
privacy, and confidentiality remain an important part of innovation and improvement in
research. Partners in improving research include the NIH, Agency for Healthcare
Research and Quality (AHRQ), and the Department of Veterans Affairs (VA).
Another measure used to improve research is working with medical colleges and
teaching hospitals to reduce conflict of interest and to gain insight on how effective
programs instituted are working (AAMC, 2015b). The AAMC (2015b) related that
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information on annual aggregate data about conflict of interest systems, disclosures
submitted by investigators to institutions, and financial conflict of interest are reported to
the appropriate federal agency to help improve research metrics and transparency
initiatives. The NIH developed strict policies and procedures that must be followed when
providing quality research (National Institute of Neurological Disorders and Stroke
[NINDS], 2014). According to NINDS (2014), several committees have been developed

to oversee appropriate unit and site set-up for clinical trials in progress. The following
steps are used to ensure research remains safe and ethical, and these steps often lead to
new products and innovation for new procedures:
1. Establish a manual of operating procedures (MOP) and ensure that clinics and
labs use the same examination procedures.
2. Use data analysis to track errors and omissions.
3. Specify quality control measures.
4. Put metrics in place to keep information confidential.
5. Obtain a signed informed consent form.
6. Practice due diligence for eligibility.
7. Communicate the plan to all involved in the research process.
8. Keep a staff roster.
9. Implement training.
10. Track participant retention, where necessary.
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Embryonic Stem Cell and Regenerative Medicine
The study of regenerative medicine has been around for more than 20 years
(Mason & Manzotti, 2010). Mason and Manzotti (2010) reported that the cell-based
therapy industry has manufactured over 675,000 units of therapy and cured more than
323,000 patients. The CIRM (2015b) discussed the potential of stem cells to treat many
diseases. The CIRM reported that in stem cell transplant, ESCs are specialized into the
necessary adult cell type and those mature cells replace damage tissue that is diseased or
injured. Other types of treatment include the replacing of neurons damaged due to a
spinal cord injury, stroke, Alzheimer’s disease, and Parkinson’s disease or other
neurological problems. In addition, this type of treatment could be used to produce
insulin to treat people with diabetes and heart muscle cells after a heart attack.
Furthermore, studying stem cells could help in understanding how to induce heart muscle
to repair itself after a heart attack as well as studying disease, identifying new drugs, or
screening drugs for toxic side effects. Thus, there is the potential for researchers to make
breakthroughs in any disease. Clinical trials for ESC-based therapies are currently
underway.
Improving Stem Cell Research in the United States
Although the controversy over embryo destruction continues, two developments
have helped the proponents’ public debate over hESC research (Hyun, 2010). Hyun
(2010) related that first is the creation of human induced pluripotent stem (iPS) cells,
which are genetically engineered to act like hESCs and second is the Obama
administration’s friendlier stance toward hESC research. The researcher noted that the
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main bioethical considerations now focuses more on how stem cell research should be
conducted instead of whether it should be conducted. Those who oppose hESC research
applauded the iPS cell revolution, which they hoped would end ESC research. However,
most stem cell researchers believe that iPS or other alternative source of stem cells do not
take away the need for ongoing hESC research.
Summary and Conclusions
Scientists have noted the potential of stems cells to treat a wide range of diseases,
such as spinal cord injury, stoke, Alzheimer’s disease, and Parkinson’s disease (CIRM,
2015b). Liberal stem cell policies in many countries, such as in the UK, China, Japan,
Belgium, and Sweden, have resulted in these countries making further progress in hESC
research by producing more stem cell lines (Nature Cell Biology, 2010). On the other
hand, policy uncertainty has affected hESC in the United States (Levine, 2011). As a
result, Levine (2011) recommended that lawmakers who are supportive of hESC research
should work to create policies that reduce the uncertainty facing stem cell scientists.
Nature Cell Biology (2010) related that each state government will create restrictive
policies for stem cell research within their borders, where several states have already
done so, but a liberal policy at the federal level also softens the tone of hESC debate and
promote greater acceptance of such research within the United States. As a result, from a
policy perspective, more remains to be done to ensure that stem cell research flourishes in
the United States.
Due to the problem that federal support and funding for hESC research in the
United States are still behind stem cell programs in many countries, the divisiveness of
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the debate over hESC research, and the continually evolving federal policies that have
further hindered research efforts (Levine, 2011; Mintron, 2013; Nature Cell Biology,
2010), in this phenomenological research study, I explored the perceptions of stem cell
researchers, stakeholders, and investors in the United States about the effects of the
current federal stem cell policy on stem cell research in the United States. I also explored
the moral disagreement with stem cell research and participants’ recommendations to
improve stem cell research policy in the United States. Rogers’s (1962) DOI theory and
Kingdon’s (1995) agenda-setting theory served as the theoretical foundation of this study.
Dresser (2010) related that the debate over stem cell research offers an opportunity to
examine a variety of ethical and policy issues raised by biomedical innovation.
Kingdon’s problem, policy, and politics streams, plus the opening of the policy window,
resulted in the issue of public funding for hESC being placed on the decision agenda.
Thus, the possibility of change is at its greatest when all three streams come together
(Soroka, 1999).
In Chapter 2, I included the introduction, literature search strategy, theoretical
foundation, Dickey-Wicker Amendment, United States national policies, international
communities’ stem cell policies, bioethics and the moral debate, embryonic stem cell
research, and a summary and conclusions. In Chapter 3, I include the introduction,
research design and rationale, role of the researcher, methodology, issues of
trustworthiness, and a summary. In Chapter 4, I include the introduction, setting,
demographics, data collection, data analysis, evidence of trustworthiness, results, and a
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summary. In Chapter 5, I include the introduction, interpretation of findings, limitations
of the study, recommendations, implications, and a conclusion.
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Chapter 3: Research Method
In this study, seven U.S. stem cell researchers’, seven U.S. stakeholders’, and
seven U.S. investors’ perceptions were explored about the effects of the current federal
stem cell policy on stem cell research in the United States, the moral disagreement with
stem cell research, and recommendations to improve stem cell research policy in the
United States. Using snowball sampling, I collected data using telephonic semistructured
interviews. Transcribed interview data were managed with NVivo, and data were
analyzed using Attride-Stirling’s (2001) six steps of thematic coding. The study was
conducted in accordance with the parameters established by Walden University’s IRB to
ensure the ethical protection of participants. The IRB approval number was 06-16-160073123. Chapter 3 includes the research design and rationale, role of the researcher,
methodology, issues of trustworthiness, and a summary.
Research Design and Rationale
This section contains the research questions and phenomenological design
rationale.
Research Questions
To explore the perceptions of 21 U.S. stem cell researchers, stakeholders, and
investors about the effects of the current federal stem cell policy on stem cell research in
the United States, the moral disagreement with stem cell research, and recommendations
to improve stem cell research policy in the United States, I asked the following research
questions:
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1. What are U.S. stem cell researchers’, stakeholders’, and investors’ perceptions
about the effects of the current federal stem cell policy on stem cell research
in the United States?
2. What are U.S. stem cell researchers’, stakeholders’, and investors’ perceptions
about the moral disagreement with stem cell research?
3. What do U.S. stem cell researchers, stakeholders, and investors recommend to
improve stem cell research policy in the United States?
Phenomenological Research Design Rationale
A phenomenological design was used to explore stem cell researchers’,
stakeholders’, and investors’ perceptions. Through the use of this design, the meaning,
structure, and essence (Dalberg, 2006) of participants’ experiences in dealing with policy
issues around stem cell research were examined. Purposive sampling, specifically
snowball sampling, was used to collect data through in-depth semistructured interviews
with 21 stem cell researchers, stakeholders, and investors in the United States. Data were
analyzed using Attride-Stirling’s (2001) six steps of thematic coding.
A quantitative research method was not used for this study because subjective
behaviors, beliefs, and opinions cannot be measured with standardized instruments.
Instead, a qualitative research method was used because it allowed for the understanding
of the complex and holistic picture of participants’ experiences. Patton (2002) reported
that qualitative research is used to explore and understand social conditions or problems
faced by individuals and groups. In this study, the qualitative research method was used
to explore the effects of the current federal stem cell policy on stem cell research in the
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United States, the moral disagreement with stem cell research, and recommendations to
improve stem cell research policy in the United States.
Five qualitative designs considered for this study included narrative research,
phenomenology, grounded theory, ethnography, and case study (McCaslin & Scott,
2003). After an extensive review of the five designs, I chose the phenomenological
design. Phenomenological research designs are used when the researcher is trying to
understand the essence of experiences about a phenomenon (Moustakas, 1994), such as
the current federal stem cell policy on stem cell research in the United States. Moustakas
(1994) reported that the use of a phenomenological design help researchers to gain a
unified vision of the essence of a phenomenon or experience.
Role of the Researcher
I served as a participant-observer during the in-depth semistructured interviews. I
had direct contact with participants as I recruited them by e-mail and telephone. I
collected interview data, which I transcribed, coded, analyzed, and interpreted. No
personal or professional relationships existed between research participants and me.
Therefore, I had no power over potential participants, and they participated without
feeling coerced or obligated to take part in the study. In addition, I had no bias against
potential participants, and I respected their rights and did not exploit them. All
participants’ perceptions were considered, and there were no conflicts of interest in the
study. Upon successful completion of this study, I will e-mail each participant a summary
of the findings.
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Methodology
This section contains the following subsections: participant selection and
sampling strategy, instrumentation and data collection, procedures, and data analysis
plan.
Participant Selection and Sampling Strategy
Snowball sampling is a subset of purposive sampling, where the researcher begins
by identifying someone who meets the criteria for inclusion in the study and then asks the
individual to recommend others whom they know meet the study’s criteria (Trochim,
2006a). Snowball sampling was used to identify participants with expertise in the field of
stem cell research. Seven stem cell researchers, seven stem cell stakeholders, and seven
stem cell investors in the United States were used in the study. Mason (2010) reported
that the sample size in qualitative studies is normally small in comparison to quantitative
studies. For phenomenological studies, Klenke (2008) reported that the sample size might
range from two to 25 participants, while Morse (1994) recommended at least six. For the
current study, 21 participants were used to explore experiences regarding stem cell
research. Saturation is the point in data collection when the collection of new data does
not shed any further light on the issue under investigation (Glaser, Strauss, & Strutzel,
1968). The relationship between saturation and sample size was sufficient in this study
because through the use of snowball sampling, I included 21 participants to obtain the
richest data possible. Saturation was reached with 21 participants. Potential participants
were recruited using the snowball sampling strategy, and included 122 men and women
who met the selection criteria of being a current stem cell researcher who worked at a
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government organization, private company, or university; a stem cell stakeholder who
was a faculty member at a university where stem cell research was being conducted; or
an investor who worked for a government organization or private company that invested
in stem cell research in the United States. Potential participants were sent an invitation
letter to participate in the study and were asked to recommend other stem cell
researchers, stakeholders, or investors who met the selection criteria (see Appendix A).
Instrumentation and Data Collection
I used a 45-minute researcher-developed interview questionnaire to collect data
about perceptions of stem cell research in the United States. The questionnaire was
structured to elicit stem cell researchers’, stakeholders’, and investors’ perceptions about
the effects of the current federal stem cell policy on stem cell research in the United
States and the moral disagreement with stem cell research. Additionally, participants
were asked about their recommendations to improve stem cell research policy in the
United States. The interview guide contained an introduction, welcome, discussion
purpose, discussion guidelines, general instructions, possible probes, interviews
questions, and a conclusion (see Appendix B). The interview questions were open ended
to provide for a deep exploration of the stem cell topic. Through the use of open-ended
questions, participants were able to provide detail, and I was able to probe deeper to gain
a better understanding of the responses (see Turner, 2010).
Procedures
I completed the NIH Office of Extramural Research Human Research Protections
training (see Appendix C). I also complied with all federal and state regulations such as
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the Georgia Department of Public Health’s (2015) directive to obtain legal informed
consent from potential participants or their legal representative prior to their participation
in the study. After I received Walden University’s IRB approval to conduct the study, I
contacted potential participants by e-mail or telephone who were known to meet the
selection criteria. Contact information for stem cell researchers, stakeholders, and
investors was obtained from personal contacts and public information available online. I
did not include anyone with whom I had a personal relationship, including family
members, friends, coworkers, or professional and personal associates, to prevent
perceived coercion to participate. I asked professional and personal associates if they
knew individuals who met the study’s criteria to get snowball sampling going. I also used
public information available online through organizations such as Microbot Medical Inc.
(2017) and Cell Therapy Foundation (2014) to obtain information about those involved in
stem cell research. I looked up their public contact information from individual
companies’ websites. I also used the NIH (2015c) stem cell information about
organizations, advocacy groups, professional associations, federal government sites, and
others involved in stem cell research. I reviewed those resources and found public contact
information for potential participants.
I sent potential participants an invitation letter and asked them to recommend
other stem cell researchers, stakeholders, or investors who met the selection criteria by
providing their personal contact information or public work contact information, but not
their nonpublic work contact information (see Appendix A). Participants were informed
that they could ask questions about the study by e-mail or telephone. Potential
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participants were asked to complete the questions on the invitation letter and e-mail them
back to me if they were interested in participating in the study. Their responses to the
questions helped me ensure that they met the selection criteria. Once I received the e-mail
responses to the questions asked on the invitation letter, I e-mailed prospective
participants the consent form and requested their consent by asking them to reply to the
e-mail with the words “I consent.” Participants were also informed that they could ask
questions before giving their consent and at any time during the interview process.
Once participants gave their consent, I contacted them by telephone or e-mail to
set up an appointment to conduct individual semistructured interviews by telephone at a
time that was convenient for them. Telephonic interviews were conducted because some
participants resided in different states. Interviews were audio-taped and took
approximately 45 minutes (see Appendix B). Before concluding the telephonic
interviews, I asked participants if they had any questions or concerns. After all questions
or concerns were addressed, I concluded the interviews and thanked participants for their
participation. It was unlikely that participation would arouse discomfort; however, I
provided participants with reasonable protection from psychological distress by
informing them that they could seek counseling by calling the Substance Abuse and
Mental Health Services Administration’s (SAMHSA’s, 2014) national helpline at 1-800662-4357 should they experience any negative effects from taking part in this study.
After the interviews were transcribed, I e-mailed each transcript to the participant
to review for accuracy. Transcription review is a quality control process that ensures the
accuracy, credibility, and validity of what was recorded during the interviews (Harper &
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Cole, 2012). I discussed the participants’ feedback with them by telephone. The
transcription review process took approximately 20 minutes. Once this study is
completed, I will e-mail a summary report of the research findings to each participant.
Data will be secured in a locked file cabinet and password-protected computer in my
private home office. I am the only one with access to the records. Data will be kept for a
period of at least 5 years, as required by Walden University. After that period, data will
be properly destroyed using techniques such as shredding and demagnetizing.
Data Analysis Plan
To analyze the interview questions, I transcribed the interviews using WebEx
audio playback. I then transferred the transcripts to NVivo analysis software, which
assisted in managing the data. The next step was to analyze the data using the AttrideStirling’s method (2001), which outlines six steps or stages of thematic coding, which is
discussed in further detail below. NVivo is a software program designed to facilitate
qualitative data analysis (Zamawe, 2015). NVivo provided a way to manage and organize
the interview transcripts so that I could logically identify thematic phrasing. NVivo
allows the researcher to upload files such as transcripts, select parts of the document, and
label them with particular descriptions (Zamawe, 2015). NVivo also produces word
frequency counts, charts of the labels that are used most often, and text searches
(Zamawe, 2015). The labels can be organized into categories, notes can be made about
links between labels and concepts, and relationships can be created between labels and
documents (Zamawe, 2015). Finally, for the results sections, tables can be created to
present data and display the major and minor themes for each research question.
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Coding and categorization of interview transcripts facilitated thematic analysis of
the interview data. I followed Attride-Stirling’s (2001) six steps on how to conduct a
thematic analysis and the steps are modified to properly fit this specific research study’s
methodology:
1. Analysis stage A: The reduction or breakdown of text: Step 1. Coding of
material: (a) devised a coding framework and (b) dissected or divided text into
text segments using the coding framework in Step 1a. Step 2. Identifying of
themes: (a) abstracted themes from coded text segments and (b) refined and
edited themes. Step 3. Constructing of thematic networks: (a) arranged
themes, (b) selected codes or the other essential perceptions of the
participants, (c) rearranged into themes and codes (with the themes as the ones
with the highest responses and the codes as the ones that followed), (d)
illustrated as thematic networks or groups, and (e) verified and refined the
networks.
2. Analysis stage B: Exploration of text: Step 4. Described and explored
thematic networks or groups: (a) described the network or group and (b)
explored the network or group. Step 5. Summarized thematic networks or
groups.
3. Analysis stage C: Integration of exploration: Step 6. Interpreted the patterns.
4. During data analysis, I found no discrepant cases. Themes and subthemes
emerged during the data analysis process, which are discussed later in the
results section in this chapter.
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I found no discrepant cases during data analysis. Themes and subthemes emerged
during the data analysis process, which are discussed later in the results section in
Chapter 4. Preliminary themes included ethical concerns, religious influence, funding
shortages, end use of stem cells, and concerns about NIH guidelines. Table 2 in Chapter 4
provides the theories, preliminary themes, and subthemes based on my literature review
and theoretical frameworks, which served as a starting point of my data analysis.
Issues of Trustworthiness
Qualitative research has richness to it and as such, data must be coded and
interpreted correctly during the collection and evaluation process to ensure a level of
trustworthiness (Moretti et al., 2011). This section is organized in the following
subsections: validity and reliability of qualitative data and ethical procedures.
Validity and Reliability of Qualitative Data
In this qualitative phenomenological study, validity and reliability were
established through credibility, transferability, dependability, and confirmability.
According to Shenton (2004), credibility or internal validity is one of the most important
factors in establishing trustworthiness and refers to how congruent the findings are with
reality. In this study, credibility was established through transcription reviews. I e-mailed
each participant the transcript of the interview and asked that they review the transcript
for accuracy. I discussed participants’ feedback with them by telephone or e-mail.
Transferability or external validity refers to the extent to which the study’s
findings can be applied to other situations (Shenton, 2004). Findings from this study
might be applicable to similar stem cell researchers, stakeholders, and investors in the
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United States who have had similar experiences. Merriam (2009) noted that rich, thick
description in reference to the setting, the participants, and the findings of the study is
one strategy that can be used to establish transferability. It is also the responsibility of the
qualitative researcher to describe the context of the study and its participants in detail so
that the possibility of replication exists. Hence, I provided a rich, thick description of the
context of the study and the participants. I also supported the findings of this study
through the use of direct quotes and summaries of participants’ interview responses.
Dependability is the qualitative counterpart to reliability. According to Shenton
(2004), the study’s processes should be reported in detail, which enables future
researchers to repeat the work. However, this does not necessarily mean that same result
will be obtained. In this study, dependability was established through audit trails, which
involves a thorough collection of documentation for all aspects of the research (Rodgers,
2008). Documentation that were used in this study included tape recorded interviews,
transcriptions of those interviews, and transcription reviews; thus, data were
authenticated by comparing these forms of data.
Confirmability is the qualitative counterpart to objectivity. Trochim (2006b)
reported that confirmability is the degree to which the research results can be confirmed
or corroborated by other researchers. Therefore, I ensured that the data and interpretations
of the findings were not a figment of my imagination, but were clearly derived from the
data (Tobin & Begley, 2004). In addition, I established confirmability through reflexivity,
which is the process of reflecting critically on the self as researcher (Merriam, 2009). I
used the strategy of reflexivity where I reflected on any biases that I may have about the
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effects of the current federal stem cell policy on stem cell research in the United States,
the moral disagreement with stem cell research, and recommended ways to improve stem
cell research policy in the United States.
Ethical Procedures
The NIH human research protection training was completed (see Appendix C). I
also complied with all federal and state regulations. The study was also conducted in
accordance with the parameters established by Walden University’s IRB to ensure the
ethical protection of research participants. The data I collected present no greater than
minimal risk and I followed Walden University’s IRB guidelines to protect the data that
were generated from the interview questions, such as the interview recordings and the
transcriptions.
Before data collection began, all participants were e-mailed a consent form that
had been approved by the Walden University IRB; thus, obtaining their permission to
participate in the study. The consent form outlined participants’ protections and ethical
guidelines that were followed during the research study. These guidelines included the
voluntary nature of the study and participants’ right to withdraw at any time without fear
of reprisal or penalty. The consent form also outlined any physical or psychological risks
that participants might experience and indicated that participants were not obligated to
complete any part of the study with which they were not comfortable. It was unlikely that
participation in this study aroused any acute discomfort; however, participants were
referred to the SAMHSA’s national helpline at 1-800-662-4357 if they experienced any
negative effects.
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Participants were provided with my contact information and the contact
information for my Dissertation Committee Chair in the event that they had any further
questions or concerns about the research. Participants were provided with the contact
information of the Walden University representative with whom they could talk privately
about their rights as participants. I respected all participants during the research process
and data collection stage. After data were collected, all identifiable data were eliminated;
therefore, the interviews were numbered or coded to match the participant. This protected
participants’ identities; however, I knew the identity of the participants. Thus, all
participants’ identity were kept confidential.
Participants were informed that the interviews would be audio-taped and that a
verbatim transcription would be made and analyzed later. I have kept all audio-recorded
data secured, which I transcribed. Only my supervising committee had access to the data.
All data are kept in a locked file cabinet and password protected computer in my personal
home office for at least 5 years, as required by Walden University. Data will be properly
destroyed after that time period using methods such as shredding and demagnetizing.
Once this study is completed successfully, a summary report of the research findings will
be e-mailed to each participant.
Summary
In this study, seven U.S. stem cell researchers’, seven U.S. stakeholders’, and
seven U.S. investors’ perceptions were explored about the effects of the current federal
stem cell policy on stem cell research in the United States, the moral disagreement with
stem cell research, and recommendations to improve stem cell research policy in the
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United States. The in-depth semistructured interviews were transcribed and transcriptions
were analyzed. Common words or phrases were grouped and labeled for coding across
categories of inquiry. Once data were grouped, subsets were compared and contrasted.
This allowed for the search of related codes and the making of inferences about these
connections or patterns.
In Chapter 3, I included the introduction, research design and rationale, role of the
researcher, methodology, issues of trustworthiness, and a summary. In Chapter 4, I
include the introduction, setting, demographics, data collection, data analysis, evidence of
trustworthiness, results, and a summary. In Chapter 5, I include the introduction,
interpretation of findings, limitations of the study, recommendations, implications, and a
conclusion.

62
Chapter 4: Results
The purpose of this qualitative phenomenological study was to explore the
perceptions of 21 U.S. stem cell researchers, stakeholders, and investors about the effects
of the current federal stem cell policy on stem cell research in the United States, the
moral disagreement with stem cell research, and recommendations to improve stem cell
research policy in the United States. I conducted in-depth telephonic semistructured
interviews with 21 stem cell researchers, stakeholders, and investors in the United States
to answer three research questions: (a) What are U.S. stem cell researchers’,
stakeholders’, and investors’ perceptions about the effects of the current federal stem cell
policy on stem cell research in the United States; (b) what are U.S. stem cell researchers’,
stakeholders’, and investors’ perceptions about the moral disagreement with stem cell
research; and (c) what do U.S. stem cell researchers, stakeholders, and investors
recommend to improve stem cell research policy in the United States? The interview
transcripts were analyzed using Attride-Stirling’s (2001) six steps of thematic analysis. In
Chapter 4, I present themes according to their respective research questions. I also
include the setting, participant demographics, data collection, data analysis, evidence of
trustworthiness, and a summary.
Setting
I used snowball sampling in the Southeast, Northeast, Midwest, and West Coast
regions of the United States. Telephonic interviews took place from July 6, 2016 to
September 29, 2016. There were no personal or organizational circumstances that may
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have influenced participants’ experiences at the time of the study or that may have
influenced my analysis of the data.
Demographics
From the 43 researchers, 47 stakeholders, and 32 investors who were initially
contacted, I chose seven stem cell researchers, seven stem cell stakeholders, and seven
stem cell investors in the United States to participate in the study. Thirteen out of 21
participants (62%) were female, and eight out of 21 participants (38%) were male. Stem
cell researchers worked at a private company or university, stem cell stakeholders were
faculty members at a univeristy where stem cell research was being conducted, and stem
cell investors worked for a government organization or private company that invested in
stem cell research in the United States. Eight female participants worked in the private
sector, four at a university, and one in the government. Two male participants worked in
the private sector, four at a university, and two in the government. Six female participants
were researchers, four were investors, and three were stakeholders. One male participant
was a researcher, three were investors, and four were stakeholders. The participant
demographics are summarized in Table 1.
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Table 1
Participants’ Demographics
Participants

Gender

Classification

Work sector

Acronym

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21

Female
Male
Male
Male
Male
Female
Male
Female
Female
Female
Female
Male
Female
Female
Female
Female
Female
Female
Female
Male
Male

Researcher
Investor
Stakeholder
Researcher
Investor
Investor
Stakeholder
Investor
Stakeholder
Investor
Stakeholder
Stakeholder
Researcher
Investor
Stakeholder
Researcher
Researcher
Researcher
Researcher
Stakeholder
Investor

Private
Government
University
Private
Government
Private
University
Private
University
Private
University
University
University
Government
University
Private
Private
Private
Private
University
Private

FRP
MIG
MSU
MRP
MIG
FIP
MSU
FIP
FSU
FIP
FSU
MSU
FRP
FIG
FSU
FRP
FRP
FRP
FPR
MSU
MIP

Data Collection
I developed an interview guide to collect data about participants’ perceptions of
stem cell research in the United States. The interview questions were used to explore
participants’ perceptions of (a) the effects of the current federal stem cell policy on stem
cell research in the United States; (b) the NIH ethical policies regarding human ESC
research and their effect on stem cell research in the United States; (c) whether U.S. stem
cell researchers have benefited from President Obama’s more relaxed funding policies;
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(d) how the Dickey-Wicker Amendment restricts the use of federal funds for creating,
destroying, or knowingly injuring human embryos; (e) how the U.S. stem cell policy has
diminished or improved U.S. stem cell research competitiveness with other countries; (f)
how the U.S. can become more competitive with other countries that they lag behind in
relation to stem cell research; (g) the moral disagreement with stem cell research; (h) how
stem cell proponents and opponents can compromise on stem cell research; and (i)
recommendations to improve stem cell research policy in the United States. Interviews
were audio-taped and took approximately 45 minutes. After the interviews were
transcribed, I e-mailed each participant the transcript and asked him or her to review it for
accuracy. The transcription review process took approximately 20 minutes. I incorporated
participants’ feedback in the transcriptions, and no participants’ feedback altered the
original responses in any way.
Data Analysis
Recorded interviews were transcribed, data were managed with NVivo, and data
were analyzed using Attride-Stirling’s (2001) six steps of thematic analysis. The steps
were modified to fit the current study’s methodology. Table 2 depicts the preliminary
themes and subthemes that served as a starting point for the data analysis, along with
their theoretical backgrounds.
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Table 2
Theoretical Origins of Preliminary Themes and Subthemes
Theories
Agenda-setting theory

Preliminary themes
Policy stream

Subthemes
• NIH guidelines
• Dickey-Wicker
Amendment
• Political orientation of
the executive branch
• Political orientation of
the legislature

Agenda-setting theory

Politics stream

•
•
•
•

Diffusion of innovations

Persuasion stage

• Religious influences
• Medical value of
research
• Misconceptions about
research, including
perceived link to
abortion

Diffusion of innovations

Knowledge stage

• Shifts in public
perception
• Advances in
knowledge (e.g.
iPSCs)

Ethical considerations
Religious influences
Funding shortages
International
competition
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1. Analysis Stage A: The reduction or breakdown of text. In Step 1, I devised a
coding framework and dissected or divided text into text segments using the
coding framework. In Step 2, I abstracted themes from coded text segments
and refined and edited themes. In Step 3, I arranged themes, selected codes or
other essential perceptions of the participants, rearranged codes into themes
(with the themes as the ones with the highest responses and the codes as the
ones that followed), illustrated as thematic networks or groups, and verified
and refined the networks.
2. Analysis Stage B: Exploration of text. In Step 4, I described the network or
group and explored the network or group. In Step 5, I summarized thematic
networks or groups.
3. Analysis Stage C: Integration of exploration. In Step 6, I interpreted the
patterns.
During the data analysis phase, no discrepant data were found. Table 3 presents
the number and percentages of the themes that emerged during data analysis in relation to
stem cell researchers’, stakeholders’, and investors’ perceptions. Number of occurrences
refers to the number of times a theme occurred in the interview transcripts. Percent of
occurrences is the total number of occurrences of the theme divided by the total number
of occurrences of all themes in the interview transcripts.
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Table 3
Theme Occurrences and Percentages for Stem Cell Researchers’, Stakeholders’, and
Investors’ Perceptions
Themes

No. of occurrences

% of occurrences

Perceptions of federal
policy

142

65%

Perceptions of moral
disagreement

44

20%

Policy recommendations

34

15%

Total

220

100%

Evidence of Trustworthiness
In this qualitative phenomenological study, I established validity and reliability
through credibility, transferability, dependability, and confirmability. I established
credibility through transcript reviews. I e-mailed each participant the transcript of the
interview and asked that he or she review the transcript for accuracy. I discussed
participants’ feedback with them by telephone or e-mail. I ensured transferability by
providing a rich, thick description of the context of the study and the participants. I also
supported the findings of this study through direct quotes and summaries of participants’
interview responses. I established dependability through the use of audit trails, where I
included documentation for all aspects of the study. Documentation included taperecorded interviews, transcripts of interviews, and transcript reviews; data were
authenticated by comparing these documents. I established confirmability by ensuring
that the data and interpretations of the findings were not a figment of my imagination, but
were clearly derived from the data. In addition, I established confirmability through
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reflexivity by reflecting on any biases that I had about the effects of the current federal
stem cell policy on stem cell research in the United States, the moral disagreement with
stem cell research, and recommended ways to improve stem cell research policy in the
United States.
Results
Based on the data analysis, three overarching themes and 14 subthemes emerged.
The research questions served as the basis for each overarching theme. Thematic analysis
Step 1 or categorization of text appears in Appendix D, which shows all of the
participants’ responses that corresponded with each overarching theme and subtheme. In
the following section, the themes and subthemes are presented according to their
corresponding research question.
Research Question 1
What are U.S. stem cell researchers’, stakeholders’, and investors’ perceptions
about the effects of the current federal stem cell policy on stem cell research in the United
States? One overarching theme and five subthemes emerged to answer this research
question. Participants’ perceptions of U.S. federal stem cell policy varied widely. Some
participants perceived the policy as beneficial, others perceived it as irrelevant, and some
perceived it as a constraint on stem cell research. Participants who perceived the federal
stem cell policy as beneficial to U.S. stem cell research expressed their approval, stating
that the Obama administration’s comparatively relaxed funding policy was more
advantageous to stem cell researchers than the Bush administration’s restrictions,
although the Obama administration’s policy was not necessarily optimal. Other
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participants reported that funding restrictions, which only affected research conducted on
hESCs, had lost much of their significance with the increasing prevalence of research
involving iPS cells and adult stem cells. Six participants (29%) indicated that current
funding restrictions prescribed by the Dickey-Wicker Amendment were invalidated by
their reliance on justifications that were perceived as irrational, and 13 participants (62%)
agreed with the amendment. Almost all participants, however, agreed with the NIH
ethical policy, with 17 of the 21 participants (81%) describing the policy as a valuable
means of promoting ethical science.
In regard to the context of each research setting, 92% of all participants believed
that the Obama administration’s more relaxed stem cell policy was as a positive step in
the right direction. Researchers’ perception on the effects of the Obama administration’s
federal stem cell policy is that it is restrictive but they are moving forward by doing
research in other countries, using less hESC research, and engaging more in adult stem
cell research. Investors’ and stakeholders’ perceptions were closely aligned in how they
perceived the Obama administration policy, where they noted that it is not very
restrictive, but federal funding on new lines of hESC research is still restrictive; thus,
research can continue with private donations. Most researchers agreed with the NIH
policy as they understood the need for strict supervision. Five of the seven investors
(71%) agreed with the NIH policy and noted that it was necessary to protect donors,
while three out of seven stakeholders (43%) agreed with the NIH policy. Researchers,
investors, and stakeholders who did not agree with the NIH policy described the policy as
confusing because it did not provide clear differences between hESCs and adult stem
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cells and their uses for research. Stakeholder and investors who disagreed with the
Dickey-Wicker Amendment described it as a religious agenda. On the other hand,
researchers discussed the limited scope of the amendment, but emphasized the
legislation’s negative effect on research. Participants agreed that stem cell policy changes
from each administration made it challenging to compete with other countries.
Researchers emphasized that the best way to be more competitive was to educate people,
increase funding, and do more clinical trials. Table 4 depicts the occurrences and
percentages for perceptions of the effects of Obama administration’s federal stem cell
policy theme and subthemes.
Theme 1: Perceptions of the effects of the Obama administration’s federal
stem cell policy. This theme has five subthemes, which are as follows: (a) overall
perceptions; (b) perceptions of the Obama administration’s funding policy, which is the
policy that was created to inform applicants and grantees of the conditions that must be
met in order for the NIH to fund stem cell research; (c) perceptions of the NIH’s ethical
policy, which was developed based on President Obama’s EO 13505 to ensure
researchers were informed of the new processes needed to conduct human stem cell
research; (d) perceptions of the Dickey-Wicker Amendment, is an amendment attached to
the appropriation bills ensuring that no federal funds get used for creating, destroying or
knowingly injuring human embryos; and (e) perceptions of competition between the
United States and other countries. Participants’ responses are categorized in the five
subthemes below.
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Table 4
Subtheme Occurrences and Percentages for Perceptions of the Effects of Current Federal
Stem Cell Policy
Theme
Subthemes
Perceptions of the
Overall perceptions
effects of the
current federal stem Funding policy
cell policy
NIH ethical policy

No. of occurrences
24

% of occurrences
17%

28

20%

24

17%

Dickey-Wicker
Amendment

24

17%

Competition with
other countries

42

29%

Total

142

100%

Subtheme 1: Overall perceptions. Participants’ perceptions of U.S. federal policy
on stem cell research varied considerably. Only a few participants expressed approval of
the Obama administrations’ policy. Participant 12 (MSU) stated, “I do believe the current
federal policy is for the betterment of science research and will have positive long-term
effects on disease and disease treatment.” Participant 13 (FRU) discussed the difference
between the policies of the Bush and Obama administrations, noting that the “current
federal stem cell policy has certainly boosted stem cell research considerably over the last
7 years.” Participant 13 also stated:
[The Obama administration’s policy] has allowed stem cell researchers more
flexibility in choosing cell lines of interest. In addition, there has been more
investment in stem cell research, which has resulted in significant milestones
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being achieved in stem cell research in the United States. Importantly, multiple
clinical trials have been initiated for stem cell therapy of degenerative diseases.
Participant 21 (MIP) indicated that the current stem cell policy is permissive
because it does not limit scientists’ abilities to address interesting and important
questions. On the other hand, Participant 7 (MSU) related that despite the thoughtfulness
of the current stem cell policy, it is still restrictive in terms of access to carry out
research. Participant 6 (FIP) related that while the current stem cell policy makes it easier
to do more research, funding is still slow due to past policies and restrictions. Participants
1, 14, 15, and 20 described the policy as a significant constraint. Participant 1 (FRP)
noted that despite all the testing that is taking place, the benefit from stem cell is still not
fully realized. Participant 14 (FIG) pointed out that restrictive policies could have a
negative effect on the international standing of U.S. stem cell research because major
research companies move their stem cell research division to “other countries where
scientists are permitted to conduct research without any restriction.” Participant 15 (FSU)
perceived the policy as negatively affecting medical research due to limiting ESC
research as well as rapid advancement in therapeutic approaches and applications.
Participant 15 also noted that the federal stem cell policy does not affect her research and
that progress has been made despite how strict the policy may be. Similarly, Participants
15 and 20 reported that while the policy does limit ongoing research, its effects are
limited due to the use of iPS cells and some researchers have moved to countries where
there is less stem cell restrictions.
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Similarly, Participant 16 (FRP) related that there may be limits on what research
can be carried out using ESCs with federal funds, but most research is concentrated on
the use of adult stems in the United States. Other part participants described the effects of
the federal policy on stem cell research as limited or negligible, such as Participant 10
(FIP) who noted that the current research that she is a part of is not affected by federal or
state regulations because they are using iPS cells, which are generated from fibroblasts
donated by patients. Similar to Participant 10, Participant 11(FSU) shared that
government restrictions are less of a concern as researchers increasingly include adultderived stem cells and iPSCs. Participant 11 further shared that few of her “colleagues
are performing research with ESCs, though this may change concurrently with changes in
policy.” Participants 3, 18, and 19 also discussed the use of adult-derived stem cells as a
viable alternative to ESCs. Participant 3 (MSU) related that the federal stem cell policy is
not very restrictive since researchers can use ESC lines as well as adult-derived stem
cells. In addition, Participant 3 noted that ESCs can be derived from nonhumans as well
as from skin cells. Participant 18 (FRP) and participant 19 (FRP) related that the policy
does not have an effect or is an issue as research is more inclusive of adult stem cells in
contrast to ESCs.
While Participant 17 (FSU) also noted the limited effects that the stem cell policy
has on research, Participant 15 pointed out a way in which federal restrictions might have
a negative effect on research despite the variety of alternatives to hESCs. Participant 15
stated, “[Federal policy] does not allow us to compare data generated from adult versus
ESC research, which [is] the only way to know if the use of iPS cells is comparable.”
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Participant 8 (FIP) related that that federal policy restrictions related only to federal
funding of research in certain areas and that alternative funding sources were available to
researchers who wanted to work in those areas:
If you mean the ban on federal funding for embryonic research put in place during
the Bush administration and lifted during the Obama administration, it only
banned the use of taxpayer dollars to pay for embryonic research. Taxpayer
dollars have always been a significant source of funding for adult stem cell
research and now iPS cell research. The ban only meant that if you wanted to do
ESC research, you’d have to get private grants or venture capital to cover the
costs. ESC research continued in labs across the country, but was largely
leapfrogged by the discovery of iPS cells in 2012.
Subtheme 2: Perceptions of the Obama administration’s funding policy. On
March 9, 2009, President Obama issued EO 13505, Removing Barriers to Responsible
Scientific Research Involving Human Stem Cells, with the goal of strengthening hESC
research in the United States (Levine, 2011; Nature Cell Biology, 2010). The Secretary of
Health and Human Services, through the Director of the NIH, may support and conduct
responsible, scientifically worthy human stem cell research, including hESC research, to
the extent permitted by law (Obama, 2009). However, President Obama’s new stem cell
policy did not approve the 21 hESC lines that were eligible under the Bush administration
(Levine, 2011). Participants’ perceptions of the Obama administration’s policy fell into
two broad categories, which are as follows: (a) Some participants believed that the
policy’s positive intentions had been realized while (b) others believed that the policy had
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been rendered partially or completely ineffective due to contextual factors. Some
participants perceived the policy as having positive effects and cited significant
advancements in knowledge that were attributed to President Obama’s executive order.
Participant 13 (FRU) stated:
Significant progress has been made in stem cell research over the last 7 plus years
and we are at the cusp of realization of its clinical potential. In addition, there has
been a great push for using stem cell as disease models and for in vitro toxicity
testing. All these advancements can be largely contributed to President Obama’s
funding policies.
Participant 21 (MIP) related the relaxation of funding policies during the Obama
administration has benefitted scientists due to “access to a greater array of hESC lines
and through a greater normalization of the field, reducing some of the complications
associated with working with these cells.” Participant 4 (MRP) related that U.S.
researchers have benefitted from relaxed policies that govern the use of NIH funds to
work on established hESC lines. For example, Participant 4 reported that “there is ample
data to show that different lines of stem cells have intrinsic differences in their ability to
differentiate into different lineages” and when researchers have the ability to use multiple
lines of ESCs in NIH-funded research, they are able “to characterize these differences
and explore the causes to ultimately help understand fundamental properties of
differentiation.” Participant 4 further noted that researchers still have a lot to learn about
stem cell function; thus, research is essential. Participant 12 (MSU) noted that relaxed
federal funding policies led to more private donations, which has been beneficial to stem
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cell researchers. Participants 4, 5, 10, 14, 16, 17, 19, and 20 described the Obama
administration’s funding policy as beneficial to stem cell researchers.
Some participants expressed approval of the current funding policy, such as
Participant 2 (MIG) who believed that the policy was beneficial and made it easier for
researchers to use federal funds to work with new ESC lines. Participant 2 also discussed
President Bush’s stem cell restrictions and noted that the restrictions for researchers in
California were not a problem as the voters in California created the CIRM through
Proposition 71 in 2004, giving the stem cell agency $3 billion to fund stem cell research
in the state. Thus, Participant 2 emphasized that while researchers in other states faced
barriers and strict limits on what they could use their stem cell research funding for, in
California, researchers did not have such problems as they could bypass the federal
government and fund their own research. On the other hand, Participant 3 (MSU) related
that the effects of the more stringent Bush administration policies had a negative effect on
current research in the United States. In addition, Participant 3 questioned whether
researchers have benefitted from the more relaxed Obama administration policy as more
researchers are doing research outside the United States, which he attributed to the Bush
administration policies. Participant 3 stated, “Once you are banned from doing something
and you move on to something else, you don’t usually turn back.” Participant 15 (FSU)
related that scientific research has benefitted from the federal stem cell policy, but noted
that the policy does not go far enough to have a real effect on medical applications.
Participant 4 noted that the Obama administration’s stem cell policy was issued through
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an EO, which can be reversed by any subsequent president; thus, researchers cannot rely
on the indefinite continuation of the current funding guidelines.
Participants 1, 6, 7, and 9 reported that while the federal stem cell policy was
favorable to stem cell research, it had not been implemented. Participant 9 (FSU) stated
that the relaxed funding policies have not really been implemented and compared stem
cell research to travelling to Cuba, which she noted “is still incredibly difficult.”
Similarly, Participant 6 (FIP) related that while there are benefits to the federal stem cell
policy, the full benefit has not been realized. Participants 1 (FRP) and 7 (MSU) related
that while the Obama administration’s stem cell policy is a positive step, stem cell
research is still stagnant and benefits have not increased from 2009 due to a lack of
bipartisan support.
Participant 5 (MIG) reported that researchers have benefitted from the relaxed
restrictions because there are many more hESC lines currently eligible for research
supported by NIH. However, Participant 5 noted that the use of iPS cells has lessened the
need for new hESC lines. In addition, Participant 5 related that the stem cells lines that
were approved for research under the Bush administration appears “to remain the most
heavily used cell lines because researchers are comfortable with them and have been
using them for years.” Participant 8 (FIP) reported that President Obama’s EO did not
make any difference in stem cell research and stated the following:
For most researchers, the problem with embryonic cells is less ethical than
scientific. Embryonic cells multiply at an extremely rapid pace and have a
propensity to form cancers. They can be used for disease modeling and drug
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screening in a lab, but will not be used in people, with the exception of a very
small number of ophthalmology projects, until their cancer-forming properties can
be controlled. In the meantime, iPS cells have leapfrogged the need to use them.
Subtheme 3: Perceptions of the NIH’s ethical policy. hESC lines have to be in
compliance with the NIH strict ethical policies (Nature Cell Biology, 2010). Applicant
institutions proposing research using hESCs derived from embryos donated in the United
States must use human embryos that were created through IVF for reproductive purposes
and that were no longer needed for this purpose (NIH, 2015a). In addition, the hESCs
must be donated by individuals who sought reproductive treatment and gave voluntary
written consent for the human embryos to be used for research purposes (NIH, 2015a).
Most participants agreed with the NIH’s ethical policy. Participant 13 (FRU) reported
that the NIH policy helped to ensure that researchers used stem cell lines responsibly:
The NIH policy restricted the generation of new stem cell lines. However, there
needs to be strict supervision on such ethical policies. ESCs have great power and
ensuring that it is handled responsibly is possible only through strict supervision.
Similar to Participant 13, Participant 4 (MRP) related that all research, including
embryonic and stem cell research, should be done ethically by following approved and
vetted standards. Participant 13 further related that the International Society for Stem Cell
Research (ISSCR) helped create the first set of standards on ethical embryonic and adult
stem cell research and recently released an updated set of guidelines. Participant 13 stated
that all scientific research benefits by following ethical scientific practices and that “there
are many benefits of the new policies and procedures that NIH uses to vet the provenance
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of the lines, including protecting patients and donors and helping to maintain the integrity
of the process.” Participant 21(MIP) described the current ethical policies as “particularly
strict;” but noted that the NIH ethical guidelines represents “a reasonable compromise
between the obligation to protect embryo and gamete donors and the desire to help
advance the science.” Participants 3, 12, and 19 also described the policy as strict while
sharing that they agreed with it. Participant 3 (MSU) also stated:
NIH strict policy . . . promoted the idea of nonembryonic use and moved research
into a different path, which is more universally useful. It also brought up the
ethical issue of how many embryos would be sacrificed to create one transplant,
which then created the ethical issue of who could afford to use this process, in
most cases, meaning only wealthy people could afford to have a chance at using
the therapy from embryonic tissues. ESCs are not very scalable, so to have
something of value, the product or service must be scalable.
Participants 6, 10, 11, 14, 16, 17, 18, and 20 agreed with the policy without any
reservations. However, Participants 5, 7, 8, and 9 expressed concerns about the NIH
policy. Participant 9 (FSU) related that while the NIH ethical policy is scientifically
informed regarding safety and is dynamic as new therapies are always developing, “the
ethical interpretations of ESC use are not scientifically informed and restrictions should
be reevaluated without political or religious input.” Participant 8 (FIP) related that ESCs
used for research purposes have always been harvested from IVF clinics with the express
permission of the individuals involved. Participant 8 stated that the NIH guidelines do not
constitute ethical policy, but clarifies the source of cells. Participant 7 (MSU) described
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the policy as a potential cause of misunderstanding, stating, “The NIH is legally bound to
the policies, and as such, has a limiting impact and causes confusion in people’s minds
about the differences between human embryonic and adult stem cells and their uses for
research.” Participant 5 (MIG) agreed with the ethics of the policy, but believed that
certain issues were not addressed. Participant 5 related that informed consent for the
donors of embryos used to create hESC lines remains an important policy, but he noted
two concerns. In regard to Participant 5 first concern, he related that “the NIH policy on
using only embryos left over from IVF may skew the source of new lines to less than
healthy embryos as these are more likely not to be implanted.” In discussing his second
concern, Participant 5 related that the Food and Drug Administration (FDA) has not kept
up with stem cell science in regard to its guidance or requirements for preclinical studies
needed to move stem cell-based therapies into clinical trials. Participant 5 emphasized
that he is not arguing that researchers should follow the Japanese model and that he has
great concerns about the Reliable and Effective Growth for Regenerative Health Options
that Improve Wellness (REGROW) Act, instead, he noted that he would like to see the
FDA “issue clear guidance and play a more active role in regulating the unregulated stem
cell clinics currently marketing unapproved, untested therapies.” Participant 5 also stated,
Finally, U.S. policy with regard to preventing the FDA from even considering
applications involving genetic engineering or modification of human embryos
should not be enshrined perpetually in law as the Dickey-Wicker amendment has
become . . . . The FDA’s process is slow, laborious, and highly inconsistent. It
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means that therapies can take up to 20 years and billions of dollars to get
approval. Very few companies can afford that time or money.
Subtheme 4: Perceptions of the Dickey-Wicker Amendment. The Dickey-Wicker
Amendment restricts the use of federal funds for creating, destroying, or knowingly
injuring human embryos. Participants’ perceptions of the amendment were divided, with
Participants 2, 4, 5, 7, 9, 13, and 21 disagreeing with the amendment, while Participants
1, 6, 10, 11, 12, 14, 16, 18, and 20 expressed their agreement with the amendment.
Participants 5, 7, and 9 noted that the amendment was irrational. Participant 9 (FSU)
stated, “I strongly disagree [with the amendment]. This is a religious agenda. Females can
discard embryos in late menstruation, yet this is not regulated. We don’t scoop them up,
protect them, [and] have funerals.” Participant 7 (MSU) related that the amendment
created a path that is based on people’s feelings than on science. Participant 5 (MIG)
related that the amendment is a clear case of the nonseparation of church and state, which
puts the beliefs of one religion over that of others and instills those beliefs in federal
legislation. Participant 5 (MIG) also noted that recent technology had limited the effects
of the amendment due to the use of iPS cell technology and the continued addition to the
NIH registry of new hESC lines created with other funds.
Participant 21 (FSU) also described the amendment’s restrictions as limited, but
still significant. Participant 21 (FSU) related that state and private funding have helped
researchers to work around the restrictions, but the restrictions are still a challenge for the
field. Participant 13 (FRU) expressed a similar opinion about the limited scope of the
amendment, but emphasized the legislation’s negative effect on research:
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While it does not restrict the use of hESCs for research purposes, it still restricts
the generation and establishment of new stem cell lines from embryos. While
there needs to be strict supervision regarding use and destruction of embryos, with
the current amendment, the field is restricted to the use of just handful of lines.
Participants 4 and 8 pointed out that IVF embryos that are not used in stem cell
research are usually discarded. Participant 4 related that although the amendment was
designed to protect embryos, it does not do so because although embryos cannot be used
for federally funded research, they are likely discarded when they are no longer needed
for fertility treatments. Similarly, Participant 8 related that individuals have three options
for embryos that are theirs, which are being cryopreserved at an IVF clinic: throw them
away, donate them to research, or continue to cover the costs of storing them indefinitely.
Participant 8 reported that most embryos are discarded.
Participant 3 (MSU) discussed the difficulty of evaluating the amendment and
noted that he did not have an answer about how the amendment restricts the use of
federal funds for creating, destroying, or knowingly injuring human embryos. Participant
3 stated:
This is a complex issue that deals with ethical issues like the use of eggs [in an] in
vitro sterilization clinic . . . . Should they be implanted in another female or used
to further research study? So, with something so complex, it may be best to not
complicate the issue by using those embryos with federal funds, without a clear
purpose in mind. The cells of embryos can become abused if people believe there
is a financial gain from it, so it must be clear what the benefit will be or should be.
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I do not have an answer for this question and believe it needs to be discussed
more at a broader level.
Similarly, Participants 1 and 17 related that the amendment should remain in
place until there is a clear understanding of how hESC can be beneficial and the
amendment should be reviewed annually for changes to funding. Participant 6 (FIP)
reported that the amendment is needed, but it is limiting in relation to federal funds.
Participant 2 (MIG) shared that while the amendment prohibits the use of federal funds
for research on human embryos, it does not limit the use of federal funds for research on
embryonic cell lines; thus, it has a limited effect on stem cell research. However,
Participant 2 noted that this could change with a different administration.
Subtheme 5: Perceptions of competition between the United States and other
countries. Participants discussed their perceptions of the extent to which U.S. federal
policy had slowed U.S. stem cell research relative to the research being conducted in
other countries. Participants 2, 5, 6, 10, 11, 12, 14, 16, 18, 19, and 21 did not believe that
the United States lagged behind other countries in relation to stem cell research.
Participants 10 and 18 shared that the policy has neither diminished nor improved stem
cell research competitiveness with other countries. Participant 21 (MIP) shared that
scientists and institutions worked around the Bush administration’s funding restrictions
with state and private funding and that the United States is among the top tier of countries
producing key stem cell research advances. Participant 5 (MIG) also described U.S.
researchers as succeeding despite the federal policy:
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The United States remains in the forefront, but other countries, the UK in
particular, have in some ways more opportunities to conduct research that it is not
possible to conduct here. My impression is that at least parts of the European
Union also allow more. Fortunately, the sheer size of the biomedical research
enterprise and the amount of funds the United States contributes to research allow
the United States to remain competitive in all but a few areas.
Participants 2 (MIG) and 21 discussed the restrictive funding policy of the Bush
administration. Participant 2 shared that the restrictions during the Bush administration
resulted in U.S. researchers being at a disadvantage compared to researchers in Europe
and Asia. However, Participant 2 noted that the United States no longer lags behind other
countries and in many ways is as or more advanced than most countries. Some
participants shared that the Obama administration’s relaxation of funding restrictions had
improved United States’ competitiveness. Participant 20 (MSU) related that under the
Bush administration, the stem cell policy was too restrictive, but the “current policy is a
good balance of ethics and ability to do research.” Participant 12 (MSU) shared that
United States’ competitiveness has improved, the country does not lag behind in stem cell
research, and an example of this is that his group has had a large growth. Similarly,
Participant 19 (FRP) agreed that the situation for U.S. researchers had been improved due
to the Obama administration’s policies, which have helped the United States to become
more competitive with other countries. Similar to Participants 12 and 19, Participant 7
shared that the Obama administration’s more expansive policy has improved
competitiveness, but researchers “are still restricted to the creation of new lines due to the
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lack of using federal funds.” Participant 12 also argued that if the stem cell policy is
further relaxed, U.S. research could have a global effect.
Some participants noted that the federal policy has hindered U.S. stem cell
research. Participant 1 (FRP) reported that stem cell research has not improved and more
research should be done. Similarly, Participant 13 (FRU) related that U.S. stem cell
policy has diminished United States’ competitiveness with other countries; specifically,
Japan and Europe. Participant 13 also noted that for the last 5 years there has been an
increase in U.S. studies; however, while such studies are at the forefront, the volume of
research and the number of stem cell researchers in the United States are still limited.
Participant 15 (FSU) indicated that restrictions on stem cell research in the U.S. might
give an advantage to other countries, such as China, since the chances for a breakthrough
and discovery are greatly increased in places other than the United States. Participant 15
also recommended that researchers and the stem cell community advocate for more
relaxed stem cell policies as some hESC lines are still needed for research since iPS cells
may not behave exactly the same as embryonic cells. Therefore, Participant 15 noted that
researchers need to continue their examination of all stem cell types since they do not
know which one will be the best to use in therapy. Participant 6 (FIP) shared that due to
limitations in the United States, companies who want to be more competitive do research
in other countries and then bring the results of their research to the United States, which
makes it very costly for everyone to reap the benefits. Participants 8 (FIP) and 9 (FSU)
agreed that federal restrictions were causing the United States to lag in stem cell research.
Participant 8 related that stem cell research in the United States is at a disadvantage due
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to stringent FDA regulatory requirements, which are stricter than those of other countries.
Participant 4 (MRP) related that the federal policy has slowed the creation of new lines of
hESCs, since that research can only be done using nonfederal funds. Participant 4 also
stated, “While funding science to the highest levels makes economic sense for our
country, stem cell research is a global enterprise, and discoveries and stem cell-derived
therapies in one country will benefit those in other countries.”
Research Question 2
What are U.S. stem cell researchers’, stakeholders’, and investors’ perceptions
about the moral disagreement with stem cell research? Based on Research Question 2
analyzed data, one overarching theme and five subthemes emerged to answer this
research question. Participants expressed a variety of perceptions of the moral debate
surrounding hESC research. Some participants believed that opposition to the research
was invalidated either by its subjective or irrational impetus or by its failure to address all
the facts. Participants also noted that the scope of the disagreement was limited to hESCs
and that emerging iPS cell technology might render it moot. Regarding the possibility of
compromise between proponents and opponents of hESC research, two participants were
pessimistic, while other participants viewed iPS cell research as an existing compromise.
Some participants believed that education about hESC research would lead to widespread
acceptance of the technology.
In regard to the context of each research setting, the majority of the participants
agreed that until religion has been removed from the stem cell debate, a compromise is
not possible between opponents and proponents of stem cell research. To improve the
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outcome of stem cell research, participants discussed the need for a bipartisan bill, greater
education, and a stable policy that does not change every 4 to 8 years. Table 5 depicts the
occurrences and percentages for perceptions of the moral disagreement subthemes.
Theme 2: Perceptions of the moral disagreement about stem cell research.
This theme has five subthemes, which are as follows: (a) understanding opposition, (b)
religious or moral objections, (c) stem cell source, (d) reasoning, and (e) the possibility of
compromise. Participants’ responses are categorized in the five subthemes below.
Table 5
Subtheme Occurrences and Percentages for Perceptions of Moral Disagreement
Theme
Perceptions of the
moral disagreement
about stem cell
research

Subthemes
Understanding
opposition

No. of occurrences
5

% of occurrences
11%

Religious or moral
objections

8

18%

Stem cell source

10

23%

Reasoning

4

9%

Possibility of
compromise

17

39%

Total

44

100%

Subtheme 1: Understanding opposition. Participants 10, 11, 12, 16, and 18 noted
that they understood, but did not agree with the ethical objections to hESC research.
Participants 10 (FIP) and 12 (MSU) related that they understood the perceptions and
concerns of the general public in regard to the use and potential misuse of human tissues
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for research purposes. Participants 11 (FSU) and 16 (FRP) acknowledged the
disagreement, but emphasized the necessity for an ongoing dialogue. Participant 11
shared that the disagreement is understandable, but the topic should be further discussed.
Participant 16 stated, “I am sympathetic to it, but at the same time, the beneficial aspects
of this research can be insurmountable, so there needs to be ongoing communication.” On
the other hand, Participant 18 (FRP) noted that everyone has a right to their own belief.
Subtheme 2: Religious or moral objections. Some participants were less
sympathetic toward opponents of hESC research. Participant 1 (FRP) abstained from
making a judgment and shared that “a lot of the moral disagreement is related to the
Christian views related to how embryos are being used to accomplish scientist goals.”
Participant 15 FSU) believed that opposition to hESC research was due to combination of
political calculation and misdirected sentiment:
I do not believe there is a moral disagreement; rather a religious perception and
power calculations to distract the electorate from important social and political
issues. Morality is intimately linked to politics in the United States. We have the
moral obligation to save lives. If the material we use was procured from
spontaneous abortions or medically recommended abortions, we are not
conducting an immoral activity.
Participant 2 (MIG) was sympathetic to stem cell opponents’ belief about stem
cell research and related that there are many people with strong religious faith who are
opposed to the use of fetal tissue or ESCs in research because they consider these a
violation of the sanctity of life. Participant 2 respected those views, but disagreed that the
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use of fetal tissue or ESCs is ethically or morally wrong. Participant 2 noted an
“obligation to pursue the use of these materials in scientific work because of their
enormous potential to save the lives of millions of people around the world who are
currently battling deadly diseases and disorders that have no cures.” Participant 5 (MIG)
reported that the moral disagreement with stem cell research is rooted primarily in
Christianity and discussed the lack of separation of church and state. Participant 5 also
noted that while the adult stem cells have many advantages, they also have limitations
when compared to hESCs.
Participant 14 (FIG) also discussed the connection between religious opposition to
hESC research as well as religious opposition to abortion. Participant 14 noted that many
opponents of stem cell research, like religious leaders, compared stem cell research to
abortion. Participant 14 noted that for the Catholic Church, life begins at conception,
which makes stem cell research comparable to homicide because it results in the
destruction of many embryos. Participant 14 noted that from a moral standpoint, stem cell
research may be perceived as wrong, but researchers are right in doing stem cell research.
Participant 4 (MRP) also discussed the connection between the opposition to abortion and
hESC research. Participant 4 noted that the misperception that hESC research is
connected to abortion will continuously entangle this research in political debates.
Participant 4 argued that embryos no longer needed for fertility treatments will be
discarded as medical waste if they are not donated to science or adopted by another
couple, which rarely occurs. Thus, stopping ESC research does not save the embryos.
Similar to Participants 4 and 14, Participant 3 (MSU) discussed the moral disagreement
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with stem cell research in relation to abortion. Participant 20 (MSU) shared that the moral
disagreement about hESC research was between an ethical consensus among medical
professionals and the subjective reactions of some private individuals. Participant 20
shared that the moral issue is a personal issue because the U.S. policy is in line with most
bioethics considerations.
Subtheme 3: Stem cell source. Three participants out of 21 (14%) noted that the
moral disagreement surrounding stem cell research depended on the source of the cells in
question. Participant 1 (FRP) stated, “In the United States, we get caught up with the
logistics, such as whether the stem cells are being used from human embryos or from
one’s own stem cells, which is two different processes, but is still misunderstood to this
day.” Participant 4 (MRP) related that the disagreement with stem cell research is over
the destruction of embryos to create hESC lines and not over stem cell research in
general. Participant 21 (MIP) related that the debate over the moral status of the embryo
will remain stagnant and will continue to shape public opinion toward the field. On the
other hand, Participant 4 was more optimistic about the chances for a satisfactory
resolution due to emerging technology. Participant 4 stated, “More companies are
moving to fibroblast stem cell [iPSC] research, so the issue will become invalid soon,
essentially making it a nonissue.”
Subtheme 4: Reasoning. Some participants questioned the validity of the debate,
not because the reason for disagreement was religious or moral, but because they
perceived the reasoning of hESC research opponents as flawed. Participant 7 (MSU)
related that the moral disagreement with stem cell research is a nonissue because if

92
people understood that most of the vaccines that “have been derived from these tissues
being discussed and if they looked further into what the actual usage is and reasons are
behind it, most people would understand the importance of the research.” Similarly,
Participant 17 (FRP) related that the moral disagreements with stem cell research are
mainly due to lack of scientific knowledge and factual information because many times
facts are misrepresented, which perpetuates a false perception. Participant 17 believed
that hESC research might be promoted by an appeal to common sense and argued that
instead of wasting stem cells, why not put them to good use that benefits all people.
Participant 8 (FIP) believed that public’s understanding of the controversy was impaired
by equivocal terminology:
There is no moral disagreement about stem cell research. You shed your skin
regularly because skin stem cells are constantly renewing and replacing damaged,
old skin. You can donate a lobe of your liver and it will grow back because liver
stem cells will regenerate it. Every tissue in your body constantly renews itself
through tissue-specific stem cells. To say you have a moral disagreement with
stem cell research is like saying you object to your liver. There is controversy
about the use of ESCs for research, but I see it as a far greater issue in the lay
public than it is in the research community. Most scientists I know find it less an
ethical problem than a scientific one. Because ESCs form cancers, their primary
contribution will continue to be disease modeling and drug screening. And the
ethical concerns about using embryonic cells have been completely leapfrogged
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by the discovery of iPS cells. Even the Vatican supports and funds adult and iPS
cell research.
Subtheme 5: The possibility of compromise. Participants 4 and 5 believed that
compromise between proponents and opponents of stem cell research was unlikely.
Participant 4 related that compromise is not possible, while Participant 21 (MIP) shared
that compromise is not likely for those with strong views on the moral status of the
human embryo. Participant 5 suggested that the benefits of hESC research might
gradually persuade its opponents:
Unfortunately, I do not think hESC opponents are willing to compromise, but
when hESC-based treatments [and] therapies for diseases that afflict them or their
family members become available, I hope they will take advantage of them and
maybe reconsider their stance.
Participants 3, 10, 15, 16, and 21 believed that deriving the necessary research
materials from uncontroversial sources would render the hESC debate moot. Participant
21 suggested that focus on less contentious technologies, such as iPS cells and use of
existing rather than new hESC lines offer some hope. Similarly, Participants 10 (FIP) and
16 (FRP) noted that continued use of iPS cells can be considered as a compromising
option. Participant 15 (FSU) noted that the use of iPS cells is a compromise with stem
cell research opponents; however, researchers still do not know the real potential of this
technology and its application to therapy. Participant 3 (MSU) suggested that contention
could be alleviated by working to develop and improve lines in which ethical issues have
been thoroughly discussed.
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Some participants recommended more effective education of the public as a
means of promoting compromise. Participant 7 (MSU) placed the burden of promoting
education on opponents of stem cell research. Participant 7 shared that compromise can
occur with the use of more meaningful questions about stem cell research outcomes,
“such as what does the research mean to my family and to the country now and into the
future.” Participant 6 (FIP) placed the burden on proponents of stem cell research,
suggesting that they should “provide a greater understanding.” Participant 12 (MSU)
referred to education and the concurrent use of uncontroversial materials as a means of
achieving a compromise:
I believe the best compromise is using other stem cell lines beyond embryonic
and making the public aware of the differences. For example, hMSCs [human
mesenchymal stem cells], which we use, are from a human, adult, healthy donor
and these cells have shown to be great in curing very devastating conditions such
as stroke or cardiac problems.
Research Question 3
What do U.S. stem cell researchers, stakeholders, and investors recommend to
improve stem cell research policy in the United States? Based on Research Question 3
analyzed data, one theme and four subthemes emerged to answer this research question.
Participants suggested that U.S. federal stem cell policy could be improved by (a)
excluding religious considerations from political discussions, (b) involving outsiders and
nonprofessionals in the debate, (c) promoting outreach education about the advantages
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and disadvantages of stem cell research for laypersons and legislators, and (d) increasing
federal funding.
In regard to the context of each research setting, researchers, investors, and
stakeholders recommended the need for increased federal funding to improve stem cell
research in the United States as well as the need to educate the general public and
lawmakers. Stakeholders recommended including people from the outside in stem cell
discussions and removing religious agendas. Table 6 depicts the occurrences and
percentages for policy recommendations subthemes.
Theme 3: Policy recommendations. This theme has four subthemes, which are
as follows: (a) funding, (b) involving outsiders, (c) excluding religion, and (d) education.
Participants’ responses are categorized in the four subthemes below.
Table 6
Subtheme Occurrences and Percentages for Policy Recommendations
Theme
Policy
recommendations

Subthemes
Funding

No. of occurrences
9

% of occurrences
26%

Involving outsiders

7

21%

Excluding religion

4

12%

Education

14

41%

Total

34

100%

Subtheme 1: Funding. Participants 1, 2, 8, 9, 20, and 21 made policy
recommendations to increase federal funding. Participant 2 (MIG) shared that it is going
to take a huge investment by the government to really push stem cell research forward.
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Participant 8 (FIP) summarized her recommendations in the form of an equation, stating,
“Streamlined process plus money equals competitive advantage, where streamlined
process referred to an acceleration of the FDA approval process. Participant 2 also
mentioned FDA requirements and noted that it is “going to take changes in the way the
FDA regulates stem cell therapies to enable the science to move ahead as fast as it needs
to.” Participants 1, 9, 20, and 21 also recommended an increase in federal funding.
Subtheme 2: Involving outsiders. Participants 3 and 7 suggested involving
outsiders and laypersons in the stem cell research discussion. Participant 3 (MSU)
recommended bringing in people from the outside, not just professionals. Similarly,
Participant 7 (MSU) also recommended the engagement of lay people who are recipients
of the therapy along with professionals in the field. Participant 7 explained that involving
the public might be an effective political agenda because “people are very similar when it
comes to saving lives. People respect human life and are more practical in their
understanding if they can relate outcomes to their own family and loved ones.”
Subtheme 3: Religion. Participant 9 (FSU) recommended the removal of
religious agendas from the dialogue, stating, “The ethical interpretations to ESC use are
not scientifically informed and restrictions should be reevaluated without political or
religious input.” In addition, Participant 9 recommended that legislators vote to overturn
religious agendas because stem cell research will not move forward until the policies
change.
Subtheme 4: Education. Some participants recommended different forms of
education to make federal policy more favorable to hESC research. Participant 9 (FSU)

97
recommended “improved science education, public announcements educating the public,
[and] encouraging open discussion of policy, ethics, and science.” Participant 14 (FIG)
shared that the general public should be educated about the benefits of stem cell research
because they do not know enough. Participant 14 recommended reaching out to
community residents. Participant 17 (FRP) recommended educational outreach where
both sides of stem cell research are discussed with stakeholders with the goal of reaching
a common, middle ground. Participant 19 (FRP) agreed with Participant 17 and
recommended that people need to be educated on the advantages and disadvantages of
stem cell research. Participant 1 (FRP) suggested that educational efforts should not only
focus on the general public, but that lawmakers should be educated as well.
Summary of Findings
The purpose of this qualitative phenomenological research study was to explore
the perceptions of 21 stem cell researchers, stakeholders, and investors in the United
States about the effects of the current federal stem cell policy on stem cell research in the
United States, the moral disagreement with stem cell research, and recommendations to
improve stem cell research policy in the United States. In-depth telephonic
semistructured interviews with 21 stem cell researchers, stakeholders, and investors in the
United States were used to address the three research questions. Using Attride-Stirling’s
(2001) six steps or stages on how to conduct a thematic analysis, three overarching
themes (perceptions of the effects of the Obama administration’s federal stem cell policy,
perception of moral disagreement about stem cell research, and policy recommendations)
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and 14 subthemes emerged in answering the research questions. The 14 subthemes are
discussed below.
First, in regard to U.S. stem cell researchers’, stakeholders’, and investors’
perceptions about the effects of the current federal stem cell policy on stem cell research
in the United States, participants discussed their perceptions of the Obama
administration’s funding policy, the NIH’s ethical policy, the Dickey-Wicker
Amendment, and competition between the United States and other countries. Findings
indicated those participants’ perceptions of U.S. federal stem cell policy varied widely as
some participants perceived the policy as beneficial, irrelevant, or a constraint on stem
cell research. Only a few participants expressed approval of the current stem cell policy.
Some participants who perceived the federal stem cell policy as beneficial to U.S. stem
cell research expressed their approval, stating that the Obama administration’s
comparatively relaxed funding policy was more advantageous to stem cell researchers
than the Bush administration’s restrictions, although the Obama administration’s policy
was not necessarily optimal. Some participant noted that while the federal stem cell
policy makes it easier to do more research, funding is still slow due to past policies and
restrictions. Some participants described the policy as a significant constraint because
despite all the testing that is taking place, the benefit from stem cell is still not fully
realized. Other participants believed that funding restrictions, which only affected
research conducted on hESCs, had lost much of their significance with the increasing
prevalence of research involving iPS cells and adult stem cells. Six participants (29%)
believed that current funding restrictions prescribed by the Dickey-Wicker Amendment
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were invalidated by their reliance on justifications that were perceived as irrational,
although 13 participants (62%) agreed with the amendment. Almost all participants,
however, agreed with the NIH ethical policy, with 17 of 21 participants (81%) describing
the policy as a valuable means of promoting ethical science. Some participants expressed
concerns about the NIH policy, such as the ethical interpretations of ESC use are not
scientifically informed and restrictions should be reevaluated without political or
religious input. Some participants highlighted that restrictive stem cell policies could
have a negative effect on the international standing of U.S. stem cell research because
major research companies move their stem cell research division to other countries where
scientists are permitted to conduct research without any restriction.
Second, in regard to U.S. stem cell researchers’, stakeholders’, and investors’
perceptions about the moral disagreement with stem cell research, participants discussed
understanding of the opposition, religious or moral objections, stem cell source,
reasoning, and the possibility of compromise. Findings indicated that participants had
different perceptions of the moral debate surrounding hESC research. Some participants
believed that opposition to the research was invalidated either by its subjective or
irrational impetus or by its failure to address all the facts. Some participants shared that
opposition to hESC research was due to combination of political calculation and
misdirected sentiment. Some participants also discussed the connection between religious
opposition to hESC research as well as religious opposition to abortion. Some
participants noted that embryos no longer needed for fertility treatments were discarded
as medical waste if they were not donated to science or adopted by another couple; thus,
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stopping ESC research does not save the embryos. Participants also noted that the scope
of the disagreement was limited to hESCs and that emerging iPS cell technology might
render it moot. Hence, some participants pointed out that the disagreement with stem cell
research is over the destruction of embryos to create hESC lines and not over stem cell
research in general. Some participants questioned the validity of the stem cell debate
because they perceived the reasoning of hESC research opponents as flawed. Regarding
the possibility of compromise between proponents and opponents of hESC research,
some participants were pessimistic, while other participants viewed iPS cell research as
an existing compromise. Some participants believed that education about hESC research
would lead to widespread acceptance of the technology.
Third, in regard to what U.S. stem cell researchers, stakeholders, and investors
recommend to improve stem cell research policy in the United States, participants
discussed funding, involving outsiders, excluding religion, and the need for education.
Findings indicated that participants believed that the U.S. federal stem cell policy could
be improved by excluding religious considerations from political discussions, involving
outsiders and nonprofessionals in the debate, promoting outreach education about the
advantages and disadvantages of stem cell research for laypersons and legislators, and
increasing federal funding. In Chapter 4, I included the introduction, setting,
demographics, data collection, data analysis, evidence of trustworthiness, results, and a
summary. In Chapter 5, I include the introduction, interpretation of findings, limitations
of the study, recommendations, implications, and a conclusion.
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Chapter 5: Discussion, Conclusions, and Recommendations
In this phenomenological study, I explored seven U.S. stem cell researchers’,
seven U.S. stakeholders’, and seven U.S. investors’ perceptions about the effects of the
current federal stem cell policy on stem cell research in the United States, the moral
disagreement with stem cell research, and recommendations to improve stem cell
research policy in the United States. I collected data through in-depth telephonic
semistructured interviews. This study was designed to answer three research questions:
(a) U.S. stem cell researchers’, stakeholders’, and investors’ perceptions about the effects
of the current federal stem cell policy on stem cell research in the United States, (b) U.S.
stem cell researchers’, stakeholders’, and investors’ perceptions about the moral
disagreement with stem cell research, and (c) U.S. stem cell researchers, stakeholders,
and investors recommendations to improve stem cell research policy in the United States.
Using Attride-Stirling’s (2001) six steps of thematic analysis, I found three
overarching themes (perceptions of the effects of the Obama administration’s federal
stem cell policy, perception of moral disagreement about stem cell research, and policy
recommendations) and 14 subthemes. Findings indicated that participants’ perceptions of
U.S. federal stem cell policy varied as some participants perceived the policy as
beneficial while others perceived it as irrelevant or a constraint on stem cell research.
Only a few participants expressed approval of the current stem cell policy. Some
participants who perceived the federal stem cell policy as beneficial noted that the Obama
administration’s comparatively relaxed funding policy was more advantageous to stem
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cell researchers than the Bush administration’s restrictions, although the Obama
administration’s policy was not necessarily optimal.
In sharing their perceptions about the moral disagreement with stem cell research,
participants discussed understanding of the opposition, religious or moral objections,
stem cell source, reasoning, and the possibility of compromise. Findings indicated that
participants had different perceptions of the moral debate surrounding hESC research
where some participants believed that opposition to the research was invalidated either by
its subjective or irrational impetus or by its failure to address all of the facts. Participants
also noted that the scope of the disagreement was limited to hESCs and that emerging iPS
cell technology might render it moot. Some participants pointed out that the disagreement
with stem cell research is over the destruction of embryos to create hESC lines and not
over stem cell research in general. Findings also indicated that participants believed that
the U.S. federal stem cell policy could be improved by excluding religious considerations
from political discussions, involving outsiders and nonprofessionals in the debate,
promoting outreach education about the advantages and disadvantages of stem cell
research for laypersons and legislators, and increasing federal funding. In Chapter 5, I
present the interpretation of findings, limitations of the study, recommendations,
implications, and a conclusion.
Interpretation of the Findings
I explored seven stem cell researchers’, seven stakeholders’, and seven investors’
perceptions in the United States about the effects of the current federal stem cell policy
on stem cell research in the United States, the moral disagreement with stem cell
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research, and recommendations to improve stem cell research policy in the United States.
This qualitative phenomenological study was designed to answer three research
questions. The findings are interpreted in the context of Rogers’s (1962) DOI theory,
Kingdon’s (1995) agenda-setting theory, and the literature review. This section contains
the following subsections: Research Question 1, Research Question 2, and Research
Question 3.
Research Question 1
What are U.S. stem cell researchers’, stakeholders’, and investors’ perceptions
about the effects of the current federal stem cell policy on stem cell research in the United
States? The results of Research Question 1 included participants’ perceptions of the
Obama administration’s funding policy, the NIH’s ethical policy, the Dickey-Wicker
Amendment, and competition between the United States and other countries.
Participants’ perceptions of U.S. federal stem cell policy varied widely as some
participants perceived the policy as beneficial while others perceived it as irrelevant or a
constraint on stem cell research. Only a few participants expressed approval of the
current stem cell policy. Some participants who perceived the federal stem cell policy as
beneficial stated that the Obama administration’s comparatively relaxed funding policy
was more advantageous to stem cell researchers than the Bush administration’s
restrictions, although the Obama administration’s policy was not necessarily optimal.
Some participants noted that although the current stem cell policy makes it easier to do
more research, funding is still slow due to previous policies and restrictions. Some
participants described the policy as a significant constraint because despite all the testing
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that is taking place, the benefits from stem cell research are not fully realized. Other
participants reported that funding restrictions, which only affected research conducted on
hESCs, had lost much of their significance with the increasing prevalence of research
involving iPS cells and adult stem cells. Six participants (29%) commented that current
funding restrictions prescribed by the Dickey-Wicker Amendment were invalidated by
their reliance on justifications that were perceived as irrational, although 13 participants
(62%) agreed with the amendment. Almost all participants agreed with the NIH ethical
policy, with 17 participants (81%) describing the policy as a valuable means of
promoting ethical science. Some participants expressed concerns that ethical
interpretations of ESC use are not scientifically informed and restrictions should be
reevaluated without political or religious input. Some participants highlighted that
restrictive stem cell policies could have a negative effect on the international standing of
U.S. stem cell research because major research companies move their stem cell research
division to other countries where scientists are permitted to conduct research without any
restriction.
Findings from Research Question 1 may be interpreted using Rogers’s (1962)
DOI theory. Restrictive stem cell policies could have a negative effect on the
international standing of U.S. stem cell research as major research companies move their
stem cell research division to other countries where scientists are permitted to conduct
research without restriction. Amidon (2005) noted that limiting the spread of innovation
slows growth. Rogers (1995) argued that diffusion, which is the means of how
information is shared among a group of people in a network, may prevent the innovation
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of a new product, idea, or practice from being accepted by others of a particular culture or
network. The DOI theory can also be applied to the finding that although the current stem
cell policy makes it easier to do research, funding is still slow due to previous policies
and restrictions. This finding is consistent with what has been reported in the literature
where differences in national regulatory approaches have generated competition to
implement stem cell programs that will give countries an edge in the global knowledge
economy (Gottweis et al., 2009). Countries such as China, India, South Korea, and
Singapore have been identified as emerging biotech powers (Wahlberg, 2012).
Some participants described the U.S. stem cell policy as a significant constraint
because despite all the testing that is taking place, the benefits from stem cell are not fully
realized. This finding can be examined using Rogers’s (1995) discussion of the diffusion
and adoption step in the innovation-development process. Rogers noted that this is the
most difficult step in the innovation-development process, which involves diffusing the
product to potential adopters. As with all new products, there is pressure to move it to
market due to the problem and need being high priority. Sometimes public funds are used
until there is a positive outcome that will be beneficial to potential adopters. The move to
market is where scientists seem to have the greatest concern around innovation, which
includes unveiling the product and putting it into practice.
Participants’ perceptions that the Dickey-Wicker Amendment was irrational and
that restrictions from the amendment are a challenge for the stem cell field are consistent
with the Kingdon’s (1995) agenda-setting theory. In regard to Kingdon’s three streams
(problems, policies, and politics), Chayabunjonglerd (2012) reported that problems with
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hESC began with the 1998 discovery that introduced new possibilities, and scientists
sought to gain more funding through government sponsorship. According to
Chayabunjonglerd, scientists argued that the Dickey-Wicker Amendment that banned the
use of human embryos in federally funded projects hindered significant advances in
health care. Chayabunjonglerd noted that the issue of federal funding of hESC research
raised the important question of whether the government should fund hESC research.
Chayabunjonglerd claimed that President Bush’s inauguration represented significant
change in the political stream, which opened a window for him to push forward his policy
on hESC research. This resulted in the policy stream, where President Bush issued a
Presidential Statement in 2001 that limited federal funding of research involving hESCs
(Chayabunjonglerd, 2012; Obama, 2009).
Some participants commented that the federal stem cell policy was beneficial to
U.S. stem cell research and expressed their approval, stating that the Obama
administration’s comparatively relaxed funding policy was more advantageous to stem
cell researchers than the Bush administration’s restrictions, although the Obama
administration’s policy was not necessarily optimal. This finding is consistent with what
has been reported in the literature. Hyun (2010) related that although the controversy over
embryo destruction continues, the Obama administration’s friendlier stance toward hESC
research has helped the proponents’ public debate over hESC research. President
Obama’s EO removed limitations on scientific inquiry and expanded the NIH support for
the exploration of stem cell research, with the purpose of enhancing the contributions of
U.S. scientists to make important discoveries and create new therapies for the benefit of
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humanity (Obama, 2009). However, despite President Obama’s reversal of some of the
barriers to hESC research, questions remain about the extent to which U.S. stem cell
researchers have truly benefited from this more relaxed federal funding policy (Nature
Cell Biology, 2010; Wolinsky, 2009).
Research Question 2
What are U.S. stem cell researchers’, stakeholders’, and investors’ perceptions
about the moral disagreement with stem cell research? The results of Research Question
2 included participants’ understanding of the opposition, religious or moral objections,
stem cell source, reasoning, and the possibility of compromise. Participants had different
perceptions of the moral debate surrounding hESC research. Some participants
commented that opposition to the research was invalidated either by its subjective or
irrational impetus or by its failure to address all of the facts. Some participants shared that
opposition to hESC research was due to a combination of political calculation and
misdirected sentiment. Some participants also discussed the connection between religious
opposition to hESC research as well as religious opposition to abortion. Some
participants noted that embryos no longer needed for fertility treatments are discarded as
medical waste if they are not donated to science or adopted by another couple, and
stopping ESC research does not save the embryos. Participants also noted that the scope
of the disagreement was limited to hESCs and that emerging iPS cell technology might
render it moot. Some participants pointed out that the disagreement with stem cell
research is over the destruction of embryos to create hESC lines and not over stem cell
research in general. Some participants questioned the validity of the stem cell debate
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because they perceived the reasoning of hESC research opponents as flawed. Regarding
the possibility of compromise between proponents and opponents of hESC research,
some participants were pessimistic while others viewed iPS cell research as an existing
compromise. Some participants believed that education about hESC research would lead
to widespread acceptance of the technology.
Findings from Research Question 2 may be interpreted using Rogers’s (1962)
DOI theory. Some participants discussed the connection between religious opposition to
hESC research and religious opposition to abortion. Rogers (2003) argued that there are
five factors that influence the adoption of innovation probability rate: (a) relative
advantage, (b) compatibility, (c) complexity, (d) trialability, and (e) observability.
Compatibility is determined by the acceptability of social or religious norms in the
country, which may forbid certain practices, attitudes, or behaviors. Findings from the
current study indicated that some participants believed that education about hESC
research would lead to widespread acceptance of the technology. Rogers also discussed
the five innovation-decision processes: (a) knowledge, (b) persuasion, (c) decision, (d)
implementation, and (e) confirmation. In the knowledge stage, individuals are exposed to
an innovation, but they do not have information about the innovation. Perhaps additional
knowledge about hESC research, such as the knowledge that embryos no longer needed
for fertility treatments are discarded as medical waste if they are not donated to science or
adopted by another couple, may lead to more widespread acceptance of hESC research.
The finding that opposition to hESC research was due to a combination of
political calculation and misdirected sentiment can be interpreted using Kingdon’s (1995)
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agenda-setting theory. In the politics stream, Kingdon noted that politics are factors that
influence agendas, such as political climate or mood and the voices of advocacy or
opposition groups. Findings indicated that participants had different perceptions of the
moral debate surrounding hESC research. This finding is consistent with the literature
indicating that the ethical and moral disagreement about hESC research and the
destruction of embryos continues between proponents of religion and science
(Doerflinger, 2010). Stem cell research remains highly controversial because there are
unresolved questions about human cloning, therapeutic abortions, and reproductive rights
(Adelson & Weinberg, 2010). Lysaght and Campbell (2012) reported that there are
concerns that have generated political and public bioethical debates. Fadel (2012)
discussed the issue of ethics in stem cell research and noted that it remains a lengthy and
heated debate in the scientific literature, religious circles, and the political arena. Fadel
noted that the debate includes the need to protect human life from the time of inception
versus curing many debilitating diseases.
Regarding the possibility of compromise between proponents and opponents of
hESC research, some participants were pessimistic, while other participants viewed iPS
cell research as an existing compromise. This finding is consistent with the literature as
those in support of hESC research have argued that it is morally permissible to use
surplus embryos for biomedical research that may save many lives (Mintrom, 2013).
However, those who oppose hESC research do not agree with this argument and have
argued that such research would still support the destruction of embryos. Levine (2011)
related that due to the divisiveness of the hESC research debate and the history of

110
policymaking in other morally charged areas, policy certainty will continue to prove
difficult. Hence, some degree of uncertainty may be unavoidable and as a result, hESC
researchers should prepare for continued policy changes, legal challenges, and other
challenges to their research. Although the controversy over embryo destruction continues,
Hyun (2010) related that the creation of human iPS cells, which are genetically
engineered to act like hESCs, have helped the proponents’ public debate over hESC
research. The researcher noted that the main bioethical considerations now focuses more
on how stem cell research should be conducted instead of whether it should be
conducted. Those who oppose hESC research applauded the iPS cell revolution, which
they hoped would end ESC research. However, most stem cell researchers believe that
iPS or other alternative source of stem cells do not take away the need for ongoing hESC
research. Thus, some participants recommended that researchers and the stem cell
community advocate for more relaxed stem cell policies as some hESC lines are still
needed for research since iPS cells may not behave exactly the same as embryonic cells.
Research Question 3
What do U.S. stem cell researchers, stakeholders, and investors recommend to
improve stem cell research policy in the United States? The results of Research Question
3 indicated that participants discussed funding, involving outsiders, excluding religion,
and the need for education. Participants believed that the U.S. federal stem cell policy
could be improved by excluding religious considerations from political discussions,
involving outsiders and nonprofessionals in the debate, promoting outreach education
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about the advantages and disadvantages of stem cell research for laypersons and
legislators, and increasing federal funding.
Findings from Research Question 3 may be interpreted using Rogers’s (1962)
DOI theory, such as some participants recommending the removal of religious agendas
from the dialogue and that legislators vote to overturn religious agendas because stem
cell research will not move forward until the policies change. Rogers (1995) noted that
groupthink tends to limit the spread of innovation. Leaders of a group exert influence
over the behaviors of individuals and adopters in their networks, such as influencing
followers’ beliefs (Anderson, 2006; Janis, 1989; Rogers, 1983). Limiting the spread of
innovation also slows down growth (Amidon, 2005). According to Amidon (2005),
individuals in political or social settings tend to accept groupthink as a form of solidarity
and unanimity.
Rogers’s (1962) DOI theory can also be attributed to participants’
recommendation to involve outsiders or laypersons as well as well as using different
forms of education to make federal policy more favorable to hESC research, such as
improved science education, public announcements educating the public, and
encouraging open discussion of policy, ethics, and science. Terin (2012) noted that
diffusion of innovation is connected to an individual’s perception of a new product or
service, while invention is new. Therefore, Therin related that with the perception of
newness, there must be knowledge about the service or product, otherwise that perception
is not relevant. In addition, any new innovation must be known among the targeted
population of potential adopters and a clear perception should be established. Once the
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knowledge about the product and service has been conveyed, there should be a theoretical
framework in place to rate the adoption of the new innovation.
Participants’ recommendation to increase funding can be attributed to Kingdon’s
(1995) agenda-setting theory. Dresser (2010) reported that in the United States, the stem
cell controversy opens a window to a larger moral problem (Dresser, 2010). According to
Dresser (2010), the social justice inquiry about what justifies the United States substantial
investment in biomedical innovation, when millions of people in the United States and
abroad are denied access to proven medical interventions, raises questions about the
priority that stem cell and other basic science studies should have in the competition for
limited resources. Dresser argued that if government officials and health advocates want
to help patients, meaningful help would also come from a system that supplied adequate
health care to more people, both across the nation and worldwide.
Participants’ recommendation for increase funding is also consistent with the
literature. Adelson and Weinberg (2010) noted that the continuous changes in the policy
by each President have been a source of great concern for representatives of states such
as California, who support hESC research. Therefore, states such as California, have
added additional revenue to the budget to further stem cell research programs. For
example, in 2004, after President Bush’s policy denied the use of federal funds to further
research, California officials created the California Research Cures Initiatives to continue
with their research after law was passed to stop federal funding to support stem cell
research and to ban those who continued their study on stem cells from using laboratories
and facilities that were supported by federal funds. California went on to create the CIRM
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to provide oversight and created funding for all research in their state. The CIRM agreed
to contribute $3 billion over a decade and create another $3 billion through the sale of
public bonds and the state general fund to aid in the study of stem cells. Gottweis et al.
(2009) emphasized that differences in national regulatory approaches have generated
competition to implement stem cell programs that will give countries an edge in the
global knowledge economy.
Limitations of the Study
There were several limitations of this study. First, findings were limited by the
snowball sample of seven stem cell researchers, seven stem cell stakeholders, and seven
stem cell investors; each category of participants contained a smaller number than the
overall sample of 21. Due to the small sample size for each category of participant,
caution has to be taken in transferring the findings to similar populations of U.S. stem
cell researchers, stakeholders, and investors. In addition, the results of the study may not
be transferrable to other populations or countries. As a result, in future research, the
sample population for each type of participant could be increased to achieve a broader
understanding of their stem cell research policy experiences. In future studies, a different
sampling strategy could also be used, such as random sampling.
Second, social desirability bias was considered as stem cell researchers,
stakeholders, and investors may have wanted to be perceived positively, so they may not
have responded honestly to the interview questions. However, I assumed that participants
would honestly and openly answer the interview questions by sharing their perceptions
about the phenomenon. Third, there were limitations with self-reported data as
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participants may not have accurately or fully evaluated themselves. However, I assumed
that participants accurately and fully self-evaluated.
Recommendations
The six recommendations for future studies are grounded in the strengths and
limitations of the study as well as the literature reviewed in Chapter 2: (a) Use random
sampling for each group of participants, (b) focus on how subsequent U.S. administration
stem cell policies affect stem cell research in the United States, (c) focus on the general
public’s knowledge of stem cell research as well as those of legislators, (d) focus on
involving outsiders and laypersons in the stem cell research discussion, (e) investigate the
divisiveness of the hESC research debate and what can be done to create a cohesive or
bipartisan federal ESC public financing policy, and (f) focus on examining and
comparing international communities’ stem cell policies. These six recommendations are
discussed in further detail below.
First, as noted in the limitations of the study section, it is recommended that in
future research studies, the sample population for each type of participant (stem cell
researchers, stakeholders, and investors) could be increased to achieve a broader
understanding of their stem cell research policy experiences. In doing this, different
sampling strategies could also be used, such as random sampling. Second, policy
uncertainty affects researchers’ plans more significantly than temporary funding bans
(Levine, 2011). Adelson and Weinberg (2010) noted that continuous changes in the
policy by each President have been a source of great concern for representatives of states.
Participants also noted that stem cell policies could change with each subsequent
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administration. Kingdon (1995) related that windows can predictably or unpredictably
appear due to events such as election results or a sudden crisis, respectively (Kingdon,
1995). Therefore, future research could focus on how subsequent U.S. administration
stem cell policies affect stem cell research in the United States, such as those of the new
Trump administration.
Third, participants suggested that educational efforts should focus on the general
public as well as lawmakers. Thus, future research studies could focus on the general
public’s knowledge of stem cell research as well as those of legislators. Fourth,
participants suggested involving outsiders and laypersons in the stem cell research
discussion; thus, future research studies could focus on this recommendation. Fifth, some
participants noted that while the Obama administration’s stem cell policy is a positive
step, stem cell research is still stagnant and benefits have not increased from 2009 due to
a lack of bipartisan support. Thus, future research could further investigate the
divisiveness of the hESC research debate and what can be done to create a cohesive or
bipartisan federal ESC public financing policy.
Sixth, participants shared that the Obama administration’s more expansive policy
has improved competitiveness, but researchers are still restricted to the creation of new
lines due to the lack of using federal funds. In addition, participants argued that if the
stem cell policy is further relaxed, U.S. research could have a global effect. Participants
argued that U.S. stem cell policy has diminished United States’ competitiveness with
other countries; such as China, Japan, and Europe. Participant also shared that due to
limitations in the United States, companies who want to be more competitive do research
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in other countries and then bring the results of their research to the United States, which
makes it very costly for everyone to reap the benefits. Thus, future research study could
focus on examining and comparing international communities’ stem cell policies, such as
those in China, Japan, Europe, India, South Korea, and Singapore, who have been
identified as emerging biotech powers (Wahlberg, 2012), with those of the United States
so that lessons can be learned and to ensure that stem cell research continues to improve
in the United States.
Implications
To improve stem cell research policy in the United States, U.S. stem cell
researchers, stakeholders, and investors recommended the exclusion of religious
considerations from political discussions, involving outsiders and nonprofessionals in the
debate, promoting outreach education about the advantages and disadvantages of stem
cell research for laypersons and legislators, and increasing federal funding. These
recommendations have several implications for stem cell policymakers to focus attention
and resources on creating a consistent federal hESC funding policy to ensure that stem
cell research continues to improve in the United States. While some participants noted
that funding restrictions, which only affected research conducted on hESCs, had lost
much of their significance with the increasing prevalence of research involving iPS cells
and adult stem cells, other participant recommended that researchers and the stem cell
community should advocate for more relaxed stem cell policies as some hESC lines are
still needed for research since iPS cells may not behave exactly the same as embryonic
cells. Thus, a bipartisan hESC funding policy will lead to positive social change in the
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health care field as hESCs can be used for cell-based therapies to replace ailing or
destroyed tissues, such as macular degeneration, spinal cord injury, stroke, burns, heart
disease, diabetes, osteoarthritis, and rheumatoid arthritis (NIH, 2015b). In addition,
hESCs can be used to treat Alzheimer’s and Parkinson’s diseases; however, the need for
transplantable tissues and organs far outweighs the available supply (CIRM, 2015b; NIH,
2015b).
Participants recommended the removal of religious agendas from the stem cell
research policy dialogue. Policy entrepreneurs, who are political actors who seek policy
changes to existing situations in areas of public policy, have faced significant opposition
to government funding and favorable regulations to advance hESC research due to
morality issues (Mintrom, 2013). The most restrictive stem cell laws are in countries
where Roman Catholicism is a dominant religion or Christian democratic parties have
been on the rise (Fink, 2008; Mintrom, 2013). Mintrom (2013) reported that the UK has a
permissive approach to the hESC research regulation and that it is correlated with the low
percentage of adults who identify with the Roman Catholic faith (9%) in the UK.
Mintrom noted that in the UK, moral issues have been widely investigated and
extensively debated; however, they have not inhibited scientific research.
Unlike the UK and other permissive countries, hESC research in the United States
is divisive and controversial, which has resulted in continuous stem cell policy
uncertainty (Levine, 2011; Levine et al., 2013; Mintrom, 2013). Participants related that
stem cell policies could change with a different administration. Thus, there is no cohesive
or bipartisan federal hESC funding policy, which stifles the United States’ standing to be
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a leading country for the advancement of hESC research (Mintrom, 2013; Sano, 2013).
As a result, U.S. hESC researchers continue to face policy fluctuations, legal challenges,
and other hurdles to their future research (Levine, 2011; Levine et al., 2013; Mintrom,
2013; Sano, 2013).
Participants recommended that outsiders and nonprofessionals should be involved
in the stem cell research policy debate and outreach education on the advantages and
disadvantages of stem cell research should be given to the general public and legislators.
Participants also related that the moral disagreements with stem cell research are mainly
due to lack of scientific knowledge and factual information because many times facts are
misrepresented, which perpetuates a false perception. Thus, with educational outreach,
where both sides of stem cell research are discussed with stakeholders, a common,
middle ground may be reached.
Participants made policy recommendations to increase federal funding as it would
increase U.S. stem cell research competitive advantage. Gottweis et al. (2009) reported
that differences in national regulatory approaches have generated competition to
implement stem cell programs that will give countries an edge in the global knowledge
economy. Hence, to compete with countries such as China, India, South Korea, and
Singapore, who have been identified as emerging biotech powers (Wahlberg, 2012), and
to ensure that everyone can reap the benefits of stem cell research, a cohesive and more
permissive federal hESC funding policy in the United States is needed. In this study, I
addressed a gap in research by making an original contribution to the public policy and
administration literature on U. S. stem cell research policy. In addition, along with the
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fields of public policy and administration, a wide array of other fields, agencies, and
organizations might be interested in the research findings as well, to include the fields of
biology and regenerative medicine, and agencies such as the CIRM and the NIH.
Conclusion
To further understand and address the problem of federal support and funding for
hESC research in the United States being behind stem cell programs in many countries
and the continually evolving federal policies that have further hindered research efforts, it
was important to obtain the perceptions of stem cell researchers, stakeholders, and
investors in the United States about the effects of the current federal stem cell policy on
stem cell research in the United States, the moral disagreement with stem cell research,
and recommendations to improve stem cell research policy in the United States because
they have expertise in the field of stem cell research.. Researchers noted that unlike the
UK and other permissive countries, hESC research in the United States are divisive and
controversial, which has resulted in continuous stem cell policy uncertainty (Levine,
2011; Levine et al., 2013; Mintrom, 2013). There is no consistent federal hESC funding
policy, which stifles the United States’ standing to be a leading country for the
advancement of hESC research (Mintrom, 2013; Sano, 2013). Levine (2011) related that
policy uncertainty affects researchers’ plans more significantly than temporary funding
bans (Levine 2011). As a result, Levine recommended that lawmakers who are supportive
of hESC research should work to create policies that reduce the uncertainty facing stem
cell scientists. Nature Cell Biology (2010) related that while each state government will
create restrictive policies for stem cell research within their borders, where several states
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have already done so, a liberal policy at the federal level also softens the tone of hESC
debate and promote greater acceptance of such research within the United States. As a
result, from a policy perspective, more remains to be done to ensure that stem cell
research improves in the United States.
Findings are directed at stem cell policymakers to focus attention and resources
on creating a hESC federal funding policy that is cohesive to ensure that stem cell
research continues to improve the United States. A bipartisan federal hESC funding
policy will lead to positive social change in the health care field as hESCs can be used for
cell-based therapies to replace ailing or destroyed tissues, such as macular degeneration,
spinal cord injury, stroke, burns, heart disease, diabetes, osteoarthritis, and rheumatoid
arthritis (NIH, 2015b). In addition, hESCs can be used to treat Alzheimer’s and
Parkinson’s diseases; however, the need for transplantable tissues and organs far
outweighs the available supply (CIRM, 2015b; NIH, 2015b). Therefore, by stem cell
researchers, stakeholders, and investors educating the general public and lawmakers
about hESC research, as well as involving the public in stem cell research discussions,
maybe a common, middle ground can be reached.

121
References
Adelson, J. W., & Weinberg, J. K. (2010). The California stem cell initiative: Persuasion,
politics, and public science. American Journal of Public Health, 100, 446–451.
doi:10.2105/ajph.2009.168120
Amidon, M. (2005). Groupthink, politics and the decision to attempt the son tay rescue.
Parameters: U.S. Army War College Quarterly, 35(3), 119–131. Retrieved from
http://www.strategicstudiesinstitute.army.mil/pubs/parameters/
Association of American Medical Colleges. (2015a). Embryonic stem cell research.
Retrieved from
https://www.aamc.org/advocacy/research/74440/embryonicstemcellresearch.html
Association of American Medical Colleges. (2015b). Research. Retrieved from
https://www.aamc.org/advocacy/research/
Attride-Stirling, J. (2001). Thematic networks: An analytic tool for qualitative research.
Qualitative Research, 1, 385–405. doi:10.1177/146879410100100307
Australia Law Reform Commission. (2015). Stem cell technologies. Retrieved from
http://www.alrc.gov.au/publications/15-stem-cell-technologies/stem-cellresearch-australia
Aznar, J., & Navarro-Illana, P. (2014). Therapeutic use of human embryonic stem cells.
Acta Bioéthica, 20, 291–292. doi:10.4067/s1726-569x2014000200017
California Institute for Regenerative Medicine. (2013). Stem cell definitions. Retrieved
from http://www.cirm.ca.gov/our-progress/stem-cell-definitions

122
California Institute for Regenerative Medicine. (2015a). Stem cell key terms. Retrieved
from https://www.cirm.ca.gov/print/3142
California Institute for Regenerative Medicine. (2015b). The power of stem cells.
Retrieved from https://www.cirm.ca.gov/patients/power-stem-cells
Canadian Institutes of Health Research. (2014). The development of guidance for human
pluripotent stem cell research in Canada. Retrieved from http://www.cihrirsc.gc.ca/e/49350.html
Cell Therapy Foundation. (2014). Advisory board. Retrieved from
http://ctf.securetree.com/About-Us/Advisory-Board
Center for Practical Bioethics. (2015). What is bioethics. Retrieved from
https://www.practicalbioethics.org/what-is-bioethics
Chayabunjonglerd, S. (2012). Entering the decision agenda. Retrieved from
https://sites.google.com/site/humanembryonicstemcellpolicy/entering-thedecision-agenda
Couch, K. A., Lane, J., & Black, D. (2012). Point/counterpoint. Journal of Policy
Analysis and Management, 31, 706–707. doi:10.1002/pam.21613
Creswell, J. W., & Miller, D. (2000). Determining validity in qualitative inquiry. Theory
into Practice, 39, 124–30. doi:10.1207/s15430421tip3903_2
Doerflinger, R. M. (2010). Old and new ethics in the stem cell debate. Journal of Law,
Medicine and Ethics, 38, 212–219. doi:10.1111/j.1748-720X.2010.00481.x
Downey, R., & Geransar, R. (2008). Stem cell research, publics’ and stakeholder views.
Health Law Review, 16(2), 69–85. Retrieved from http://mckinneylaw.iu.edu/ihlr/

123
Dresser, R. (2010). Stem cell research as innovation: Expanding the ethical and policy
conversation. Journal of Law, Medicine, and Ethics, 38, 332–341.
doi:10.1111/j.1748-720X.2010.00492.x
Fadel, H. E. (2012). Developments in stem cell research and therapeutic cloning: Islamic
ethical positions, a review. Bioethics, 26, 128–135. doi:10.1111/j.14678519.2010.01840
Fink, S. (2008). Politics as usual or bring religion back in? The influence of parties,
institutions, economic interests, and religion on embryo research laws.
Comparative Political Studies, 41, 1631–1656. doi:10.1177/0010414007309203
Fukushima, M. (2013). Between the laboratory and the policy process: Research,
scientific community, and administration in Japan’s chemical biology. East Asian
Science, Technology and Society: An International Journal, 7, 7–33.
doi:10.1215/18752160-2074955
Georgia Department of Public Health. (2015). Guidance to research using human
subjects. Retrieved from
http://dph.georgia.gov/sites/dph.georgia.gov/files/related_files/site_page/IRB%20
Manual.pdf
Glaser, B. G., Strauss, A. L., & Strutzel, E. (1968). The discovery of grounded theory;
Strategies for Qualitative Research. Nursing Research, 17, 364.
doi:10.1097/00006199-196807000-00014

124
Gottweis, H., Salter, B., & Waldby, C. (2009). The global politics of human embryonic
stem cell science: Regenerative medicine in transition. Basingstoke, England:
Palgrave Macmillan.
Gough, F. (2013). Deliberating or dithering? Ireland and human embryonic stem cell
research. European Journal of Health Law, 20, 145–165. doi:10.1163/1571809312341266
Gratwohl, A., Schwendener, A., Baldomero, H., Gratwohl, M., Apperley, J.,
Niederwieser, D., & Frauendorfer, K. (2010). Changes in the use of hematopoietic
stem cell transplantation: A model for diffusion of medical technology.
Haematologica, 95, 637–643. doi:10.3324/haematol.2009.015586
Harper, M., & Cole, P. (2012). Member checking: Can benefits be gained similar to
group therapy? Qualitative Report, 17(2), 510–517. Retrieved from
http://www.nova.edu/ssss/QR/QR17-2/harper.pdf
Holland, S., Lebacqz, K., & Zoloth, L. (2001). The human embryonic stem cell debate:
Science, ethics, and public policy. Cambridge, MA: MIT Press.
Hyun, I. (2010). The bioethics of stem cell research and therapy. Journal of Clinical
Investigation, 120, 71–75. doi:10.1172/JCI40435
International Stem Cell Forum. (2016). Welcome. Retrieved from http://www.stem-cellforum.net/
Janis, I. L. (1972). Victims of groupthink. Boston, MA: Houghton Mifflin.
Janis, I. L. (1989). Crucial decisions: Leadership in policymaking and crisis
management. New York, NY: Free Press.

125
Kearl, M. (2015). Dickey-Wicker Amendment, 1996. Retrieved from
https://embryo.asu.edu/pages/dickey-wicker-amendment-1996
Keiper, A., & Levin, Y. (2010). Stem cells, life and the law. Human Life Review, 36(3),
110–112. Retrieved from http://www.humanlifereview.com/
Kingdon. J. W. (1995). Agendas, alternatives, and public policies. New York, NY:
Harper Collins.
Kingdon, J. W. (2003). Agendas, alternatives, and public policies. New York, NY:
Longman.
Kington, R. S. (2011). National institutes of health guidelines on human stem cell
research. Retrieved from
http://stemcells.nih.gov/policy/pages/2009guidelines.aspx
Klenke, K. (2008). Qualitative research in the study of leadership. Cambridge,
MA:Emerald Group Publishing.
Kretchmar, J. (2009). Groupthink. Research starters sociology. Retrieved from
http://www.academicpub.com/map/items/29469.html
LeCompte, M. D., & Schensul, J. J. (1999). Analyzing and interpreting ethnographic
data. In M. D. LeCompte & J. J. Schensul (Eds.), Ethnographer’s toolkit (pp. 45–
81). Walnut Creek, CA: Sage.
Levine, A. D. (2011). Policy uncertainty and the conduct of stem cell research. Cell Stem
Cell, 8, 132–135. doi:10.1016/j.stem.2011.01.002

126
Levine, A. D., Lacy, T. A., & Hearn, J. C. (2013). The origins of human embryonic stem
cell research policies in the US states. Science and Public Policy, 40, 544–558.
doi:10.1093/scipol/sct005
Lysaght, T., & Campbell, V.A. (2013). Broadening the scope of debates around stem cell
research. Bioethics, 27, 251–256. doi:10.1111/j.1467-8519.2012.01963.x
Lysaght, T., & Capps, B. J. (2012). Public discourses of stem cell science in Singapore
(1997-2010). New Genetics and Society, 31, 342–358.
doi:10.1080/14636778.2012.662058
Marzotto, T., & Alt, P. M. (2012). The ups and downs of stem cell research: The impact
of policy uncertainty. Journal of Health and Human Services Administration, 35,
331–351. Retrieved from http://jhhsa.spaef.org/
Mason, C., & Manzotti, E. (2010). Regenerative medicine cell therapies: Number of units
manufactured and patients treated between 1988 and 2010. Regenerative
Medicine, 5, 307–313. doi:10.2217/rme.10.37
Mason, M. (2010). Sample size and saturation in PhD studies using qualitative
interviews. Forum: Qualitative Social Research, 11(3), 8. Retrieved from
http://www.qualitative-research.net/index.php/fqs/article/view/1428/3027
McCaslin, M. L., & Scott, K. W. (2003). The five-question method for framing a
qualitative research study. Qualitative Report, 8(3), 447–461. Retrieved from
http://tqr.nova.edu/
Merriam, S. B. (2009). Qualitative research: A guide to design and implementation. San
Francisco, CA: Jossey-Bass.

127
Microbot Medical Inc. (2017). Contact. Retrieved from
http://www.microbotmedical.com/contact/
Mintrom, M. (2013). Policy entrepreneurs and controversial science: Governing human
embryonic stem cell research. Journal of European Public Policy, 3, 442–457.
doi:10.1080/13501763.2012.761514
Mittal, S. (2013). Stem cell research: The India perspective. Perspectives in Clinical
Research, 4, 105. doi:10.4103/2229-3485.106408
Moretti, F., van Vliet, L., Bensing, J., Deledda, G., Mazzi, M., Rimondini, M., Fletcher, I.
(2011). A standardized approach to qualitative content analysis of focus group
discussions from different countries. Patient Education and Counseling, 82, 420–
428. doi:10.1016/j.pec.2011.01.005
Morse, J. M. (1994). Designing funded qualitative research. In N. K. Denzin & Y. S.
Lincoln (Eds.), Handbook of qualitative research (2nd ed., pp.220–235).
Thousand Oaks, CA: Sage.
Moustakas, C. (1994). Phenomenological research methods. Thousand Oak, CA: Sage.
Mudur, M. (2005). India plans to audit clinical trials. British Medical Journal, 331, 1044.
doi:10.1136/bmj.331.7524.1044-b
National Institutes of Health. (2009). Stem cell information. Retrieved from
https://stemcells.nih.gov/info/basics.htm
National Institutes of Health. (2011). Federal policy. Retrieved from
http://stemcells.nih.gov/policy/Pages/Default.aspx

128
National Institutes of Health. (2014). National institute of neurological disorders and
strokes: Developing a manual of procedures. Retrieved from
https://www.ninds.nih.gov/sites/default/files/mop.pdf
National Institutes of Health. (2015a). National Institutes of Health guidelines on human
stem cell research. Retrieved from
http://stemcells.nih.gov/policy/pages/2009guidelines.aspx
National Institutes of Health. (2015b). Stem cell basics. Retrieved from
http://stemcells.nih.gov/info/basics/pages/basics6.aspx
National Institutes of Health. (2015c). Stem cell information. Retrieved from
http://stemcells.nih.gov/info/pages/resources.aspx
Nature Cell Biology. (2010). Human embryonic stem cell research in the US: Time for
change? Nature Cell Biology, 12, 627. doi:10.1038/ncb0710-627
Obama, B. H. (2009). Executive Order 13505 of March 9, 2009: Removing barriers to
responsible scientific research involving human stem cells. Retrieved from
http://www.gpo.gov/fdsys/pkg/FR-2009-03-11/pdf/E9-5441.pdf
Patton, M. Q. (2002). Qualitative research and evaluation methods (3rd ed.). Thousand
Oaks, CA: Sage.
Pew Research Center. (2013). The global catholic population. Retrieved from
http://www.pewforum.org/2013/02/13/the-global-catholic-population/
Rodgers, B. (2008). Audit trail. In L. Given (Ed.), The SAGE encyclopedia of qualitative
research methods (pp. 44–45). Thousand Oaks, CA: Sage.
Rogers, E. M. (1962). Diffusion of innovations. Glencoe, Illinois: Free Press of Glencoe.

129
Rogers, E. M. (1995). Diffusion of innovations (4th ed.). New York, NY: The Free Press.
Rogers, E. M. (2003). Diffusion of innovations (5th ed.). New York, NY: The Free Press.
Sahin, I. (2006). Detailed review of Rogers’ diffusion of innovations theory and
educational technology-related studies based on Rogers’ theory. Turkish Journal
of Educational Technology, 5(2), 14–23. Retrieved from http://www.tojet.net/
Sano, S. (2013). A national cohesive policy in stem cell research (Master’s thesis).
Available from ProQuest Dissertations and Theses database. (UMI No. 1542050)
Shenton, A. K. (2004). Strategies for ensuring trustworthiness in qualitative research
projects. Education for Information, 22, 63–75. Retrieved from
http://www.iospress.nl/journal/education-for-information/
Small, S., & Doherty, K. (2011). Regulation of stem cell research in the United Kingdom.
Retrieved from http://www.eurostemcell.org/regulations/regulation-stem-cellresearch-united-kingdom
Soroka, S. (1999). Policy agenda-setting theory revisited: A critique of Howlett on
Downs, Baumgartner and Jones, and Kingdon. Canadian Journal of Political
Science, 32, 763–772. doi:10.1017/s000842390001698x
Substance Abuse and Mental Health Services Administration. (2014). National helpline.
Retrieved from http://www.samhsa.gov/find-help/national-helpline
Therin, F. (2012). Innovation diffusion. In Encyclopedia of new venture management (pp.
262–264). Thousand Oaks, CA: Sage.

130
Tobin, G. A., & Begley, C. M. (2004). Methodological rigour within a qualitative
framework. Journal of Advanced Nursing, 48, 388–396. doi:10.1111/j.13652648.2004.03207.x
Trochim, W. M. K. (2006a). Nonprobability sampling. Retrieved from
http://www.socialresearchmethods.net/kb/sampnon.php
Trochim, W. M. K. (2006b). Qualitative validity. Retrieved from
http://www.socialresearchmethods.net/kb/qualval.php
Turner, D. W., III (2010). Qualitative interview design: A practical guide for novice
investigators. Qualitative Report, 15(3), 754–760. Retrieved from
http://www.nova.edu/ssss/QR/QR15-3/qid.pdf
Wahlberg, A. (2012). China as a ‘emerging biotech power’. Third World Quarterly, 33,
619–632. doi:10.1080/01436597.2012.657421
Waldby, C., & Carroll, K. (2012). Egg donation for stem cell research: Ideas of surplus
and deficit in Australian IVF patients’ and reproductive donors’ accounts.
Sociology of Health and Illness, 34, 513–528. doi:10.1111/j.14679566.2011.01399
Waters, J. (2016). Phenomenological research guidelines. Retrieved from
https://www.capilanou.ca/psychology/student-resources/researchguidelines/Phenomenological-Research-Guidelines/
Waugh, W. L., Jr., & Waugh, W. W. (2004). Phenomenology and public administration.
International Journal of Organization Theory and Behavior, 7(3), 405–431.
Retrieved from http://pracademics.com/index.php/ijotb

131
Withrow, E. (2007). Global trade in human eggs thriving. The Washington Post.
Retrieved from http://www.washingtonpost.com/wpdyn/content/article/2007/01/27/AR2007012700661.html
Zamawe, F. C. (2015). The implication of using NVivo software in qualitative data
analysis: Evidence-based reflections. Malawi Medical Journal, 27, 13–15.
doi:10.4314/mmj.v27i1.4
Zucchi, K. (2015). Investing in the healthcare sector. Retrieved from
http://www.investopedia.com/articles/stocks/08/investing-in-healthcare.asp

132
Appendix A: Invitation to Participate and Recommendation Request

Dear Name Will Be Inserted Here,
My name is Dorothy Moore and I am currently a doctoral student at Walden University. I
am exploring the perceptions of stem cell researchers, stakeholders, and investors in the
United States about the effects of the current federal stem cell policy on stem cell
research in the United States, the moral disagreement with stem cell research, and their
recommendations to improve stem cell research policy in the United States.
I would greatly appreciate your participation.
Your participation would involve participating in a telephone interview which would take
about 45 minutes. Interviews will be conducted at a time that is convenient for you.
The information from the interviews will be kept strictly confidential and no one who
participates will be identified in any way.
If you have any questions about the study, please feel free to e-mail me at [E-mail
address redacted] or give me a call at [Phone number redacted].
If you are interested in participating in the study and/or would like to recommend another
stem cell researcher who works at a government organization, private company, or
university; a stem cell stakeholder who is a faculty member at a univeristy where stem
cell research is being conducted; or an investor who works for a government organization
or private company that invests in stem cell research in the United States, please
complete the questions below in a reply e-mail to me.
Thank you in advance for your consideration and assistance with my research project.
Sincerely,

Dorothy Moore
Dorothy Moore
[Phone number redacted]
[E-mail address redacted]
If you are interested in participating in the study and/or would like to recommend
another stem cell researcher, stakeholder, or investor to be a participant in the
study, please complete the questions below in a reply e-mail to me at [E-mail address
redacted] :
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1. Are you a stem cell researcher who works at a government organization, private
company, or university? (please select by bolding your answer)
a. Yes
b. No
2. Are you a stem cell stakeholder who is a faculty member at a univeristy where
stem cell research is being conducted? (Please select by bolding your answer)
a. Yes
b. No
3. Are you a stem cell investor who works for a government organization or
private company that invests in stem cell research in the United States,
stakeholder, or investor? (Please select by bolding your answer)
a. Yes
b. No
4. What is your gender? (Please select by bolding your answer)
a. Male
b. Female
5. What is your telephone number and preferred e-mail address?
6. Would you be willing to share your perceptions about about the effects of the
current federal stem cell policy on stem cell research in the United States, the
moral disagreement with stem cell research, and your recommendations to
improve stem cell research policy in the United States, which will take
approximately 45 minutes in a telephone interview?
7. If you participate in the study, would you be willing to verify the accuracy on
your interview transcript that would be e-mailed to you at a later date after the
interview has been completed and the interview has been transcribed?
8. Is there another stem cell researcher who works at a government organization,
private company, or university; a stem cell stakeholder who is a faculty
member at a univeristy where stem cell research is being conducted; or an
investor who works for a government organization or private company that
invests in stem cell research in the United States that you would like to
recommend to be a participant in this study? If so, please provide their
personal contact information or public work contact information that is
available online, but please do not provide their nonpublic work contact
information as it is considered private information.
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Appendix B: Interview Guide
Interview Guide
Introduction
•

Welcome participant and introduce myself.

•

Explain the general purpose of the interview and why the participant was chosen.

•

Discuss the purpose and process of interview.

•

Explain the presence and purpose of the recording equipment.

•

Outline general ground rules and interview guidelines such as being prepared for
the interviewer to interrupt to assure that all the topics can be covered.

•

Address the assurance of confidentiality.

•

Inform the participant that information discussed is going to be analyzed in
aggregate form and participant’s name will not be used in any analysis of the
interview.

Discussion Purpose
The purpose of study is to explore the perceptions of stem cell researchers,
stakeholders, and investors in the United States about the effects of the current federal
stem cell policy on stem cell research in the United States, the moral disagreement with
stem cell research, and their recommendations to improve stem cell research policy in the
United States.
Discussion Guidelines
Interviewer will explain:

135
Please respond directly to the questions and if you don’t understand the question,
please let me know. I am here to ask questions, listen, and answer any questions you
might have. If we seem to get stuck on a topic, I may interrupt you. I will keep your
identity, participation, and remarks private. Please speak openly and honestly. This
session will be tape recorded because I do not want to miss any comments.
General Instructions
When responding to questions that will be asked of you in the interview, please
exclude all identifying information, such as your name and names of other parties. Your
identity will be kept confidential and any information that will permit identification will
be removed from the analysis.
Possible Probes
•

Could you elaborate more on that?

•

That was helpful, but could you provide more detail?

•

Your example was helpful, but can you give me another example to help me
understand further?

Interview Questions
1. What do you perceive to be the effects of the current federal stem cell policy on
stem cell research in the United States? If clarity about the federal stem cell
policy is needed: President Obama issued an executive order, titled, Removing
Barriers to Responsible Scientific Research Involving Human Stem Cells, with the
goal of strengthening human embryonic stem cell research in the United States
(Levine, 2011; Nature Cell Biology, 2010). The Secretary of Health and Human
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Services, through the Director of the NIH, may support and conduct responsible,
scientifically worthy human stem cell research, including human embryonic stem
cell research, to the extent permitted by law (Obama, 2009). However, President
Obama’s new stem cell policy did not approve the 21 hESC lines that were
eligible under the Bush administration (Levine, 2011).
2. What are your thoughts about the National Institutes of Health strict ethical
policies regarding human embryonic stem cell research and its effect on stem cell
research in the United States? If clarity about the NIH policy is needed: Human
embryonic stem cell lines have to meet the National Institutes of Health strict
ethical policies (Nature Cell Biology, 2010). Applicant institutions proposing
research using human embryonic stem cells derived from embryos donated in the
United States should be derived from human embryos that were created using in
vitro fertilization for reproductive purposes and were no longer needed for this
purpose (NIH, 2015a). In addition, the human embryonic stem cells were donated
by individuals who sought reproductive treatment and gave voluntary written
consent for the human embryos to be used for research purposes (NIH, 2015a).
3. What are your perceptions about whether U.S. stem cell researchers have really
benefited from President Obama’s more relaxed funding policies?
4. What are your thoughts about how the Dickey-Wicker Amendment restricts the
use of federal funds for creating, destroying, or knowingly injuring human
embryos? Possible Probe: What steps can be taken to eliminate the DickeyWicker Amendment?
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5. What are your perceptions on how the U.S. stem cell policy has diminished or
improved U.S. stem cell research competitiveness with other countries?
6. What are your thoughts on how the U.S. can become more competitive with other
countries that they lag behind in relation to stem cell research?
7. What are your perceptions about the moral disagreement with stem cell research?
8. What are your thoughts on how stem cell proponents and opponents can
compromise on stem cell research?
9. What do you recommend to improve stem cell research policy in the United
States?
Conclusion
•

Discuss the transcription review process with participant, ask and answer any
questions, and thank the participant for his or her time.
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Appendix C: NIH Certificate

Certificate of Completion
The National Institutes of Health (NIH) Office of Extramural Research
certifies that Dorothy Moore successfully completed the NIH Webbased training course “Protecting Human Research Participants”.
Date of completion: 08/06/2015
Certification Number: 1808435
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Appendix D: Thematic Analysis Step 1 or Categorization of Text
Research Question 1
Research Question 1: What are U.S. stem cell researchers’, stakeholders’, and
investors’ perceptions about the effects of the current federal stem cell policy on
stem cell research in the United States?
Thematic Label 1: What are U.S. stem cell researchers’, stakeholders’, and
investors’ perceptions about the effects of the current federal stem cell policy on
stem cell research in the United States.
Theme 1: Perceptions of the effects of the current federal stem cell policy.
Subtheme 1: Overall perceptions:
Participant 12 stated:
I do believe the current federal policy is for the betterment of science research and will
have positive long-term effects on disease and disease treatment.
Participant 13 related:
Current federal stem cell policy has certainly boosted stem cell research considerably
over the last 7 years. [The Obama administration’s policy] has allowed stem cell
researchers more flexibility in choosing cell lines of interest. In addition, there has been
more investment in stem cell research, which has resulted in significant milestones being
achieved in stem cell research in the United States. Importantly, multiple clinical trials
have been initiated for stem cell therapy of degenerative diseases.
Participant 21 reported:
The current policy is fairly permissive and does not limit scientists’ abilities to address
most interesting and important questions.
Participant 7 noted:
The policy is restrictive. Although I appreciate the thoughtfulness behind the policy, it is
still restrictive in terms of access to the research taking place.
Participant 6 stated:
The current federal stem cell policy makes it easier to do more research, but funding is
still slow to roll out, due to past policies and restrictions.
Participant 1 explained:
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The current policy does not give access to the research as it should. With all the testing
that is taking place, the benefit from stem cell is still not fully realized by many because
of access.
Participant 14 reported:
Stem cell policy has an impact. Major research companies move their stem cell research
division to other countries where scientists are permitted to conduct research without any
restriction.
Participant 15 stated:
These policies limit stem embryonic cell research and more importantly rapid
advancement in therapeutic approaches and applications. The current stem cell policy
does not affect my research. To my knowledge, as a scientist, progress has been made
despite strict current policies.
Participant 20 related:
This policy does limit ongoing research in this important area. However, I understand
that there is limited impact on research.
Participant 16 reported:
There may be limits on what research could be carried out using ESCs with federal funds,
but most research is concentrated with the use of adult stems in the United States.
Participant 10 stated:
The current research that I am a part of is not affected by federal or state regulations. We
are using iPS cells, induced pluripotent stem cells, which are generated from fibroblasts
donated by patients.
Participant 11 noted:
I feel that governmental restrictions are less and less of a concern as research increasingly
includes adult-derived stem cells and iPS cells. Few of my colleagues are performing
research with ESCs, though this may change concurrently with changes in policy.
Participant 18 stated:
The policy does not have an impact, as research is more and more inclusive of adult stem
cells versus ESCs.
Participant 19 stated:
Current policy is not an issue as ESC research is being done less and more adult stem
research is being completed.
Participant 3 related:
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The current policy as it stands is not very restrictive since people are able to use ESC
lines as well as adult derived stem cells. In addition, ESCs can be derived from
nonhumans as well as produced from skin cells.
Participant 17 noted:
Stem cell policy has a limited impact, if any, at this time.
Participant 15 stated:
[Federal policy] does not allow us to compare data generated from adult versus ESC
research, which [is] the only way to know if the use of iPS cells is comparable.
Participant 8 stated:
If you mean the ban on federal funding for embryonic research put in place during the
Bush administration and lifted during the Obama administration, it only banned the use of
taxpayer dollars to pay for embryonic research. Taxpayer dollars have always been a
significant source of funding for adult stem cell research and now iPS cell research. The
ban only meant that if you wanted to do ESC research, you’d have to get private grants or
venture capital to cover the costs. ESC research continued in labs across the country, but
was largely leapfrogged by the discovery of iPS cells in 2012.
Subtheme 2: Perceptions of the Obama administration’s funding policy:
Participant 13 stated:
Significant progress has been made in stem cell research over the last 7-plus years and we
are at the cusp of realization of its clinical potential. In addition, there has been a great
push for using stem cell as disease models and for in vitro toxicity testing. All these
advancements can be largely contributed to President Obama’s funding policies.
Participant 21 stated:
The relaxation of funding policies during the Obama administration has almost certainly
benefitted scientists. This has come, in part, through access to a greater array of hESC
lines and through a greater normalization of the field, reducing some of the complications
associated with working with these cells.
Participant 4 elaborated further on the benefits of the relaxed funding policy:
U.S. researchers have absolutely benefitted from the relaxed policies governing the use of
NIH funds to work on already established lines of hESCs. For example, there is ample
data to show that different lines of stem cells have intrinsic differences in their ability to
differentiate into different lineages. Having the ability to use multiple lines of ESCs in
NIH-funded research allows scientists to characterize these differences and explore the
causes to ultimately help understand fundamental properties of differentiation. We are a
long way from understanding stem cell function, so research like this is essential.
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Participant 12 noted that relaxed federal funding policies stimulated private funding
sources:
Relaxed funding policies lead to more pharma and private donations, which is a good
thing, and stem cell researchers have been the beneficiary.
Participants 4, 5, 10, 14, 16, 17, 19, and 20 gave responses that agreed in substance
with those quoted above, describing the Obama administration’s funding policy as
beneficial to stem cell researchers.
Participant 2 believed that the current funding policy was beneficial and added:
It’s easier for researchers to now use federal funds to work with new ESC lines. That
wasn’t true for most of the United States before President Obama lifted the federal
restrictions.
Participant 2 also noted that the relaxation of funding restrictions was not equally
urgent for all researchers and stated:
President Obama’s decision to lift the restrictions imposed by President Bush has
certainly made it a lot easier for researchers around the United States to do work
involving ESCs. Those restrictions were not really a problem as the voters of this state
created CIRM through Proposition 71 in 2004, giving the stem cell agency $3 billion to
fund this kind of work California. While researchers in other states faced huge barriers
and strict limits on what they could use their stem cell research funding for, in California,
we had no such problems as we could bypass the Feds and fund it ourselves.
Participant 3 described the lingering effects of the more stringent policies of the
Bush administration as having a negative effect on current research in the United
States. This participant stated:
Not sure if anyone has benefitted from the more relaxed policy as more people are doing
more research outside the United States, which is a push from the Bush legacy. Once you
are banned from doing something and you move on to something else, you don’t usually
turn back.
Participant 15 stated:
Yes, scientific research has benefitted from these policies, but they did not go far enough
to have a real impact on medical applications.
Participant 4 noted that the Obama administration’s policy, which rests on an
executive order, can be reversed by any subsequent president, such that researchers
cannot rely on the indefinite continuation of the current funding guidelines:
I would characterize the environment as unstable, especially around presidential
elections, where the new president with a different ideology can rescind the order with
the stroke of a pen.
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Other participants expressed the perception that while the current policy was
favorable to research, it had not been put into effect. Participant 9 stated:
The relaxed funding policies have not really been implemented, kind of like travel to
Cuba, it really is still incredibly difficult.
Similarly, Participant 6 stated:
The full benefit has not been realized, but clearly there are benefits.
Participant 7 suggested a reason why the policy might have failed to have its
intended effect:
[The policy] is definitely a good thing, but we still are stagnant in the research and its
use. The benefit has not increased much from 2009 as the bipartisan support needed is not
available.
This response was echoed by Participant 1:
In 2009, when President Obama did the EO that removed the barriers to responsible
research, it should have been a good thing, but we still are stagnant in the research and its
use; therefore, the benefit has not increased much from 2009 as the bipartisan support
needed is not available.
The alternatives to hESC were also described as depriving President Obama’s EO
of some of its effect. Participant 5 stated:
Researchers have definitely benefitted from the relaxed restrictions, as there are many
more hESC lines currently eligible for research supported by NIH. That said, the advent
of iPS cell has to some extent lessened the need for new hESC lines. Additionally, the
preponderance of the Bush lines, those approved for research under President Bush,
appear to remain the most heavily used cell lines because researchers are comfortable
with them and have been using them for years.
Participant 8 indicated that President Obama’s executive order had been deprived
of much of its intended force by the nature of hESCs:
I don’t think [the EO] makes any difference. For most researchers, the problem with
embryonic cells is less ethical than scientific. Embryonic cells multiply at an extremely
rapid pace and have a propensity to form cancers. They can be used for disease modeling
and drug screening in a lab, but will not be used in people, with the exception of a very
small number of ophthalmology projects, until their cancer-forming properties can be
controlled. In the meantime, iPS cells have leapfrogged the need to use them.
Subtheme 3: Perceptions of the NIH’s ethical policy:
Most participants expressed agreement with the NIH ethical policy. Participant 13
expressed that the NIH policy helped to ensure that scientists used the technology
responsibly:
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The NIH policy restricted the generation of new stem cell lines. However, there needs to
be strict supervision on such ethical policies. ESCs have great power and ensuring that it
is handled responsibly is possible only through strict supervision.
Participant 4 expressed a similar perception, citing the importance of ethical science
and the value of the NIH policy in promoting it:
I think all research should be done ethically by following approved and vetted standards.
Embryonic and adult stem cell research is no different. The ISSCR helped create the first
set of standards on ethical embryonic and adult stem cell research and recently released
an updated set of guidelines. There are many benefits of the new policies and procedures
that NIH uses to vet the provenance of the lines, including protecting patients and donors
and helping to maintain the integrity of the process. All scientific research benefits by
following ethical scientific practices.
Participant 1 stated:
I would describe the current ethical policies as particularly strict.
Participant 21 stated:
The NIH ethical guidelines represent, in my view, a reasonable compromise between the
obligation to protect embryo and gamete donors and the desire to help advance the
science.
Participants 3, 12, and 19 also described the policy as “strict” while expressing
agreement with it.
Participant 3 related:
NIH strict policy . . . promoted the idea of nonembryonic use and moved research into a
different path, which is more universally useful. It also brought up the ethical issue of
how many embryos would be sacrificed to create one transplant, which then created the
ethical issue of who could afford to use this process, in most cases, meaning only wealthy
people could afford to have a chance at using the therapy from embryonic tissues. ESCs
are not very scalable, so to have something of value, the product or service must be
scalable.
Participants 6, 10, 11, 14, 16, 17, 18, and 20 agreed with the policy without
reservation.
Other participants expressed misgivings about the policy. Participant 9 stated:
[The NIH ethical policy] is scientifically informed regarding safety. It is dynamic as new
therapies are always developing. The ethical interpretations of ESC use are not
scientifically informed and restrictions should be reevaluated without political or
religious input.
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Participant 8 expressed the belief that the ostensibly ethical policy was actually
unrelated to ethics:
ESCs used for research purposes have always been harvested from IVF clinics with the
express permission of the individuals involved. The NIH guidelines do not constitute
ethical policy, they just clarify the source of cells.
Participant 7 described the policy as a potential cause of misunderstanding:
The NIH is legally bound to the policies, and as such, has a limiting impact and causes
confusion in people’s minds about the differences between human embryonic and adult
stem cells and their uses for research.
Participant 5 agreed with the ethics of the policy and believed that certain
additional issues remained unaddressed, stating:
Informed consent for the donors of embryos used to create hESC lines remains an
important policy.
Participant 5 added two objections. The first of these objections was expressed in
these terms:
The NIH policy on using only embryos left over from IVF may skew the source of new
lines to less than healthy embryos, as these are more likely not to be implanted.
The second objection was stated as follows:
The FDA has not kept up with the science in regard to its guidance or requirements for
preclinical studies needed to move stem cell-based therapies into clinical trials. I am not
arguing for following the Japanese model and I also have grave misgivings about the
REGROW Act, rather I would like to see the FDA issue clear guidance and play a more
active role in regulating the unregulated stem cell clinics currently marketing
unapproved, untested therapies. Finally, U.S. policy with regard to preventing the FDA
from even considering applications involving genetic engineering [or] modification of
human embryos should not be enshrined perpetually in law as the Dickey-Wicker
Amendment has become . . . . The FDA’s process is slow, laborious, and highly
inconsistent. It means that therapies can take up to 20 years and billions of dollars to get
approval. Very few companies can afford that time or money.
Subtheme 4: Perceptions of the Dickey-Wicker Amendment:
Participants’ opinions of the amendment were divided, with some interviewees
expressing strong disagreement for various reasons, but with a number expressing
assent (i.e., Participants 1, 10, 11, 12, 14, 16, 18, and 20). Of those participants who
disagreed, three related that the amendment’s impetus was irrational. Participant 9
stated:
I strongly disagree [with the amendment]. This is a religious agenda. Females can discard
embryos in late menstruation, yet this is not regulated. We don’t scoop them up, protect
them, have funerals, etc.
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Participant 7 stated:
The amendment is unfortunate. It created a path that is based more on people’s feelings
than on science.
Participant 5 had a legal objection:
I think Dickey-Wicker is a clear case of the nonseparation of church and state. The
amendment puts the beliefs of primarily one religion over that of others and instills those
beliefs in federal legislation.
Participant 5 also noted that recent technology had limited the amendment’s effect:
Fortunately, with the advent of iPS cell technology and the continued addition to the NIH
registry of new hESC lines created with other funds, the amendment is not the barrier it
once was.
Participant 21 also described the amendment’s restrictions as limited but still
significant:
State and private funding have helped work around this restriction, but this is clearly a
key challenge for the field.
Participant 13 expressed a similar opinion about the limited scope of the
amendment, but emphasized the legislation’s negative effect on the research that fell
within its purview:
While it does not restrict the use of hESCs for research purposes, it still restricts the
generation and establishment of new stem cell lines from embryos. While there needs to
be strict supervision regarding use and destruction of embryos, with the current
amendment, the field is restricted to the use of just handful of lines.
Two participants pointed out that IVF embryos, which are not used in stem cell
research, will usually be discarded. Participant 4 stated:
In theory, the amendment was designed to protect embryos, but in fact it does not do so.
Although the embryos cannot be used for federally funded research, they will likely be
discarded when they are no longer needed for fertility treatments.
Similarly, Participant 8 stated:
You have three options for embryos that are yours and being cryopreserved at [an] IVF
clinic: throw them away, donate them to research, or continue to cover the costs of
storing them indefinitely. Most of them are discarded.
Participant 3 discussed the difficulty of evaluating the amendment:
This is a complex issue that deals with ethical issues like the use of eggs [in an] in-vitro
sterilization clinic . . . . Should they be implanted in another female or used to further
research study? So, with something so complex, it may be best to not complicate the
issue by using those embryos with federal funds, without a clear purpose in mind. The
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cells of embryos can become abused if people believe there is a financial gain from it, so
it must be clear what the benefit will be or should be. I do not have an answer for this
question and believe it needs to be discussed more at a broader level.
Participant 17 also believed that more information was needed before the
amendment could be properly evaluated and that enforcing it was a more prudent
course of action than overturning it:
The Dickey-Wicker Amendment should remain as is until there is a clear understanding
of what and how hESC can be a benefit.
Participant 1 also viewed the amendment as a prudent precaution:
I believe that the Dickey-Wicker Amendment should stay in place. As with any
exploratory science, one can go overboard, so the amendment should stay in place and
continue to be reviewed annually for changes to funding, if necessary.
Participant 6 agreed with the amendment, but emphasized its negative effect on the
funding of research:
The Dickey-Wicker Amendment is needed, but it is limiting, where federal funds are
concerned.
Participant 2 pointed that the effect on funding was limited:
While the Dickey-Wicker Amendment prohibits the use of federal funds for research on
human embryos, it does not, at least under the current interpretation, limit the use of
federal funds for research on embryonic cell lines. So in that sense, it really has a limited
impact on stem cell research. Of course, that could change with a different
administration.
Theme 5: Perceptions of competition between the United States and other countries:
A number of respondents did not believe that the United States lagged behind other
countries (i.e., Participants 2, 5, 6, 10, 11, 12, 14, 16, 18, 19, and 21).
Participant 10 believed that federal policy had no effect on U.S. competitiveness:
I do not think the policy has either diminished or improved competitiveness with other
countries.
Participant 18 expressed the same perception:
Policies have no effect on improving or diminishing competitiveness with other
countries.
Participant 21 suggested that U.S. researchers were succeeding despite the federal
policy:
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Scientists and institutions worked around [the Bush administration’s funding restrictions],
with state and private funding and the United States is clearly among the top tier of
countries producing key stem cell research advances.
Participant 5 also described U.S. researchers as succeeding despite the federal
policy:
The United States remains in the forefront, but other countries, the UK in particular, have
in some ways more opportunities to conduct research that it is not possible to conduct
here. My impression is that at least parts of the EU also allow more. Fortunately, the
sheer size of the biomedical research enterprise and the amount of funds the United States
contributes to research allow the United States to remain competitive in all but a few
areas.
Participant 2 echoed Participant 21’s reference to the restrictive funding policy of
the Bush administration:
The restrictions [during the Bush administration] clearly put U.S. researchers at a
disadvantage compared to scientists in Europe and Asia . . . [but] I don’t think the United
States lags behind other countries any more. In many ways, we are as advanced if not
more so than most countries.
Participant 20 shared that the Obama administration’s relaxation of funding
restrictions had improved U.S. competitiveness. Participant 20 stated:
Under Bush, it was too restrictive. The current policy is [a] good balance of ethics and
ability to do research.
Participant 12 stated:
I think U.S. competitiveness has improved, as seen with the large growth within my
group alone. From attending world and international stem cell conferences, I do not
believe we lag in comparison with other countries.
Participant 19 agreed that the situation for U.S. researchers had been improved:
I think the policies [of the Obama administration] have helped the U.S. become more
competitive with other countries.
Similarly, Participant 7 stated:
Obama’s more expansive policy has improved competitiveness. We are still restricted to
the creation of new lines due to the lack of using federal funds. More people are not
aware that this is an ongoing issue. With wider bandwidth, U.S. research could be felt on
a global basis.
Other participants agreed that federal policy had an inhibitory effect on U.S. stem
cell research. Participant 1 stated:
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We have not improved [and] as a country, we could be doing far more than what we are
doing.
Participant 13 related:
U.S. stem cell policy has certainly diminished U.S. competitiveness with other countries,
in particular Japan and Europe. Over the last 5 years, we are experiencing some boost in
U.S.-based studies. While such studies are at the forefront, the volume of research and
number of stem cell researchers in the United States is still limited.
Participant 15 indicated that restrictions on stem cell research in the United States
might give an advantage to other countries:
U.S. stem cell policies might have actually boosted stem cell research in countries like
China, since the chances for a breakthrough and the first to discovery are greatly
increased in places other than the United States.
Participant 15 also explained why U.S. researchers could not simply evade
legislative constraints by focusing their efforts on fields of inquiry that were subject
to fewer restrictions:
In the current environment, scientists and the community need to fight for more relaxed
policies on stem cell research. For now, some hESC lines are still needed for research,
since iPS cells may not behave exactly the same as embryonic cells. Therefore, we need
to continue to examine all stem cell types since we do not know yet which one will be the
best to use in therapy.
Participant 6 viewed the effect of federal restrictions as primarily economic:
There are limitations in America, but companies who want to be more competitive, do
research outside the country, and transfer it back in, so it becomes very costly for
everyone to reap the benefits.
Participants 8 and 9 agreed that federal restrictions were causing the United States
to lag in stem cell research, with Participant 8 adding:
Stem cell research, all research in the United States is disadvantaged by stringent FDA
regulatory requirements, far stricter than those of other countries.
Participant 4, however, while acknowledging the disadvantageous effect of federal
policy, viewed international research as a cooperative endeavor from which the
United States would ultimately benefit:
[Federal policy] has certainly slowed the creation of new lines of hESCs, since that
research can only be done using nonfederal funds. While funding science to the highest
levels makes economic sense for our country, stem cell research is a global enterprise,
and discoveries and stem cell-derived therapies in one country will benefit those in other
countries.
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Research Question 2
Research Question 2: What are U.S. stem cell researchers’, stakeholders’, and
investors’ perceptions about the moral disagreement with stem cell research?
Thematic Label 2: What are U.S. stem cell researchers’, stakeholders’, and
investors’ perceptions about the moral disagreement with stem cell research.
Theme 2: Perceptions of the moral disagreement about stem cell research.
Subtheme 1: Understanding opposition:
Participants 10, 11, 12, 16, and 18 described themselves as understanding, but not as
agreeing with the ethical objections to hESC research. Participant 12 stated:
I understand the perceptions and concerns of the lay public in regards to the use of human
tissues for research.
Similarly, Participant 10 related:
I understand the concerns of the general public with regards to the use and potential
misuse of human tissues for research purposes.
Two participants acknowledged the validity of disagreement but emphasized the
necessity for an ongoing dialogue. Participant 11 stated:
The disagreement is understandable and it is a topic worthy of ongoing discussion.
Participant 16 stated:
I am sympathetic to it, but at the same time the beneficial aspects of this research can be
insurmountable, so there needs to be ongoing communication.
Participant 18 spoke in more general terms:
I believe everyone has their right to their own belief.
Subtheme 2: Religious or moral objections:
Participant 1 perceived the source of the opposition as a reason to abstain from
giving a judgment:
I don’t have an opinion, as a lot of the moral disagreement is related to the Christian
views related to how embryos are being used to accomplish scientist goals.
Participant 15 believed that opposition to hESC research issued from a combination
of political calculation and misdirected sentiment:
I do not believe there is a moral disagreement, rather a religious perception and power
calculations to distract the electorate from important social and political issues. Morality

151
is intimately linked to politics in the United States. We have the moral obligation to save
lives. If the material we use was procured from spontaneous abortions or medically
recommended abortions, we are not conducting an immoral activity.
Participant 2 expressed sympathy with the beliefs of opponents of stem cell
research, but expressed a belief similar to that of Participant 15, to the effect that
moral concern was more properly directed toward the promotion of a life-saving
technology:
There are many people of strong religious faith who are opposed to the use of fetal tissue
or ESCs in research, considering these a violation of the sanctity of life. We respect those
views completely. However, we don’t agree that either of these approaches is ethically or
morally wrong, a view Congress has supported since the 1950s. In fact, we feel we have
an obligation to pursue the use of these materials in scientific work because of their
enormous potential to save the lives of millions of people around the world who are
currently battling deadly diseases and disorders that have no cures.
Participant 5 reiterated his earlier statement to the effect that moral opposition to
stem cell research, when it took the form of legislation, was unconstitutional:
The moral disagreement with stem cell research is rooted primarily in Christianity and . .
. raises the beliefs of one religion, or some branches thereof, above those of others and is
a clear instance of lack of separation of church and state. Adult stem cells are great, but
they have limitations that cannot, yet, possibly never be overcome that hESCs do not
have, and to hold them up as a reason not to conduct hESC research is a specious
argument.
Participant 14 noted the connection between religious opposition to hESC research
and religious opposition to abortion:
Many opponents of stem cell research, like religious leaders, compared stem cell research
to abortion. For the Catholic Church, for example, life begins at conception, making the
stem cell research comparable to homicide because it results in the destruction of many
embryos. Although scientists are right, but from a moral standpoint, it could be conceived
as wrong.
Participant 4 made the connection between opposition to abortion and opposition to
hESC research:
The misperception that this issue, hESC research, is tied to abortion will forever entangle
it in a political quagmire. The fact remains that those embryos no longer needed for
fertility treatments will be discarded as medical waste if not donated to science or
adopted by another couple, which is exceptionally rare. Stopping ESC research is not
saving embryos.
Participant 3 made a similar point:
[The moral disagreement] is a complex issue because of the abortion issue.
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Participant 20 indicated a context for the debate by sharing the perception that the
moral disagreement about hESC research was between an ethical consensus among
medical professionals and the subjective reactions of some private individuals:
This moral issue is a personal issue. The U.S. policy is in line with most bioethics
considerations.
Subtheme 3: Stem cell source:
Several participants noted that the moral disagreement surrounding stem cell
research depended to a great extent on the source of the cells in question.
Participant 1 stated:
In the United States, we get caught up with the logistics, such as whether the stem cells
are being used from human embryos or from one’s own stem cells, which is two different
processes, but is still misunderstood to this day.
Participant 4 stated:
The disagreement is fundamentally over the destruction of embryos for the purpose of
creating lines of hESCs and not [over] stem cell research in general.
For Participant 21, identifying moral concern over the embryo as the point of
contention was a reason for pessimism about the prospects of compromise:
The debate over the moral status of the embryo isn’t going anywhere and will continue to
shape public opinion toward the field.
Participant 4 was optimistic about the chances for a satisfactory resolution by a
consideration of emerging technology:
More companies are moving to fibroblast stem cell [iPS cell] research, so the issue will
become invalid soon, essentially making it a nonissue.
Subtheme 4: Reasoning:
A few participants questioned the validity of the debate, not because the reason for
disagreement was religious or moral, but because they perceived the reasoning of
hESC research opponents as flawed. Participant 7 stated:
It is simple, the moral disagreement is a nonissue, because if people only understood that
the majority of the vaccines have been derived from these tissues being discussed and if
they looked further into what the actual usage is and reasons are behind it, most people
would understand the importance of the research.
The idea that disagreement was a result of ignorance was echoed by Participant 13:
Moral disagreements are largely from lack of scientific knowledge and factual
information. Often facts are misrepresented, which perpetuates a falsified perception.
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Participant 17 believed that hESC research might be promoted by an appeal to
common sense:
I think it’s a gray area, but rather than waste stem cells, why not put them to a good use
that benefits all humanity?
Participant 8 believed that public’s understanding of the controversy was impaired
by equivocal terminology:
There is no moral disagreement about stem cell research. You shed your skin regularly
because skin stem cells are constantly renewing and replacing damaged, old skin. You
can donate a lobe of your liver and it will grow back because liver stem cells will
regenerate it. Every tissue in your body constantly renews itself through tissue-specific
stem cells. To say you have a moral disagreement with stem cell research is like saying
you object to your liver. There is controversy about the use of ESCs for research, but I
see it as a far greater issue in the lay public than it is in the research community. Most
scientists I know find it less an ethical problem than a scientific one. Because ESCs form
cancers, their primary contribution will continue to be disease modeling and drug
screening. And the ethical concerns about using embryonic cells have been completely
leapfrogged by the discovery of iPS cells. Even the Vatican supports and funds adult and
iPS cell research.
Subtheme 5: The Possibility of Compromise:
Two participants believed that compromise between proponents and opponents of
stem cell research was unlikely. Participant 4 stated:
I don’t see how a compromise is possible.
While Participant 21 left only slightly more room for optimism:
Compromise is not likely for those with strong views on [the] moral status of the human
embryo.
Participant 5 suggested that the benefits of hESC research might gradually
persuade its opponents:
Unfortunately, I do not think hESC opponents are willing to compromise, but when
hESC-based treatments [and] therapies for diseases that afflict them or their family
members become available, I hope they will take advantage of them and maybe
reconsider their stance.
Five participants believed that deriving the necessary research materials from
uncontroversial sources would render the debate moot. Participant 21 stated:
Focus on less contentious technologies [such as] IPS cells and use of existing rather than
new hESC lines offer some hope.
Similarly, Participant 3 suggested that contention could be alleviated:
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By working to develop [and] improve lines in which ethical issues have been thoroughly
discussed.
Participant 16 stated:
I believe that continued use of iPS cells can be considered as a compromising option.
Participant 10 stated:
I believe iPS cells are a compromise on stem cell research.
However, Participant 15 pointed out that iPS cells might fail as a means of
circumventing moral contention:
The use of iPS cells is a compromise with stem cell research opponents; however, we do
not yet know the real potential of this technology and its application to therapy.
Other participants recommended more effective education of the public as a means
of promoting compromise. Participant 7 placed the burden of promoting education
on opponents of stem cell research:
They can find compromise by asking the more meaningful questions about stem cell
research outcomes, such as what does the research mean to my family and to the country
now and into the future.
Participant 6 placed the burden on proponents of the research, suggesting that they
should “provide a greater understanding.”
Participant 12 referred to education and the concurrent use of uncontroversial
materials as a means of achieving a compromise:
I believe the best compromise is using other stem cell lines beyond embryonic and
making the public aware of the differences. For example, hMSCs, which we use, are from
a human, adult, healthy donor and these cells have shown to be great in curing very
devastating conditions such as stroke or cardiac problems.
Research Question 3: What do U.S. stem cell researchers, stakeholders, and
investors recommend to improve stem cell research policy in the United States?
Thematic Label 3: What do U.S. stem cell researchers, stakeholders, and investors
recommend to improve stem cell research policy in the United States.
Theme 3: Policy recommendations.
Subtheme 1: Funding:
All six participants who made policy recommendations related to federal funding
believed that it should be increased. Participant 2 stated:
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It’s going to take a huge investment by the government to really push this research along.
Participant 8 summarized her recommendations in the form of an equation:
Streamlined process plus money equals competitive advantage, where streamlined
process referred to an acceleration of the FDA approval process.
Participant 2 also mentioned FDA requirements:
It’s going to take changes in the way the FDA regulates stem cell therapies to enable the
science to move ahead as fast as it needs to.
Participants 1, 9, 20, and 21 also recommended an increase in federal funding.
Subtheme 2: Involving outsiders:
Two participants suggested involving laypersons in the discussion. Participant 3
recommended:
Bringing in people from the outside and not just the professionals.
Similarly, Participant 7 stated:
Engage lay people, who are recipients of the therapy, and not just those who are
professionals in the field.
Participant 7 also elaborated on the reasons why involving the public might be an
effective political agenda:
People are very similar when it comes to saving lives. People respect human life and are
more practical in their understanding if they can relate outcomes to their own family and
loved ones.
Subtheme 3: Religion:
Participant 9 proposed the removal of religious agendas from the dialogue, stating:
The ethical interpretations [to] ESC use are not scientifically informed and restrictions
should be reevaluated without political or religious input.
Participant 9 added that legislators should:
Vote to overturn religious agendas [and] until the policies change, the science can’t move
forward.
Subtheme 4: Education:
Other participants recommended various forms of education as a means of making
federal policy more favorable to hESC research. Participant 9 recommended:

156
Improved science education, public announcements educating the public, [and]
encouraging open discussion of policy, ethics, and science.
Participant 14 stated:
The general public do not know enough about the benefits of stem cell research.
Education is needed.
Participant 14 recommended:
Reaching out to our community.
Similarly, Participant 17 suggested:
Educational outreach so that both sides of the good and bad are discussed with
stakeholders and a common, middle ground is reached. Hard to do but attemptable.
Participant 19 agreed with Participant 17 in recommending even handed education:
People need to be educated on the advantages and disadvantages.
Participant 1 suggested that educational efforts should not be focused solely on the
general public, stating:
Educate the population and the lawmakers.

